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SUMMARY 
 
Germinal centres (GC) are formed during adaptive immune responses to defend our body 
against invading pathogens. During GC reactions antigen-specific high-affinity antibodies 
are produced through an intricated T – B cell crosstalk. In the last decades, the identification 
of a T cell subset specialized in controlling GC reactions, the T follicular helper (Tfh) cells, 
was a major scientific breakthrough. Within GCs, Tfh cells support B cell affinity maturation 
and class switch recombination. In addition, T follicular regulatory (Tfr) cells were recently 
described as GC regulators. Tfr cells are derived from thymic Foxp3+ Treg cells and undergo 
a still poorly defined, Bcl-6-dependent, multistep differentiation pathway within secondary 
lymphoid tissues. Throughout this process, Tfr cells enforce tolerance and limit 
autoantibody-mediated autoimmune diseases by regulating Tfh – GC B cell interactions. 
Although the biology of human blood and tissue Tfh cells has been established, the biology 
and ontogeny of human blood Tfr cells, defined as CXCR5+Foxp3+ T cells, still remains 
elusive. 
 
This work focused on Tfr cells in human adaptive immunity and autoimmunity. We have 
shown that human blood CXCR5+Foxp3+ Treg cells constitute a circulating counterpart of 
GC bona fide tissue Tfr cells. Indeed, those blood Tfr cells increase after the induction of 
GC responses by vaccination, and they are absent from human umbilical cord blood, where 
non-maternal foreign antigens are not present. However, blood Tfr cells are immature cells 
which fail to fully regulate humoral responses, suggesting these cells are not fully competent 
Tfr cells. To address the biological significance of blood Tfr cells in autoimmunity, we 
studied patients with a systemic autoimmune disease (Sjögren’s syndrome) characterized by 
abnormal generation of autoantibodies within lymphoid structures ectopically formed in 
exocrine glands. Unexpectedly, Sjögren’s syndrome patients had a striking increase in blood 
Tfr cells, as well as an increase in blood Tfr/Tfh ratio. In addition, we established the 
relationship between blood Tfr and Tfh cells and abnormal immune responses in the target 
organ of an autoimmune disease. Patients with ectopic lymphoid structures in their salivary 
glands had the highest blood Tfr/Tfh ratio, suggesting this ratio may be a novel biomarker 
of ectopic lymphoid activity in Sjögren syndrome. 
 
Autoimmunity of follicular origin poses a considerable clinical challenge. Following the 
 2 
 
discovery of Tfr cells as GC “fine tune” regulators, targeting Tfr cell responses may 
constitute a novel and highly selective approach for the treatment of autoantibody-mediated 
autoimmune diseases.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords 
Germinal centres; T follicular helper cells; T follicular regulatory cells; Autoimmunity; 
Sjögren syndrome. 
 3 
 
SUMÁRIO 
 
Durante as respostas imunológicas adaptativas formam-se centros germinativos, onde, 
através de interações celulares complexas, entre linfócitos T e linfócitos B, são produzidos 
anticorpos. Os anticorpos produzidos nos centros germinativos apresentam elevada 
afinidade e especificidade contra os antigénios que iniciaram a resposta imunológica, 
constituindo, por isso, um elemento essencial na defesa do organismo face a agentes 
invasores. Nas últimas décadas foi identificado o tipo de linfócitos T que, por interagir com 
linfócitos B de forma especializada, é responsável pela formação dos centros germinativos: 
as células T foliculares de ajuda (Tfh). No centro germinativo, as células Tfh são 
responsáveis pela maturação de afinidade e mudança de classe das imunoglobulinas dos 
linfócitos B. Recentemente foi descrito um outro tipo de linfócitos T especializado na 
regulação das interações entre as células Tfh e os linfócitos B que ocorrem nos centros 
germinativos, evitando a desregulação destas respostas e prevenindo o desenvolvimento de 
doenças autoimunes. Estes linfócitos designam-se células T foliculares reguladoras (Tfr). As 
células Tfr diferenciam-se nos órgãos linfoides secundários a partir de células T reguladoras 
formadas no timo e que expressam Foxp3. Esta via de diferenciação é ainda pouco 
conhecida, mas envolve vários processos que dependem da aquisição de expressão de Bcl-6 
por parte das células T reguladoras. Contudo, o significado biológico e a função destas 
células (definidas como células T CXCR5+Foxp3+) no sangue dos seres humanos não é 
conhecido, contrariamente ao que acontece com as células Tfh, cuja biologia já foi 
estabelecida em humanos.    
 
Este trabalho foi desenvolvido com o objetivo de estudar as células Tfr nas respostas 
imunológicas adaptativas (fisiológicas) e nas doenças autoimunes, em seres humanos. O 
trabalho experimental desenvolvido permitiu estabelecer, pela primeira vez, que as células 
T CXCR5+Foxp3+ existentes no sangue humano constituem um compartimento circulante 
das células Tfr formadas nos órgãos linfoides secundários. De facto, verificou-se um 
aumento destas células sanguíneas estas células após a vacinação e a sua ausência no sangue 
do cordão umbilical, onde não existem antigénios exógenos, para além dos maternos. 
Contudo, as células Tfr do sangue são imaturas e não são capazes de regular eficazmente a 
produção de anticorpos, pelo que as células T CXCR5+Foxp3+ do sangue humano não 
apresentam a mesma diferenciação funcional que as células Tfr dos órgãos linfoides 
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secundários. Para estudar a importância destas células nas doenças autoimunes estudaram-
se doentes com síndrome de Sjögren. Esta doença autoimune sistémica é caracterizada pela 
formação ectópica de estruturas linfoides nas glândulas exócrinas. A produção de 
autoanticorpos ocorre maioritariamente nestas estruturas onde existem interações T – B 
patológicas. Contrariamente ao esperado, as células Tfr, descritas como apresentando 
funções reguladores, encontram-se aumentadas no sangue dos doentes com síndrome de 
Sjögren, tal como o rácio Tfr/Tfh. Este trabalho permitiu ainda estabelecer a relação entre as 
células Tfh e Tfr e os fenómenos imunológicos que ocorrem nos órgão-alvo desta doença 
autoimune. De facto, os doentes com formação ectópica de estruturas linfoides nas glândulas 
salivares são os que apresentam os valores mais elevados do rácio Tfr/Tfh, pelo que este 
rácio pode constituir um novo marcador para a identificação de doentes com formação 
ectópica de estruturas linfoides.  
 
As doenças autoimunes cuja patogénese está relacionada com a perda de tolerância nos 
centros germinativos continuam a ser um desafio clinico e terapêutico. O desenvolvimento 
de fármacos capazes de modular a resposta células Tfr pode constituir uma nova abordagem 
terapêutica para estas doenças autoimunes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Palavras-chave 
Centros germinais; Células T foliculares de ajuda; Células T foliculares reguladoras; 
Autoimunidade; Síndrome de Sjögren. 
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SUMÁRIO EXTENSO 
 
Apesar dos avanços científicos das últimas décadas, a complexidade dos mecanismos 
imunológicos que estão implicados na patogénese de várias doenças continua a ser um dos 
mais relevantes desafios da medicina moderna.  
 
O sistema imunitário apresenta uma ambiguidade intrínseca: ao mesmo tempo que garante 
a proteção do organismo humano contra agentes invasores, através de mecanismos celulares 
e humorais potentes, o sistema imunitário integra mecanismos homeostáticos de tolerância 
para o self. A indução e manutenção de tolerância é, por isso, uma importante função do 
sistema imunitário, particularmente relevante na prevenção de respostas imunológicas 
inapropriadas contra o próprio organismo. As respostas humorais são um dos mais 
especializados e desenvolvidos mecanismos efetores do sistema imunitário. Estas respostas 
garantem a produção de anticorpos (específicos para o antigénio que iniciou a resposta) nos 
centros germinativos, através de interações celulares complexas entre linfócitos B e 
linfócitos T. As células T foliculares de ajuda (Tfh) constituem um tipo de linfócitos 
especializados na ativação e diferenciação de linfócitos B nos centros germinativos, sendo 
caracterizadas pela expressão do gene Bcl-6, do recetor CXCR5 (que permite a sua migração 
para a zona folicular dos órgãos linfoides) e moléculas diretamente envolvidas na 
estimulação de linfócitos B, tais como ICOS, CD40L e PD-1. A ausência das células Tfh é 
suficiente para impedir o estabelecimento de centros germinativos, constituindo uma causa 
de imunodeficiências primárias. Apesar da sua indiscutível importância na proteção contra 
agentes invasores, a desregulação das células Tfh pode culminar em respostas humorais 
excessivas capazes de promover o desenvolvimento de doenças autoimunes mediadas por 
autoanticorpos.  
 
A manutenção da tolerância imunitária (e a consequente prevenção da autoimunidade) são 
uma das reconhecidas e amplamente estudadas funções das células T reguladoras (Treg), 
habitualmente definidas pela expressão do gene Foxp3. Recentemente foi identificado um 
subtipo de células Treg especializado na regulação das interações que ocorrem entre 
linfócitos B e células Tfh nos centros germinativos. Estas células T foliculares reguladoras 
(Tfr) expressam Foxp3 e diferenciam-se a partir de células Treg nos órgãos linfoides 
secundários, por mecanismos ainda pouco conhecidos. Durante a sua diferenciação as 
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células Tfr, tal como as células Tfh, adquirem a expressão de Bcl-6, CXCR5, PD-1 e ICOS, 
mas também a de CTLA-4 (um dos seus principais mecanismos efetores). Apesar do seu 
potencial papel na prevenção de doenças autoimunes mediadas por autoanticorpos, existem 
vários aspetos da biologia das células Tfr (definidas como células T CXCR5+Foxp3+) que 
não são conhecidos, sobretudo em seres humanos. O estudo desta população celular em seres 
humanos é de grande relevância antes de uma eventual translação terapêutica deste 
conhecimento. Contudo, o estudo das células Tfr em humanos tem sido limitado pelo difícil 
acesso a órgãos linfoides secundários (onde estas células se formam e exercem a sua função).   
 
Este trabalho foi desenvolvido com o objetivo de estudar, em seres humanos, as células Tfr 
em respostas humorais (adaptativas) fisiológicas e em doenças autoimunes sistémicas.  
 
Após a identificação das células Tfh nos órgãos linfoides secundários foi descrito um subtipo 
de linfócitos T circulantes com características fenotípicas e funcionais de células Tfh. Apesar 
de também terem sido identificados linfócitos T CXCR5+Foxp3+ no sangue humano (antes 
da primeira descrição das células Tfr) o seu significado biológico e a sua ontogenia não 
foram esclarecidos. Através da caracterização fenotípica de células T CXCR5+Foxp3+ em 
vários tecidos humanos e de ensaios funcionais demonstrou-se neste trabalho, pela primeira 
vez, que as células T CXCR5+Foxp3+ do sangue humano constituem um compartimento 
circulante das células Tfr formadas nos órgãos linfoides secundários. Esta conclusão 
fundamenta-se nas seguintes observações: a) a percentagem desta população celular no 
sangue aumenta após a vacinação contra o vírus da gripe; b) no sangue do cordão umbilical 
(onde não existem antigénios exógenos para além dos maternos) não existem células Tfr, 
embora se observem células Treg ativadas; c) estas células não existem no timo humano, 
pelo que a sua diferenciação ocorre nos órgãos linfoides periféricos; d) a estimulação in vitro 
com anti-CD3/CD28 não é suficiente para a expressão de CXCR5 pelas células Treg, 
demonstrando que a expressão de CXCR5 não é um mero marcador de ativação de células 
Treg (pelo contrário, a sua expressão é estável e funcionalmente relevante: as células Tfr são 
o único tipo de células Treg sanguíneas capazes de migrar a favor de um gradiente de 
CXCL13, responsável in vivo pela migração celular em direção às zonas foliculares); e, e) 
as células Tfr do sangue suprimem in vitro a proliferação de células Tfh. Contudo, 
contrariamente ao descrito para as células Tfr efetoras (presentes nos tecidos de ratinhos), o 
compartimento circulante não é capaz de suprimir completamente a produção de anticorpos 
(apesar de inibir a ativação de linfócitos B). De facto, as células Tfr do sangue humano são 
 7 
 
imaturas (ou seja, não terminalmente diferenciadas), emergindo – dos tecidos linfoides – 
antes da interação com as células B, que é necessária para completar a sua diferenciação. 
Esta observação efetuada em doentes com uma imunodeficiência primária caracterizada pela 
ausência de células B demonstra que as células Tfr do sangue humanas não refletem a 
capacidade reguladora de respostas humorais do sistema imunitário.  
 
Os mecanismos fisiopatológicos das doenças autoimunes sistémicas caracterizadas pela 
presença de autoanticorpos envolvem a perda de tolerância imunitária e podem, por isso, 
refletir respostas desreguladas de células Tfh e/ou Tfr. A síndrome de Sjögren é uma doença 
autoimune caracterizada por um processo inflamatório crónico das glândulas exócrinas 
(responsável pela xerostomia e xeroftalmia típicas desta doença) que pode atingir o sistema 
nervoso central, o rim e as vias respiratórias, acarretando ainda um risco significativo de 
evolução para linfoma. No contexto do processo inflamatório crónico desenvolvem-se, nas 
glândulas salivares, estruturas linfoides ectópicas, onde interações patológicas entre 
linfócitos T e linfócitos B culminam na produção de autoanticorpos. Para o diagnóstico da 
SS está recomendada a realização de uma biopsia das glândulas salivares, para além da 
pesquisa de autoanticorpos no sangue e de uma observação oftalmológica. Para estudar a 
relevância biológica e clínica das células Tfr do sangue nas doenças autoimunes foram 
colhidas amostras de sangue e de glândulas salivares de doentes com suspeita clínica de 
síndrome de Sjögren. Contrariamente ao esperado, as células Tfr, bem como o rácio Tfr/Tfh, 
encontram-se aumentadas no sangue dos doentes com síndrome de Sjögren (quando 
comparados com um grupo controlo recrutado simultaneamente). O aumento do rácio 
Tfr/Tfh correlaciona-se significativamente com a infiltração das glândulas salivares por 
linfócitos T e linfócitos B, permitindo discriminar os doentes com síndrome de Sjögren que 
apresentam a lesão histológica típica desta doença (designada sialadenite focal) dos doentes 
que não apresentam este achado histológico. Desta forma foi possível estabelecer, pela 
primeira vez, uma relação entre a população de células Tfr do sangue e a ocorrência de 
fenómenos imunológicos patológicos nos órgão-alvo de doenças autoimunes. Como se 
identificaram in situ células CXCR5+Foxp3+ nas lesões de sialadenite focal foi possível 
concluir que não existe exclusão anatómica destas células das estruturas linfoides ectópicas. 
estes locais. Por isso, integrando o conhecimento obtido quando se investigaram as células 
Tfr em respostas humorais fisiológicas, é possível que a perpetuação dos centros 
germinativos (um fenómeno reconhecido na autoimunidade) com respostas humorais 
persistentes e crónicas esteja na base do aumento destas células no sangue. Do ponto de vista 
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clínico, os resultados deste trabalho apontam para a utilização do rácio Tfr/Tfh do sangue 
humanos para identificar os doentes com síndrome de Sjögren que apresentam sialadenite 
focal – um fator prognóstico desta doença – sem recorrer à realização da biopsia.  
 
As doenças autoimunes cuja patogénese está relacionada com a perda de tolerância nos 
centros germinativos continuam a ser um desafio clinico e terapêutico. O desenvolvimento 
de fármacos capazes de modular a resposta células Tfr pode constituir uma nova abordagem 
terapêutica para estas doenças autoimunes. O presente trabalho definiu o ontogenia e a 
biologia das células Tfr do sangue humano, permitindo, no futuro, que possam ser tentadas 
estratégias terapêuticas para modular estas respostas. Por outro lado, a utilização de um 
parâmetro não invasivo, que integra a informação sobre a frequência destas células no 
sangue humano – o rácio Tfr/Tfh – ao estratificar os doentes com SS que apresentam 
interações celular patológicas entre linfócitos T e linfócitos B nos órgãos-alvo da doença, 
pode ser útil na seleção dos melhores candidatos para as novas terapêuticas que se tem 
desenvolvido para modular estas interações celulares. 
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1. The Immune System 
 
Some of the greatest discoveries in life sciences and medicine arose from ethically 
questionable experiments. Edward Jenner launched Modern Immunology in such a way. He 
injected the material from a cowpox pustule into the arm of an 8-year-old boy. When this 
boy was later intentionally inoculated with smallpox, the disease did not develop. Janner’s 
landmark treatise on vaccination was published in 1798 and led to the widespread acceptance 
of this method for inducing immunity to infectious diseases. 
 
The immune system is historically regarded as the cells and molecules responding in a 
coordinated way to defend our body against invading threats. Cellular and biochemical 
defence mechanisms poised to respond rapidly and universally to invaders constitute the first 
line of defence, called Innate Immunity. Evolving during exposure to pathogens, the 
Adaptive Immunity, is characterized by the exquisitely ability to distinguish different 
substances (specificity), and to respond more vigorously to repeated exposures to the same 
pathogen (memory). Albeit immune responses were classically divided into two strands, the 
fundamental unity of immune responses is now widely recognized. 
 
The cornerstones of the adaptive immune system are two broad sets of antigen-responsive 
cells: B and T lymphocytes. B lymphocytes are responsible for antibody production, using 
antibody in a membrane protein form as their antigen-binding receptors. Antibodies are 
capable of neutralizing pathogens (Humoral Immunity). By contrast, T cell receptors 
recognize a complex consisting of an antigen-derived peptide bound into a specialized 
groove in class I or class II major histocompatibility complex (MHC) molecules. As such, T 
cell recognition of antigen occurs on the surface of cells expressing these peptide/MHC 
complexes (Cell-mediated Immunity). 
 
To fulfil the complexity of immune responses lymphoid tissues have evolutionally 
differentiated into highly organized structures, broadly classified as into primary and 
secondary lymphoid organs. Primary lymphoid organs comprise bone marrow and the 
thymus and are primarily responsible for the development of B and T lymphocytes. 
Secondary lymphoid organs (lymph nodes, spleen, and mucosal-associated lymphoid 
tissues) are critical for mounting high-affinity adaptive immune responses upon antigenic 
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challenge.  
 
Lymphocytes are derived from pluripotent hematopoietic stem cells (HSC) present in the 
foetal liver and bone marrow. Common lymphoid progenitor derived from HSC give rise to 
lymphocytes committed to T cell lineage, under Notch-1 and GATA3 transcription factors, 
or to lymphocytes committed to B cell lineage, under EBF, E2A and Pax-5 transcription 
factors1,2. While B cell-committed lymphocyte precursors mature in the bone marrow (B-1 
cells derived from foetal liver HSC and B-2 cells from bone marrow HSC), T cell-committed 
lymphocyte precursors circulate to the thymus, where they complete their maturation (γδ T 
cells from foetal liver HSC and αβ T cells from bone marrow HSC). Development of mature 
B and T cells is a complex process that contains numerous intrinsic steps at which the 
developing cells are tested and continue to mature only if a preceding step has been 
successfully completed. The rearrangement of antigen receptor genes (BCR in B cells and 
TCR in T cells), by V(D)J recombination3, is the key event for maturation, as the correct 
rearrangement is essential for survival signals delivered to developing lymphocytes. 
 
To mount high-affinity immune responses, B cells interact with T cells in the outer T cell 
zones of secondary lymphoid organs and differentiate along either the follicular or 
extrafollicular pathway. In the follicular pathway, activated B cells form germinal centres 
(GC) and exit these specialized structures as long-lived antibody-producing plasma cells or 
memory B cells that can respond and re-diversify to secondary challenges. In the 
extrafollicular pathway, B cells migrate to splenic bridging channels or junction zones and 
the borders between T cell zones and the red pulp, forming clusters of short-lived 
plasmablasts. The mechanisms responsible for this fate decision remain poorly defined, 
although various studies suggest that BCR affinity for the foreign antigen, the amount of 
antigen-receptor engagement, and costimulatory signals received from T cells might all be 
involved4–8. 
 
GCs are transient and specialized structures that form within secondary lymphoid tissues 
following follicular B cell differentiation. The GC was first described by Walther Flemming 
in 1884 as one of the major sources of lymphocytes throughout the body9. Although, his 
assumption proved to be wrong, GCs were found to be specialized structures where B cells 
expressing high-affinity antibodies develop and differentiate into antibody-secreting plasma 
cells and memory B cells under the critical help of T cells (T cell-dependent antibody 
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responses)4,10,11. Indeed, within GCs, B cells proliferate at a rate that is unparalleled in 
mammalian tissues and their immunoglobulin variable region genes are diversified by 
somatic hypermutation. This process results in the generation of mutant clones that have a 
broad range of affinity for the immunizing antigen. Throughout these processes of clonal 
proliferation, somatic hypermutation and selection, the affinity of B cell clones increases, in 
a phenomenon known as affinity maturation6,12,13. Although, GCs may not be an absolute 
requirement for affinity maturation, the selective advantage conferred by these specialized 
structures might be as an adaptation that supports a complex mechanism of cellular 
amplification and selection in response to antigens, while simultaneously limits the 
consequent risk of autoreactivity14. 
 
In 1968 a trio of publications by Miller and Mitchell described that GC B cell selection and 
antibody responses required matching thymus-derived T cell responses. Using cell transfer 
experiments, they showed that the co-transfer of both T and B cells to irradiated mice was 
absolutely necessary for robust antibody responses after immunization of mice with sheep 
red blood cells (SRBC)10.  
 
While the specialized formation of GC and T – B cell crosstalk are critical to provide 
protection against a broad range of invading pathogens, the stochastic nature of somatic 
hypermutation makes the generation of self-reactive B cell clones an almost certain by-
product of routine GC responses to foreign antigens15. Failure of the immune system to 
enforce tolerance readily leads to the development of autoimmune disease and allergies. 
Therefore, the chief challenge of the immune system is to provide robust protection against 
pathogens while ensuring tolerance to self-antigens and innocuous non-self-antigens.  
 
 
2. T Cell Mediated Humoral Immunity 
 
2.1. Thymic T Cell Development 
 
Development of T cells consists of several processes that require the dynamic relocation of 
developing lymphocytes into, within and out of multiple thymic environments, as well as an 
intricate crosstalk between T-cell committed lymphocytes, or thymocytes, and thymic 
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stromal cells16,17. Thymus seeding by lymphoid progenitor cells starts by the eight week of 
human gestation, initially by CCL21 and CCL25-mediated chemotactic attraction18,19, and 
then through PSGL-1 and P-selectin20. Lymphoid progenitor cells begin their maturation as 
CD4-CD8- double negative (DN) thymocytes. The cells that succeed in generating in-frame 
TCRβ rearrangement will assemble the pre-TCR complex, formed by TCRβ, pre-TCRα, 
CD3 and ζ proteins. The pre-TCR complex mediates the selection of developing DN 
thymocytes that productively rearranged β chain of the TCR. Along with the Delta-Notch 
interaction and signals delivered by IL-721,22, the successful expression of the pre-TCR, 
initiates recombination at the α chain of the TCR, and the signals for further transition to the 
CD4+CD8+ double positive (DP) stage.  
 
DP thymocytes that are newly generated in the thymic cortex contain the unselected 
repertoire of T cells. DP thymocytes interact through their TCR with self-peptide-MHC 
complexes expressed by stromal cells (cTEC and dendritic cells). Following TCR 
recognition of peptide-MHC ligands at low avidity interactions, DP thymocytes are induced 
to receive signals for survival and further differentiation into single positive (SP) 
thymocytes. This process, called positive selection, enriches for “useful” T cells17. By 
contrast, high avidity interactions elicit signals that lead to deletion of thymocytes, by 
apoptosis, in a process called negative selection17. This process contributes to elimination of 
self-reactive T cells, thereby decreasing autoimmunity potential. Positively selected DP 
thymocytes are induced to differentiate into SP CD4+CD8- (if TCR recognizes MHC class 
II molecules) or CD4-CD8+ (if TCR recognizes MHC class I molecules) thymocytes and 
relocate to the thymic medulla, throught CCR7-mediated chemotaxis towards medullary 
CCL19 and CCL21 gradients. The environmental cues, cellular signals and transcription 
factors involved in CD4/CD8-lineage choice are still being elucidated. The “kinetic 
signalling model” proposes that TCR-signalled DP thymocytes first terminate CD8 gene 
transcription and assess the effect of absent CD8 gene transcription on TCR signalling. If 
TCR-mediated positive selection signals persist in the absence of CD8 gene transcription 
(MHC class II signalling), thymocytes differentiate into CD4+ T cells. If TCR-mediated 
positive selection signalling ceases in the absence of CD8 transcription (MHC class I 
signalling), thymocytes differentiate into CD8+ T cells. Thus, the CD4/CD8-lineage choice 
is not a stochastic phenomenon, but a tightly regulated process by multiple clues, including 
IL-7 signalling and the orchestrated transcriptional activities of Th-POK, RUNX3, TOX and 
GATA323.  
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The final stage of thymocyte maturation is accompanied by further deletion of self-reactive 
thymocytes that have escaped negative selection in the cortex. Such additional deletion in 
the medulla seems to be particularly important in establishing central tolerance to tissue-
specific antigens. This process is mediated by autoimmune regulator (AIRE)-dependent 
expression of tissue specific antigens by mTEC24–26. Central tolerance is also ensured by 
production of Foxp3-expressing regulatory T (Treg) cells in thymic medulla27,28. 
 
Mature naïve CD4+ T cells and CD8+ T cells egress from the thymus and circulate towards 
secondary lymphoid organs. After activation, effector CD4+ T cells (Th cells) are mainly 
responsible for recruiting effector innate cells and for providing help to B cells leading to 
autoantibody production29. On the other hand, CD8+ T cells (CTL cells) are mainly 
responsible for killing host-infected cells, through cytotoxic mechanisms30. 
 
2.2. CD4+ T Cell Diversity 
 
CD4+ T cells constitute a highly heterogenous population of thymic derived lymphocytes. 
Besides cytokine-producing effector T-helper (Th) cells derived from naïve CD4+ T cells, 
CD4+ T cells also comprise thymic derived (or naturally occurring) Foxp3-expressing Treg 
cells.   
 
The process of forming effector CD4+ T cells begins when the TCR on naïve CD4+ T cells 
recognises peptide-MHCII complexes on dendritic cells (DCs) in secondary lymphoid 
organs. Signals through TCR and antigen-presenting cell-derived costimulatory molecules 
(namely, CD80/CD86) trigger the naïve cells to divide and became effector cells, as 
postulated by Burnet’s clonal selection theory31,32. Depending on the nature of cytokines 
produced by the innate immune system, inexperienced CD4+ T cells undergo a 
differentiation process toward distinct Th lineages able to tailor their responses to the 
character of the threat encountered29. The initial insights for such diversity came from studies 
examining antigen-specific T cell clones from immunized mice33,34. It was postulated that 
Th1 cells orchestrated a phagocytic and intracellular defence, and Th2 cells orchestrated a 
nonphagocytic and extracellular defence. This binary division of labour was proved to be 
wrong after the discovery of Th17 cells35,36.  
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Briefly, INF-γ and IL-12 secretion by DCs promote Th1 program in naïve T cells by inducing 
the expression of T-bet through STAT4 signaling29,37–40. On the other hand, IL-4 secretion 
by DCs induces GATA3 expression through STAT6 signalling on naïve T cells29,40–44. These 
Th2 cells will became specialized producers of IL-4, IL-5 and IL-13. IL-17-producing Th17 
fate is instructed by upregulation of RORγT, by TGF-β, IL-6, IL-23 and IL-21 signalling 
(through STAT3)29,40,45–48. Although this paradigm was a useful construct for understanding 
cell-mediated immunity, flexibility and plasticity of CD4+ T cells is now widely accepted40. 
 
More recently, a CD4+ T cell subset specialized in B cell-helping functions was identified. 
These cells upregulate Bcl-6 (through STAT3 signalling) becoming IL-21-producing Tfh 
cells.  
 
2.3. T Follicular Helper Cells 
 
A CD4+ T cell subset specialized in B cell help was first proposed at the turn of the 
millenium49–51. Schaerli, Breitfeld and Kim described a subset of CXCR5-expressing T cells 
in human tonsils co-localized with mantle and light-zone B cells. Using in vitro assays, they 
showed that CXCR5+CD4+ T cells selectively migrated toward a CXCL13/BCA-1 gradient, 
secreted IL-4 and IL-10 (but not other Th1/Th2 cytokines) and specifically promoted IgA 
and IgG production by B cells. These T helper cells were highly prone to apoptosis as almost 
all cells expressed Fas/CD9549. The impact of CXCR5+CD4+ T cells in IgM production was 
more controversial in these pioneering studies, as only two studies demonstrated a significant 
increase in IgM secretion by B cells co-cultured with CXCR5+CD4+ T cells compared to 
CXCR5-CD4+ T cells49,50. Additionally, a subset of CXCR5-exppressing CD4+ T cells was 
identified in peripheral blood with the capacity to proliferate in response to allogenic 
macrophages, but these blood cells did not prove to be specialized in B cell help as compared 
to blood CXCR5-CD4+ T cells. Conversely, in light of more recent and robust evidence, 
blood CXCR5+CD4+ T cells were also found to be capable of providing help to B cells (see 
below)52–56.  
 
Subsequent studies showed that GC T cells in human tonsils highly expressed Bcl-6, 
providing the first clue of a lineage defining transcription factor57. In fact, the existence of 
Tfh cells was only widely accepted after BCL-6 was identified as a lineage-defining 
transcription factor of Tfh cells58–60. A range of experiments – including the use of Bcl6-/- 
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CD4+ T cells, constitutive expression of BCL-6 in antigen-specific CD4+ T cells, and 
manipulation of the expression of Blimp-1 (a potent antagonist of Bcl-6) – showed that the 
expression of Bcl-6 by CD4+ T cells is necessary and sufficient for Tfh cell differentiation 
and that Tfh cells are the unique providers of T cell help to B cell for the generation of most 
high affinity class-switched antibodies. Moreover, Bcl-6 expression was found to be induced 
by IL-6 and IL-21 and to drive Tfh cell differentiation, as it promotes upregulation of 
CXCR5, ICOS and PD-159–61. Notably, Bcl-6 is not only required for the multifaceted Tfh 
cell biology, but also to repress alternative Th1, Th2 and Th17 cell fates60,62. 
 
Following the identification of Bcl-6, the study of Tfh cells has markedly increased. Stages 
of Tfh cell differentiation, inductive signals, migration patterns, Tfh cell memory and 
plasticity, and Tfh cell function have been extensively studied63.  
 
Antigen presentation by MHCII-expressing cells is absolutely required for priming naïve 
CD4+ T cells and initiating Th subset differentiation. Likewise, Tfh cells require antigen 
presentation by DCs for their differentiation64. DCs induce Tfh cell differentiation through 
antigen presentation, co-stimulation through CD80/86:CD28, ICOSL:ICOS, and 
OX40L:OX40 signalling, and by generating a favourable cytokine milieu. Compared to Th1, 
Th2, and Th17 cells, the differentiation of Tfh cells requires persistent TCR stimulation64,65. 
Moreover, TCR dwell time on peptide:MHCII complex may also instruct the fate of naïve T 
cells, as naïve T cells with longer TCR-peptide:MHCII dwell time preferentially 
differentiate into Tfh cells66,67. CD28 and ICOS signalling are both critical checkpoints 
during Tfh cell differentiation68–72. The unique dependence of Tfh cells on ICOS co-
stimulation is thought to be mediated through PI3K signalling. Activation of PI3K-Akt 
pathway by ICOS engagement phosphorylates Foxo1 and leads to its nuclear exportation 
and degradation. Foxo1 inactivation removes its repression of Bcl-6 expression, and its 
activation of KLF2 expression, thus promoting Tfh cell formation70,73,74. Additionally, these 
co-stimulatory molecules are also important for Tfh cell maintenance69,74. Besides CD28 and 
ICOS, OX40 was also shown to amplify Tfh cell development and GC responses, by 
cooperating with ICOS75,76. A suitable cytokine microenvironment is also essential for Tfh 
cell differentiation. IL-6 secreted by DCs potentiates Tfh cell lineage commitment and 
differentiation through STAT1 and STAT3 pathways, although other factors, such as high 
IL-21 and low  IL-2, are also required77–80. While, IL-21 have a redundant action with IL-6, 
the former was shown to contribute to an autocrine regulation of Tfh cell formation61,81,82. 
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Among all cytokines which orchestrate GC responses, IL-2 has been regarded as one key 
regulator of T cell progenies upon DC priming. Indeed, low IL-2 concentration is required 
to maintain Bcl-6-dependent transcriptional program in developing Tfh cell and to allow GC 
formation, as IL-2 suppress Bcl-6 and induce Blimp-1 (via STAT5 activation)83–86. Thus, 
Tfh cell development may not rely so much on a particular set of instructions from DCs. 
Instead, their development may depend more on a chance escape from a IL-2 enriched 
environment that favours terminal Th effector cell differentiation combined with a chance 
encounter with B-cell follicle environment83. Interestingly, some activated DCs were found 
to be able to quench T-cell-derived IL-2 by producing membrane bound and soluble CD25 
(the high affinity Il-2 receptor), thus favouring Tfh cell differentiation87. 
 
Although, DC role in Tfh cell differentiation is unquestionable, DC priming alone is not 
sufficient to induce fully competent Tfh cells. Indeed, developing Tfh cells require 
sequential antigen presentation and cell-to-cell interactions with cognate B cells at the T-B 
border64,88. Following the initial DC priming, developing Tfh cells migrate to the T-B border 
and form cognate T-B cell conjugates. These conjugates are stabilized by homotypic 
interactions between the SLAM family members CD84 and Ly108, which thereafter signal 
via SAP89,90. In the absence of SAP, or antigen-presenting cognate B cells, GC Tfh cells do 
not form, demonstrating the absolute requirement for cognate T-B interactions in full 
development of Tfh cells63,89,90. At this stage of the immune response, activated B cells act 
as the dominant antigen presenting cell (APC) further supporting Tfh cell development 
through CD80/CD86, ICOSL, and CD40 co-stimulatory signals61,64,69,91,92. Recently, 
Watanabe and colleagues found that while CD80/CD86 was required on DCs, CD40 was 
required on B cells for the generation of antigen-specific Tfh cells92. Additionally, bystander 
B cells may act independently of cognate interactions, by providing ICOSL to developing 
Tfh cells, thereby promoting their migration toward the B cell follicle72. 
 
All these biological processes shape the transcriptional profile of a naïve T cell toward a 
distinctive Tfh cell gene profile. In several murine studies it was established that Bcl-6, c-
Maf, BATF, IRF4, STAT1, STAT3, STAT4, Notch1, Notch2, Ascl2, TCF-1, and LEF-1 
positively influence Tfh cell program; while Foxo1, Foxp1, Blimp1, KLF2, negatively 
influence Tfh cell program58–61,63,73,74,79,86,93–103. This molecular machinery is responsible for 
the acquisition of specific migration capacity toward B cell follicles on secondary lymphoid 
tissues and of specialized effector functions by developing Tfh cells. Ascl2 and Bcl-6 (via 
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Blimp-1 repression) induce CXCR5 upregulation which, along with downregulation of 
CCR7 directly by Bcl-6, promotes Tfh cell migration toward CXCL13-abundant 
follicles62,98,104,105. As described above, Tfh cells get access to GC light zone after previous 
interactions with cognate B cells at the T-B border. Within GCs the provision of help from 
Tfh cells to GC B cells comes in the form of CD40 ligation and cytokine signals, namely IL-
2163. Interaction with CD40L is required for maintenance of established GC responses, 
continued survival of GC B cells, and formation of high-affinity bone marrow plasma 
cells106–110. Tfh cell-derived IL-21, by maintaining Bcl-6 expression, in GC B cells, controls 
the maintenance and optimal affinity maturation of the GC response111,112. Besides IL-21, 
Tfh cells can shape their cytokine secretion accordingly with the stimulus that induced the 
GC reaction. Tfh cells were found to secrete IL-4 in type 2 induced responses and IFN-γ in 
type 1 induced responses, thereby modulating class switch of B cells toward IgG1 and 
IgG2a, respectively113–115. It is still debatable whether Tfh cells modulates class switch 
recombination taking advantage of cytokines produced by Th cells outside the GC or two 
distinct IFN-γ-producing and IL-4-producing Tfh cells directly modulate class switch 
recombination in type 1 and type 2 immune responses, respectively. Our group is currently 
approaching this important question using RNA-Seq data generated from sorted TCR-
specific Tfh cells differentiated under type 1 and type 2 conditions.   
 
2.3.1. Circulating Tfh Cells and Human-Specific Tfh Cell Features 
 
Tfh cell discovery remarkably uncovered the biology of CXCR5+CD4+ T cells in human 
blood, known since 1994116. Several independent observations have recently established that 
Tfh-committed cells can egress from lymph nodes comprising a memory compartment of 
Tfh lineage cells52–56. The concept that blood CXCR5+CD4+ T cells are generated from cells 
committed to Tfh fate is based on two main lines of evidence.  
 
First, blood CXCR5+CD4+ T cells were shown to selectively promote in vitro activation and 
class switch recombination of B cells53–56. Chevalier and colleagues found that CXCR5+ T 
cells sorted from human blood were more efficient at providing B cell help (compared to 
CXCR5- T cells), as a higher proportion of activated B cells, as well as higher supernatant 
IgA and IgG concentrations, were found in co-cultures upon superantigen stimulation53. 
CXCR5+ T cells provided help to B cells in a ICOS and IL-10-dependent manner, as the use 
of ICOS and IL-10 blocking antibodies abrogated the secretion of IgA and IgM by activated 
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B cells53. In those experimental conditions, CXCR5+ T cells secreted high amounts of IL-
17, IL-10, and IL-2153,82,111,112. Moreover, CXCR5+ T cells were found to upregulate Bcl-6 
and c-Maf upon in a greater extended than in CXCR5- T cells upon in vitro stimulation53. In 
another report, Morita and colleagues clearly showed human blood CXCR5+ T cells were 
necessary and sufficient to induce activation-induced cytidine deaminase (AID) 
upregulation and Ig secretion by B cells, which survive and upregulate activation markers 
(such as CD38) upon in vitro stimulation with superantigens and CXCR5+ T cells, but not 
with CXCR5- T cells54. They further validated that human blood CXCR5+ T cells produce 
IL-21 and IL-10 upon superantigen stimulation54. Furthermore,  IgA and IgM titres in co-
culture supernatants markedly decreased when IL-21-blocking antibodies were used54. The 
use of superantigens (such as SEA, SEB, SEE and TSST-1) greatly improved the 
experimental design to study T-B interactions, as superantigens promote cognate 
interactions more similar to physiological cell interaction in vivo52. The second evidence 
relies on studies with blood samples from primary immunodeficient patients with severely 
impaired GC formation due to deficiency of IL-10R, CD40L, NEMO, BTK, ICOS, IL-12R, 
STAT3 loss of function; presenting also a profound and selective reduction of blood 
CXCR5+CD4+ T cells71,117–119. 
 
Although, this compelling evidence suggests human blood CXCR5+ T cells are counterparts 
of bona fide GC Tfh cells, there are many differences between these two cell populations. 
Whereas, the vast majority of blood Tfh cells express CD45RO, CD62L and CCR7, tissue 
Tfh cells downregulate CCR7 to gain access to GC, as described above49–51,105. In great 
contrast to GC Tfh cells, most blood Tfh cells are in a quiescent state and lack the expression 
of Bcl-6, PD-1 and ICOS, suggesting that Bcl-6-dependent transcriptional program is 
dispensable for the maintenance of blood memory Tfh cells52,54,56,120. Hence, human blood 
Tfh cells express elevated levels of c-Maf, suggesting that while Bcl-6 is required for Tfh 
cell differentiation, c-Maf is required for the maintenance of Tfh cell phenotype and/or 
function53,55,121. 
 
Human Blood Tfh Cell Diversity 
Extensive analysis of human blood Tfh cells have further revealed phenotypic and 
functionally distinct subsets (Table 1). 
 
As described above, more than 70% of human blood CXCR5+CD45RO+ Tfh cells are Ki-
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67- quiescent cells which lack expression of ICOS and PD-1, while expressing CCR752,55,56. 
He and colleagues reported that blood Tfh cells are heterogeneous and are composed of 
CCR7+PD-1- and CCR7-PD-1+ subsets. These two subsets showed distinct kinetics 
following seasonal influenza vaccination, as only CCR7-PD-1+ Tfh cells increased upon 
vaccination56. By comparing these results with mice transferred with congenic marked 
Ovalbumin (OVA)-specific OT-II cells and then immunized with OVA in alum, He and 
colleagues proposed that CCR7-PD-1+ Tfh cells reflect tissue Tfh cell responses56. 
Additionally, they demonstrated that CXCR5+CCR7- Tfh cells sorted from human blood 
were more efficient in supporting plasma cell differentiation and IgG production, compared 
to CXCR5+CCR7+ Tfh cells, upon in vitro TCR stimulation56. Using a different experimental 
design, Morita and colleagues demonstrated that human blood CXCR5+ Tfh cells were 
composed of three subsets according to expression of CXCR3 and CCR6 chemokine 
receptors54. The T-bet+CXCR3+CCR6- Tfh1, GATA-3+CXCR3-CCR6- Tfh2, and 
RORγt+CXCR3-CCR6+ Tfh17-like cells were proved functionally distinct54. Whereas Tfh1, 
Tfh2 and Tfh17-like cells were able to secrete the defining cytokines of their Th 
counterparts, namely IFN-γ (Tfh1), IL-4, IL-5 and IL-13 (Tfh2), and IL-17 and IL-22 
(Tfh17), only Tfh2 and Tfh17-like cells produced IL-21, induced activation of naïve B cells, 
and supported class switch recombination upon in vitro stimulation with superantigens54. 
This was further confirmed in GC Tfh cells from human tonsils in which T-bet was found to 
diminish the Tfh cell program required to provide help to B cells122. Taking advantage of 
these findings, Locci and colleagues used gene expression microarrays to demonstrate that 
PD-1+CXCR3- Tfh cells were the blood Tfh cell subset which most closely resemble GC Tfh 
cells (sorted from human tonsils)55. Using in vitro co-cultures under the presence of 
superantigens, PD-1+CXCR3- Tfh cells displayed the strongest capacity to induce IgG and 
IgM secretion by memory B cells55. 
 
The clinical relevance of blood Tfh cell subsets is supported by vaccination studies. 
Following seasonal influenza vaccination, the emergence of blood ICOS+CXCR3+ Tfh cells 
correlated with the development of protective antibodies120,123. Thus, Tfh cell subsets could 
serve as potential biomarkers for monitoring antibody responses in vaccination and 
infectious diseases. However, it is somehow unexpected that Bentebibel and colleagues 
correlated blood CXCR3+ Tfh cells with humoral responses. Indeed, CXCR3-expressing Tfh 
cells were previously shown to be non-efficient helpers54,55,122.  The help activity of blood 
ICOS+CXCR3+ Tfh cells was limited to memory B cells (and not to naïve B cells) upon in 
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vitro stimulation with superantigens120. Therefore, it is likely that ICOS+CXCR3+ Tfh cells 
specifically evoke memory humoral responses which bypass de novo GC reactions. 
 
Table 1: Human blood Tfh cell subsets 
Adapted from Schmitt at al52 
 
Follicular (activation) markers 
ICOS 
PD-1 
ICOS+ 
PD-1+ 
 
   
C
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CXCR3+ 
CCR6 
Quiescent 
Tfh1 
Activated 
Tfh1 
   
CXCR3 
CCR6 
Quiescent  
Tfh2 
Activated 
Tfh2 
   
CXCR3 
CCR6+ 
Quiescent 
Tfh17 
Activated 
Tfh17 
 
Distinctive Features of Human Tfh Cells 
Although, several studies have established that Tfh cells from humans and mice are similar 
at the transcription level, a parallel body of work implies a largely different group of 
cytokines in human Tfh cell differentiation62,117,121,124–128. Schmitt and colleagues 
systematically analysed the upregulation of Tfh-signature molecules by sorted naïve CD4+ 
T cells from human blood cultured in the presence of several combinations of cytokines plus 
anti-CD3/CD28 stimulation126. TGF-β plus IL-12 or TGF-β plus IL-23 induced upregulation 
of CXCR5, ICOS, Bcl-6, and downregulation of Blimp-1. These cytokine combinations also 
increased the proportion of IL-21-expressing T cells in the end of culture and efficiently 
enabled those T cells to provide help to memory B cells, measured by IgG concentration in 
culture supernatants126. These findings suggest that TGF-β co-opts redundant signalling via 
STAT3/STAT4 (induced by IL-12 and IL-23) to promote Tfh cell differentiation in humans. 
While, preformed in artificial systems, the reduced Tfh cell and GC responses observed in 
patients lacking functional IL-12Rβ1, the receptor for IL-12 and IL-23, corroborates the IL-
12 requirement for human Tfh cell differentiation in physiological conditions117.  
 
 
3. Regulation of Humoral Responses 
 
To ensure clonal selection of high affinity B cell clones, GC reaction is tightly regulated by 
complex molecular signals at multiple stages.  
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3.1. Germinal Centre Reaction and Cell Dynamics 
 
Following immunization, IgD+ naïve B cells are activated and move to the outer follicular 
zone of secondary lymphoid organs. Here, they present antigenic peptides on MHCII to 
specialized subsets of separately-activated CD4+ T helper cells5,129. The antigen-activated B 
cells harbouring the highest BCR affinity for the immunizing antigen eventually gain access 
to the follicle centre and populate the specialized follicular dendritic cell (FDC) 
network5,6,130. After these initial steps of GC reaction, two main compartments become 
evident: the dark and light zones, as initially proposed by Röhlich in 1930. The dark zone is 
formed by densely packed B cells (classically called centroblasts) undergoing rapid 
proliferation and somatic hypermutation. This Darwinian process results in the generation 
of B cell clones (classically termed centrocytes) expressing surface antibodies with a wide 
range of affinities for the immunizing antigen. These cells then travel to the light zone where 
they compete for binding to immune complexes presented by highly ordered surface units 
of FDC (termed iccosomes), and for survival and differentiation signals provided by T helper 
cells4,63,131–135. During the course of cognate T-B cell interaction in the light zone, a subset 
of B cells additionally undergo activation-induced cytidine deaminase (AID)-mediated class 
switch recombination136,137. A great work by Victora and colleagues confirmed that T cell 
help, and not direct competition for antigen is the limiting factor for B cell selection within 
GCs135,138. Therefore, it seems that within the context of the GC , the role of the BCR is 
primarily to capture and internalize antigen rather than to induce BCR signalling6,135. 
Ultimately, high-affinity GC B cell clones differentiate into plasmablasts and memory B 
cells after repeated rounds of expansion, diversification and selection. This cyclic re-entry 
sustains the population of cells that proliferate within the dark zone and maintains the GC 
reaction over time5,6,136. Although, the precise mechanisms driving the fate decision of GC 
B cells are still being elucidated, Tfh cell help was found to favour plasma cell differentiation 
(and not memory B cell differentiation) in a CD40L-dependent manner108–110,139,140. 
 
The dark and light zones of the GC are organized by expression of CXCR4 and CXCR5, 
respectively. These chemokine receptors on B cells are required to guide B cell migration 
toward CXCL12-enriched dark zone (populated by CXCR4hi B cells) and CXCL13-enriched 
light zone (populated by CXCR4lo B cells)131,135. These phenotypic states are the result of a 
timed B cell-intrinsic program: Bcl-6 is required for the establishment of the specialized dark 
zone-associated gene expression programme that allows somatic hypermutation, MYC and 
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REL are required for recirculation between dark and light zones, and IRF4 is required for 
class switch recombination and plasma cell differentiation in the light zone5,6,136,141. 
Recently, McHeyzer-Williams and colleagues proposed that CD83 (required for cognate T-
B interaction in the light zone) and POLH (which encodes the DNA polymerase required for 
somatic hypermutation in the dark zone) expression defines four sequential and cyclic GC 
B cell-stages5,142.  Overall, like Ian MacLennan proposed in 1994, GC is functionally 
polarized into a dark zone in which B cells divide and a light zone in which B cells are 
activated and selected based on their affinity for antigen (via Tfh cells). Rather than 
differentiating linearly from centroblast to centrocytes and then to plasma or memory B cells, 
GC B cells are constantly shifting between two closely related but functionally distinct 
states, which are associated with positioning in either dark or light zones132,139. 
 
Throughout this process, BCR signalling, FDC and Tfh cells derived signals, as well as 
antigen immunogenicity, availability and clearance all contribute to maintain GC tolerance 
(Table 2). However, an additional regulatory cell mechanism is required to ensure systemic 
tolerance and to control humoral responses.  
 
Table 2: Mechanisms that control germinal centre B cells responses 
Adapted from Vinuesa at al143 
 Control of quality Control of quantity 
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 Positive selection: BCR signals (TC21, 
PI3K, CD45 and SPIB), B cell – FDC 
synapse (DOCK8 and ICAM1) and Tfh 
cell derived signals (CD40L and IL-21) 
 Negative selection: Tfh cell signals 
(CD95L) 
 Development and proliferation: IRF8 
and PU.1, Bcl-6, IL-21R, TLRs, and 
Myd88 
 Pro-apoptotic programme: high AID, 
CD95 and BIM, and low Bcl-2 and Bcl-
XL 
   
A
n
ti
g
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 Immunogenicity and availability: post-
translational modification, structural 
features, development isoforms and 
abundant TLR ligands exposed on 
apoptotic cells. 
 Genetic differences in expression: HLA 
and antigen gene variants 
 Disposol of apoptotic cells by tangible 
body macrophages: MFGE8, DNaseI, 
MER and C1q 
 
3.2. Regulatory T Cells 
 
Negative selection in the thymus leads to elimination or inactivation of self-reactive T 
cells17. In the periphery, the requirement of simultaneous engagement of TCRs by a cognate 
peptide-MHC complex and the T cell costimulatory receptor CD28 by CD80/CD86 
reinforces self-tolerance144. However, these tolerance mechanisms appear insufficient to 
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counter the threat of immune-mediated pathology without a specialized subset of T cells 
acting to restrain immune responses towards self. 
 
The existence of thymic generated T cells involved in immune tolerance were first revealed 
in neonatal thymectomy mice studies performed by Nishizuba, back in 1969145. This 
specialized subset of T cells (Treg cells) engaged with suppressive functions was later found 
to constitutively express IL-2 receptor α-chain (CD25)146. However, a seminal advance in 
the understanting of tolerance induced by Treg cells came with the identification of and the 
X-linked transcription factor forkhead box P3 (Foxp3) by Hori and colleagues in 2002147–
149. Fontenot and colleagues generated mixed bone marrow chimeras by reconstituting 
lethally irradiated mice with T cell-depleted bone marrow mixed at 1:1 ratio with bone 
marrow from either Foxp3-sufficient and -deficient mice. Treg cells were generated only 
from Foxp3-sufficient precursors, clearly demonstrating the requirement of Foxp3 for the 
development of Treg cells148. Foxp3 is not only an absolute requirement for thymic 
differentiation of Tregs, but also for their suppressive function, as retroviral transfer of 
Foxp3 gene into CD25-CD4+ T cells confers suppressive properties and Cre-mediated 
ablation of conditional Foxp3 allele in Treg cells results in a loss of suppressive 
function148,150. Subsequent studies have also identified similar Foxp3-expressing Treg cells 
in human blood and lymphoid tissues151. 
 
The importance of Treg cells on the control of antibody responses has been long known152–
155.  Indeed, mice and humans with loss-of-function mutation in the Foxp3 gene suffer from 
a fatal, early-onset, T cell-dependent, lymphoproliferative, immune-mediated disorder 
manifested by autoantibody-mediated autoimmunity (diabetes, thyroiditis, haemolytic 
anaemia) and increased levels of circulating GC-produced antibodies, namely IgG and IgE, 
called immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) 
in humans and scurfy condition in mice156–160. Moreover, chronic ablation of Treg cells in 
adult healthy Foxp3DTR mice caused a scurfy-like disease, which can be rescued by adoptive 
cell transfer of Treg cells148,161.  
 
Further studies elucidated the mechanisms of humoral suppression by Treg cells. Lim and 
colleagues have established the existence of a CD69- human tonsil Treg cell subset with B 
cell suppressive function162,163. Upon activation, this subset upregulated CXCR5, acquiring 
the capacity to migrate towards CXCL13-enriched GC. In their in vitro assays, Lim and 
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colleagues demonstrated that these cells suppressed class-switch recombination by B cells, 
as they inhibited immunoglobulin production and AID expression. Direct killing of B-cells 
by mice pre-activated (by anti-CD3 TCR stimulation) CD4+CD25+ T cells was also 
demonstrated164. This effect was mediated by a granzyme B-dependent, partially perforin-
dependent, apoptotic pathway. Interestingly, antigen-pulsed B cells were more susceptible 
to death, suggesting a non-random regulatory mechanism164. These findings were further 
confirmed in a Systemic Lupus Erythematosus (SLE) mousee model and in SLE patients. 
Treg cells sorted from SLE patients inhibited the secretion of IgG by inducing B cell 
apoptosis, under the presence of CD40L, IL-4, and IL-10165. 
 
In addition to thymic derived Treg (tTreg) cells, many studies have identified Foxp3-
expressing Treg cells induced from naïve CD4+ T cells in peripheral tissues, called 
peripherally-derived Treg (pTreg) cells. While the mechanisms and complexity of pTreg 
cells are still not fully understood pTreg cells are generated following specific (non-self) 
antigen stimulation in particular environments and under the presence of TGF-β and IL-228. 
Additionally to Foxp3-expressing Treg cells, IL-10 producing Treg (Tr1) and TGFβ 
producing Treg (Th3) cells, which work in a cell contact independent manner to induce 
tolerance to foreign antigens in specific tissue environments, have also been described166–
170. Albeit identified in humans, the biological relevance of Tr1 and Th3 cells for human 
immune tolerance remains largely undefined29,167,168.  
 
Thymic Development of Treg Cells 
Thymic development of Treg cells requires two steps. First, high-affinity interactions 
between TCR of CD4+CD8- SP thymocytes and self-peptide-MHCII complexes presented 
by thymic stromal cells, as well as costimulatory signals (namely CD28 and CD40) takes 
place (TCR-dependent step). After this stage, Foxp3-CD25+CD4+CD8- tTreg cell precursors 
will require further stimulation by IL-2, IL-7 and IL-15 to fully express Foxp3 and 
differentiate into tTregs (TCR-independent step)27,28,171,172.  
 
During thymic development the emergence of CD4+CD8+ DP thymocytes with self-reactive 
TCR is required for the differentiation of tTreg cells172,173. Compelling evidence suggests 
that thymic Treg cell development occurs when TCR avidity for self-antigens lies between 
the TCR avidities that drive positive selection and negative selection28,172. In addition to the 
requirement for distinct TCR specificities174–176, thymic Treg cell development is typically 
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governed by intraclonal competition for an antigen-specific niche, suggesting that antigens 
themselves are likely to be rare and tissue specific172,177. Assuming TCR self-reactivity 
drives the thymic selection of Treg cells based on TCR signal strength (which broadly 
encompasses affinity, avidity and antigen-APC availability), molecular signals downstream 
of the TCR will further guide the development of Treg cells. After TCR engagement a variety 
of downstream molecules, including AKT, mTOR, NFAT and NF-kB will link TCR signals 
to Foxp3 transcription172. NF-kB pathway appears to be the main downstream pathway 
guiding thymic development of Treg cells, as mice with mutations in genes encoding 
components of this signalling cascade, such as PKCθ, CARMA1, Bcl-10, TAKI, IKKβ, and 
cREL, displayed dramatic decreases in the frequency of tTreg cells28,172,178–181. While, NF-
kB pathways leads to Foxp3 expression, AKT-mTOR is inhibitory to differentiation of 
Tregs, via inhibition of FOXO1 and FOXO3, which have recently been shown to be required 
for thymic development of Treg cells28,172,182–184. Although, CD28-deficient mice have a 
dramatic reduction in the frequency of tTreg cells, recent evidence suggests that the primary 
role of CD28 signals (as well as of CD40 signals), is to enhance either the efficiency of 
development and/or the survival of Tregs, and not to promote selection of thymocytes into 
the lineage of Foxp3-expressing cells28,172,185–187. During TCR-dependent selection process 
CD4+CD8- SP thymocytes upregulate CD25 through NF-kB activation. CD25 activation by 
IL-2 induce Foxp3 expression, through STAT5, establishing fully differentiated Treg 
cells28,172,188–192. In addition to IL-2, some lines of evidence suggest that IL-7, IL-15, and 
TGF-β signals are also involved in thymic development of Treg cells, particularly by 
conferring survival advantage to precursors of Tregs28,172. 
 
The development of tTregs is closely associated with medullary APCs in the thymus, 
namely, mTEC and bone-marrow-derived APCs (including DCs)172,187,193,194. However, it 
remains unknown whether each type of thymic APC is responsible for the generation of 
Tregs with unique TCR specificities, as mTECs and various DC subsets differ in their ability 
to express, capture and present antigens172. mTEC are also likely to present different antigens 
owing to the stochastic expression of tissue-specific antigens regulated by AIRE24–26,195.  
 
Functional Specialization of Treg Cells 
Although the main cell biological aspects of Treg cells have been broadly established, 
defining experimentally the key mediators of Treg cell function proved surprisingly difficult. 
From a functional perspective, the various potential suppression mechanisms used by Treg 
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cells can be grouped into four categories: a) suppression by inhibitory cytokines; b) 
suppression by cytolysis; c) suppression by metabolic disruption; d) suppression by 
modulation of DC maturation and/or function28,196,197.  
 
The contribution of IL-10, TGF-β and IL-35 inhibitory cytokines to the function of Treg 
cells is still controversial. Although, Treg cells control inflammatory responses in murine 
models of colitis and asthma in a IL-10 dependent manner, blocking IL-10 with neutralizing 
antibodies or transferring IL-10-deficient Treg cells did not change the course of 
disease198,199. Importantly, while the central tenet of Treg cell function is their prevention of 
autoimmune responses, Treg cell-specific deletion of IL-10 did not result in the development 
of spontaneous systemic autoimmunity200. These findings suggest that Treg cell-derived IL-
10 may function restrictively in the control of inflammatory responses196,200. TGF-β role as 
a mediator of Treg cell function is even more controversial. However, since the report that 
exosome membrane-tethered TGF-β enhanced suppressive function of Treg cells in tumour 
microenvironment re-surfaced the interest in this cytokine201,202. IL-35 was recently added 
to the Treg cell portfolio, as IL-35 was proven sufficient for Treg cell-mediated activity203. 
 
Granzyme A and B-dependent cytolysis has also been pointed out as a regulatory mechanism 
of Treg cells, specifically targeting B cells164,204,205.  
 
A long-standing proposed mechanism for Treg cell function is metabolic disruption, mainly 
by IL-2 depletion, a critical survival cytokine for effector cells164,196,206. Again, some studies 
questioned the role of IL-2 depletion as a bona fide Treg cell tool, since CD25-deficient Treg 
cells (which are not able to consume IL-2) kept their suppressive capacity in vitro190,207. 
Conversely, other studies demonstrated that Treg cells induce IL-2-deprivation mediated 
apoptosis208. Interestingly, Treg cells were also found to suppress effector cells by generating 
pericellular adenosine (by the action of ectoenzymes CD39 and CD73) and to transfer potent 
inhibitory second messenger cAMP into effector T cells209–213. 
 
In addition to the direct effect of Treg cells on T-cell function, Treg cells also modulate the 
maturation and/or function of DCs, mainly through CTLA-4-mediated mechanisms (detailed 
description in next sections)155,214–217. 
 
Overall, several models have been proposed to support a cell-intrinsic and -extrinsic function 
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of Treg cells. How might these multiple mechanisms be integrated and used productively by 
Treg cells is still unclear. It has been proposed that Treg cells use predominantly one or two 
crucial suppressive mechanisms (consistently in various regulatory settings), but Treg cells 
are able to alter their phenotype, migration and function in response to specific cues196,197. 
Additionally, Treg cells seem to be also involved in biological processes beyond 
suppression, namely tissue repair and anti-inflammatory protection218.  
 
These possible mechanisms have been discussed from the perspective of the existence of a 
single homogeneous Treg cell population. However, to function properly, Treg cells must 
modulate the activities of a wide variety of cellular components of both the innate and the 
adaptive systems, and this depends on their ability to come into physical proximity with their 
targets. Therefore, Treg cells need to operate in specific tissues and microenvironments. 
Thereby, Treg cells are a heterogeneous population formed by distinct cell subsets to ensure 
a tissue and context-specialized function197. Several groups demonstrated that Treg cells use 
canonical Th cell-associated transcription factors (namely, T-bet, IRF4 and STAT3) to 
maintain or restore immune homeostasis during polarized Th1, Th2 and Th17 cell-driven 
immune responses197,219–222. Furthermore, CCR7lowCD62LlowCD44hiKLRG1+CD103+ 
tissue-resident Treg cell subsets are required to maintain immunological tolerance, namely 
in the skin, lung and gut223–225. 
 
Distinctive Features of Treg Cells in Humans 
Human Treg cells were first characterized as CD4+CD25+ T cells in 2001 by several groups 
based on the finding in 1995 that mouse Treg cells constitutively express CD25146,226–230. 
Following the identification of Foxp3 as the gene leading to pathology in scurfy mice, Foxp3 
was confirmed as a master regulator of human Treg cells151,156,158,159. Whereas, both murine 
and human Treg cells express Foxp3, Treg cells are not the unique Foxp3-expressing cell 
population in the human immune system. Indeed, a significant proportion of human activated 
T cells was found to express (transiently) Foxp3 without acquiring any regulatory activity231–
234. Importantly, some peripheral blood non-regulatory Foxp3low T cells might actually 
produce IL-17 and IFN-γ pro-inflammatory cytokines, as shown by Miyara and 
colleagues235. Increasing the complexity of field is the fact that Treg cells are highly 
heterogenous in humans171,236.  
 
Given the known similarities between mouse and human thymocyte development, it is likely 
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that developmental requirements described above for mice Treg cells are similar for human 
Treg cell differentiation. Contrasting to murine studies, Foxp3 expression by thymocytes 
was observed at DP stage in humans, which concomitantly expressed ICOS, GITR and 
CTLA-4237–240. Like in mice thymus, human Treg cell development requires TCR 
stimulation and several signalling and molecular factors, namely, JAK3/STAT-5, Notch, 
CD80/CD86, ICOS/ICOSL, CD40/CD40L, TSLP, as well as cytokines, such as IL-2 and IL-
15240–244. In humans, a unique structure in the thymic medulla, called Hassall’s corpuscles, 
may contribute to form a TSLP-enriched niche to support Treg cell precursors171,241,242. 
 
Unlike murine Treg cells, human Treg cells have two distinct and clearly defined subsets: 
CD45RO-(CD45RA+)CD25lowFoxp3low resting and CD45RO+(CD45RA-)CD25hiFoxp3hi 
effector Treg cells171,235. The existence of a resting Treg cell population in humans was 
reported by several groups245–248. Resting Treg cells have a comparable in vitro suppressive 
capacity and Foxp3-expression levels with their effector counterparts235,245–247. Hence, 
resting Treg cells are enriched for recent thymic emigrants (as they have a higher T cell 
receptor excision circle (TREC) content and decrease with aging) and are Ki67low quiescent 
cells245–247. Importantly, resting Treg cells proliferate and acquire the expression of CD45RO 
upon in vitro stimulation, suggesting that resting Treg cells represent a pool of Treg cells 
recently emigrated from the thymus which will convert into effector Treg cells upon 
peripheral activation171,235,247. Albeit considered naïve, CD45RA-expressing Treg cells must 
have undergone some TCR signalling,  as peripheral maintenance of Treg cells requires 
continuous TCR stimulation, presumably by self-antigens249,250. Effector Treg cells are 
highly proliferative and apoptotic prone activated cells, expressing high levels of GITR, 
CD95 and CTLA-4235,247. ICOS and HLA-DR expression have been also shown to define 
two effector Treg cell subsets226,251,252. Indeed, Ito and colleagues demonstrated that ICOS+ 
and ICOS- effector Treg cells actively produce, respectively, the inhibitory cytokines IL-10 
and TGF-β in vitro251. Similarly, Baecher-Allan and colleagues claimed that  HLA-DR-
expressing Treg cells are a subset of terminally differentiated Treg cells with superior 
suppressive capacity as compared to HLA-DR- Treg cells252. 
 
The precise molecular mechanisms of suppression of human Treg cells remain to be 
determined, as functional studies with human Treg cells have been exclusively performed in 
vitro171. With this caveat, some studies have found that human Treg cells cannot suppress 
pro-inflammatory cytokine production and proliferation in conditions in which effector T 
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cells were strongly activated171,226,253. 
 
3.3. T Follicular Regulatory Cells 
 
In 2011, the earlier observations showing that Foxp3-expressing Treg cells were required to 
control humoral responses gained a new importance following the identification of Tfr cells 
as a specialized cell subset by three independent groups (including our own)254–256. This 
Foxp3+ T cell subset co-expressed, simultaneously, markers of Treg and Tfh cells, therefore 
maintaining a suppressive function and gaining ability to access B cell follicles and GCs 
(Table 3).    
 
Table 3: Phenotypic markers of Treg, Tfr and Tfh cells in mice 
Adapted from Sage at al257–260 
 
Treg cells Tfr cells Tfh cells 
 
Lymph 
Nodes 
Blood 
Lymph 
Nodes 
Blood 
R
eg
u
la
to
ry
 
m
a
rk
er
s 
Foxp3 ++ ++ ++   
Blimp-1 + + ?   
CTLA-4 ++ +++ ++ + ? 
CD25 +++ ++ ++   
GITR ++ +++ ?   
       
F
o
ll
ic
u
la
r 
m
a
rk
er
s 
Bcl-6  + ? ++ ? 
BTLA  ++ ? ++ ? 
CXCR5  ++ ++ +++ ++ 
ICOS + +++ + ++ + 
PD-1 +/ ++ ? ++ ? 
 
Our group found a population of Foxp3+ T cells within GC of different mouse models 
following immunization with OVA in alum. This regulatory T cell population peaked at day 
12 after immunization, when the total number of T cells within GC is already decreasing. 
This population shared regulatory and follicular markers with Treg and Tfh cells, 
respectively256. In parallel, Chung and colleagues found a population of CXCR5+Bcl-
6+Foxp3+ T cells in human tonsils and in mice. This population was present in organs with 
spontaneous GC reactions, and were also increased in draining lymph nodes upon 
immunization with keyhole limper hemoyanin (KLH) in complete Freund’s adjuvant 
(CFA)254. Finally, Linterman and colleagues also found a population of CXCR5+PD-
1+Foxp3+ T cells following SRBC immunization that resembled activated Treg cells, but 
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they also co-expressed many known Tfh cell markers. Notably, Tfr cells did not express the 
Tfh cell molecules IL-21, IL-4 or CD40L255.  
 
Although, Tfr cells are now considered to be the major regulator of humoral responses to 
limit potential autoimmune reactions, this function might not be unique to Tfr cells. Other 
cell subsets, namely Qa-1-restricted CD8+ T cells, might play a role in abrogating Tfh cell 
responses261,262.   
 
Since their discovery, Tfr cells have been regarded as a putative important player in the 
pathogenesis of human diseases characterized by disrupted GC responses, like autoimmune 
and chronic infectious diseases. In recent years, Tfr cells have been extensively studied. 
While, many aspects of Tfr cell biology were already established in mouse models, their 
origin, differentiation and function in humans remains elusive.  
 
3.3.1. Biology of Tfr Cells 
 
The first three studies describing Tfr cells reported these cells derived from thymic Treg 
cells254–256. Chung and coworkers showed that when wild-type naïve CD4+ T cells and 
CXCR5-Foxp3+ Treg cells with different congenic markers where co-transferred into T cell-
deficient (Tcrb-/-) mice, virtually all Tfr cells were generated from Treg cells (and not naïve 
CD4+ T cells) following KLH-CFA immunization254. Linterman and colleagues observed 
that TCR transgenic CD25- T cells, recognizing hen egg lysozyme (TCRHEL), did not 
differentiate into Tfr cells following HEL immunization (even though they readily gave rise 
to Tfh cells)255. Additionally, Tfr cells were shown to derive only from thymic Foxp3+CD4SP 
T cells (but not Foxp3-CD4SP T cells)255. Our group used another model of T cell-deficient 
(Tcra-/-) mice as recipient of wild-type Tfh and thymic Treg cells to demonstrate that only 
the PD-1-CXCR5-Foxp3GFP+ thymic Treg cells could differentiate into Tfr cells256.  
 
Recently, Aloulou and colleagues used MHC class II tetramers to demonstrate the existence 
of a small population of antigen-specific Tfr cells. This population emerged following 
myelin oligodendrocyte (MOG) in CFA immunization of Mog-/- mice (where MOG acts like 
a foreign antigen) and wild-type mice (although less extensively)263. Moreover, in CXCR5-
/- bone marrow chimeras, where all T cells lack CXCR5, antigen-specific Tfr cells originated 
from transferred naïve CD4+ T cells (sorted from Foxp3-depleted mice), showing that Tfr 
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cells can arise from peripherally-induced Treg cells263. While, these interesting findings 
suggest that the origin and TCR specificity of Tfr cells may be different in non-self and self-
induced immune responses, recent work from our group highly supports the origin of Tfr 
cells from thymic Foxp3+ Treg cells264. Using adoptive cell transfer models, we observed 
that transferred OVA-specific TCR-transgenic CD4+ T cells from Rag-/- mice (devoid of 
Foxp3+ Treg cells) into Rag-sufficient mice did not give rise to Tfr cells following OVA-
IFA immunization. These results confirmed previous reports, and further validated Tfr cell 
origin from Foxp3+ thymic Treg cells under physiological conditions, as lymphopenia in 
Rag-/- hosts (where original experiments were performed) induce T cell homeostatic 
proliferation and expansion265,266. Importantly, we found that recruitment of Tfr cells into 
GC was independent of the immunizing antigen. Indeed, while most Tfh cells found within 
GC of OVA-immunized C57BL/6 mice derived from OVA-specific TCR-transgenic CD4+ 
T cells, no OVA-specific Tfh cells were found within GC of β-lactoglobulin-immunized 
mice. On the contrary, virtually no OVA-specific Tfr cells were found within GC of mice in 
the two immunizing conditions (OVA-specific TCR-transgenic Foxp3+ T cells specifically 
recognized and proliferated in the presence of OVA)264. The lack of specificity of Tfr cells 
towards the immunizing non-self-antigen was further observed by the lack of antigen-
specific MHC class II tetramer-positive cells upon immunization with the corresponding 
antigen. Indeed, we could not detect antigen-specific tetramer-positive Tfr cells in any of the 
conditions tested264. Also, Tfr cells did not preferentially proliferate or survive in vitro with 
immunizing antigen signals when compared with a control antigen. Therefore, it is 
reasonable to assume that activation and recruitment of Tfh and Tfr cells into GC is governed 
by different signals. To further address specificity of Tfr cells, we sequenced the TCRα-
chain (TRA gene) of Tfr, Tfh, and Treg cell populations from immunized TCRβ-restricted 
mice (with the cells sorted at the peak of GC reaction). The TCR repertoire analysis showed 
that, although Tfr cells are an oligoclonal population, they have a TCR repertoire that 
resembles the repertoire of Treg cells, but that is different from that of Tfh cells264. The 
oligoclonal expansion of Tfr cells (which is consistent with their generation only following 
immune adaptive reactions) provides evidence for the existence of a driving (self) antigen 
for Tfr cell differentiation. Sage and colleagues consistently demonstrated that Tfr cells 
sorted from mice immunized with different 4-hydroxy-3-nitrophenylacetyl hapten (NP) 
conjugated antigens  (NP-HEL and NP-OVA) equally suppressed B and Tfh cells sorted 
from NP-OVA in CFA immunized mice258. Although, these experiments were performed in 
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vitro, they indicate that Tfr cells do not require specificity to the immunizing antigen for 
their suppressive capacity. 
 
While, the differentiation of Tfr cells is still not as characterized as the differentiation of Tfh 
cells, Tfr cells seem to undergo a multistep Bcl-6-dependent differentiation process like Tfh 
cells.  
 
For Tfh cells, such complex process starts during T cell priming by DCs and continues 
throughout T-B interactions until Tfh cells differentiate into mature GC Tfh cells (as 
described above)63–65,115. Like other naïve CD4+ T cells, Tfr cell differentiation is initiated 
at the time of T-cell priming by DCs, as diphtheria toxin-induced depletion of Foxp3DTR 
Treg cells at the time of immunization results in the lack of Tfr cells, despite the recovery of 
Treg cells and normal GC formation255,267. Sage and colleagues established the DC 
requirement for Tfr cell differentiation by depleting DCs with diphtheria toxin in CD11c-
DTR bone-marrow chimeric mice258. In these experimental settings, transfer of NP-OVA-
pulsed LPS-activated DCs led to expansion of Tfr cells (as well as Tfh cells) in the draining 
lymph node of recipient mice. Additionally, antigen presentation by DCs (and not only 
survival and co-stimulatory signals) was required for Tfr cell differentiation, as Ciita-/- DCs 
(which are unable to present antigens) were impaired in their ability to induce Tfr cell 
differentiation258,268. However, the DC subsets most directly responsible for stimulating Tfr 
cell differentiation remain unclear.  
 
The full differentiation into GC Tfr cells is also dependent on B-cell interactions. When mice 
lacking B cells (MT mice) were immunized with NP-OVA or SRBC a significant reduction 
in lymph node Tfr cells were observed258,255. Moreover, Linterman and colleagues showed 
SAP-deficient Sh2d1a-/- mice have virtually no Tfr cells following SRBC immunization, 
clearly showing B-cell dependency of Tfr cells, similarly to Tfh cells89,255. Notwithstanding, 
B-cell requirement for Tfr cell differentiation is controversial. Indeed, B cells were only 
required for development of full differentiated Tfr cell differentiation, as putative Tfr cells 
were found in blood of MT mice following immunization258. This population of circulating 
Tfr cells had a lower expression of ICOS and a less suppressive capacity, when compared to 
Tfr cells sorted from lymph nodes. Although some Tfr cells were found in blood of 
unimmunized mice, Tfr cells were shown to originate upon first contact with DCs and before 
full commitment to the GC fate. The same study also showed that circulating Tfr cells can 
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persist in the system for long periods of time and be later recruited into the GC to suppress 
further responses258. These studies suggest that Tfr cell effector activity is initiated during 
contact with DCs in the T cell zone, strengthened in the inter-follicular region during contact 
with B cells, and optimized in the GC (Figure 1). 
 
Another similarity between the differentiation processes of Tfr and Tfh cells is the 
requirement of TCR stimulation and co-stimulatory signals through CD28 and ICOS63–
65,70,73,115. The CD28 requirement for Tfr cells commitment was first shown with bone-
marrow chimeras, with mixed CD28-deficient and -sufficient cells, under which conditions 
both Tfr and Tfh cells originated exclusively from CD28-sufficient cells255. These results 
were later corroborated by a study showing the absence of Tfr and Tfh cells in CD28-/- and 
in Icos-/- mice260.  
 
 
Figure 1: Tfr cell differentiation signals and pathway.  
Tfr cells originate from thymic Treg cells upon DC priming (from activated DCs). This process 
involves antigen / MHC II signals, as well as CD28 and ICOS signalling. This first step of Tfr cell 
differentiation is inhibited by IL-21, IL-2, and PD-1L. After this process Tfr cells upregulate Bcl-
6, CXCR5, PD-1 and ICOS. CXCR5 will guide the cells toward CXCL13 enriched B-cell zones 
(follicles and GC). At the T-B border, Tfr cells receive full differentiation signals from activated 
B cells (it is not known whether these are cognate B cells) in a SAP, ICOS and PD-1-depentend 
manner. PD-1L is also an inhibitory signal at this stage. Throughout this process CD25 expression 
decreases. 
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There are, however, some differences between the differentiation processes of Tfr and Tfh 
cells. A striking difference is that only the differentiation of Tfr cells seems to be affected 
by co-inhibitory signals (Figure 1). PD-1 signalling exclusively inhibit Tfr cell 
differentiation, as Pdcd1-/- (PD-1 deficient) mice had higher frequencies of Tfr cells both in 
lymph nodes and blood (but normal frequencies of Tfh cells) following MOG-CFA 
immunization260. CXCR5-Foxp3+ Treg cells transferred from Pdcd1-/- mice showed a greater 
capacity for CXCR5 upregulation, suggesting that PD-1 specifically controls Tfr cell 
differentiation from thymic Treg cells260. The direct impact of PD-1 in Tfr cell differentiation 
was also corroborated by the lower proliferating rate (analysed by Ki-67 expression) of 
Pdcd1-/- Tfr cells. A lower proliferative rate excluded increased cell maintenance as the 
mechanism for Tfr cell expansion in Pdcd1-/- mice. PD-1 represses Tfr cell differentiation 
prior to B-cell interaction, as blood Tfr cells were also increased in PD-1 deficient mice260. 
Importantly, in elegant in vitro assays, Sage and colleagues showed a greater suppressive 
capacity of Pdcd1-/- Tfr cells (measured by proliferation of Tfh responder cells and 
supernatant IgG1 concentration)260. PD-L1 (expressed by all B cell and DC subsets) 
mediates the role of PD-1 signalling in Tfr cell differentiation, since only PD-L1-deficient 
mice (but not PD-L2-deficient mice) could replicate the Tfr phenotype observed in PD-1-
deficient mice260.  
 
Another inhibitory molecule that has a negative impact on Tfr cell differentiation is CTLA-
4. Two groups showed that Tfr cells expressed higher amounts of CTLA-4 in comparison to 
total Treg population, thus CTLA-4 was proposed as a universal marker of functionally 
competent Tfr cells259,269. However, CTLA-4 expression on Tfr cells was identical to CTLA-
4 expression on activated CD44+ Treg cells, suggesting that the enhanced CTLA-4 
expression by Tfr cells might be a result of their activated state rather than an intrinsic 
difference from non-follicular Treg cells269. These two groups demonstrated that deletion of 
CTLA-4 led to an increased frequency and absolute numbers of Tfr cells259,269. Sage and 
colleagues showed an expansion of Tfr cells in lymph nodes and blood by CTLA-4 depletion 
induced by tamoxifen administration to UBC-ERT-iCre+Ctla4F/F mice three days before 
immunization with NP-OVA in CFA259. Using this system, these authors circumvented the 
effects of germline deletion of CTLA-4 known to induce spontaneous development of 
systemic lymphoproliferation, fatal T-cell-mediated autoimmunity and hyperproduction of 
immunoglobulin E214. Conditional deletion of CTLA-4 in Treg cells (using tamoxifen 
administration in Ctla4 floxed mice bred to Foxp3-ERT2-Cre-GFP knockin mice) 
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recapitulated the impact of global CTLA-4 deletion both in vitro and in vivo259. Wing and 
colleagues used CTLA-4flox/flox, CTLA-4flox/wt and CTLA-4wt/wt Foxp3IRES-Cre+ hemizygous 
male mice to demonstrate an expansion of Tfr cells as well as greatly increased spontaneous 
GC formation in the complete absence of CTLA-4 in Treg cells (as CTLA-4flox/wt showed 
normal levels of Tfr cells)269. Although, CTLA-4 depletion greatly impacts Tfr cell 
population, whether this is due to a direct effect on differentiation or on cell maintenance is 
still not clear. 
 
The cytokine IL-21 also has a negative impact on Tfr cell numbers even though it supports 
Tfh differentiation (with IL-6 redundancy) (Figure 1)61,81,270–272. Jandl and colleagues 
studied follicular T cells and humoral responses in Il21r-/- mice. Ki-67+ proliferating Tfr cells 
specifically expanded following SRBC immunization (no expansion of Tfh cells was 
observed) in IL-21 receptor-deficient mice. To prove a Tfr cell-intrinsic role of IL-21 
receptor, Jandl and colleagues used 1:1 mixed bone marrow chimeras with Il21-/- Thy1.2 T 
cells and WT Thy1.1 T cells. IL-21 receptor-deficient T cells preferentially differentiate into 
Tfr cells following SRBC immunization270. Interestingly, CD25 expression levels on IL-21 
receptor-deficient Tfr cells approximated that of their Treg cell precursors, leading to a 
heightened signalling in response to IL-2 (as Il21-/- Tfr cells greatly expanded after Il-2:IL-
2mAb complexes administration and increased STAT5 phosphorylation after recombinant 
IL-2 antibody treatment)270. Using different in vitro approaches, Jandl and colleagues 
showed that Bcl-6-deficient CD4+ T cells had an increased CD25 expression, and an 
increased frequency of CD25hi T cells upon IL-21 neutralization270. Therefore, they 
proposed that IL-21 induces Bcl-6 expression which in turn limits CD25, the reduction of 
CD25 expression then leads to lower responsiveness to IL-2, consequently IL-21 restrains 
Tfr cell expansion by limiting CD25+ Tfr cell proliferation. Consistently, Ding and 
colleagues revealed that IL-21 can suppress Tfr cell differentiation in BXD2 autoimmune 
mice273. Tfr cells were found to be increased in Il21-/- BXD2 mice, in parallel with a 
reduction in GC B cells and GC size in that murine model273. In in vitro systems, they found 
that IL-21 induced STAT3 phosphorylation and decreased Foxp3 expression, by a Akt-
dependent mechanism273. Whether the IL-21-induced decrease in Foxp3 expression by 
already formed Tfr cells is sufficient to reduce Tfr cell numbers in vivo is not known. 
Nevertheless, as IL-21 is mainly secreted by Tfh cells and orchestrate several components 
of humoral responses, Tfr cell differentiation inhibition by IL-21 evoke a feedback control 
mechanism in the GC response82,274. Another study also supports IL-21 as a repressor 
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cytokine for Tfr cells. Sage and colleagues found that IL-21 diminished Tfr cells 
proliferation (based on proportion of Ki-67+ Tfr cells) in cocultures with Tfh and B cells272.  
 
The work by Jandl and colleagues showed that Tfr cells comprise cells that express CD25 
and cells that lack CD25270. Although, CD25- Tfr cells express higher levels of Bcl-6, 
proliferation of CD25+ Tfr cells was responsible for the expansion of Tfr cells in IL-21 
receptor deficient T cells, where the lack of IL-21 receptor signalling limit Bcl-6 
expression270. How Tfr cells cope with IL-2/CD25 signalling (critical for Treg cell 
development and maintenance) and Bcl-6-dependent T follicular program (which is 
repressed by IL-2/CD25 signalling) has been regarded as one of the most intriguing features 
of Tfr cells28,83–85,87,223,275. Recently, three independent groups confirmed that Tfr cells have 
low CD25 expression276–278. Wing and colleagues showed that both CD25- and CD25+ Tfr 
cells differentiated and expanded upon NP-OVA in alum immunization. However, while 
CD25+ Tfr cells persist after the peak of GC reaction, CD25- Tfr cells followed a kinetic 
response similar to Tfh cells (albeit with a later peak), suggesting that only CD25- Tfr cells 
followed a GC-like kinetic response276. Moreover, CD25- Tfr cells more closely resembled 
Tfh cells when their gene profile was analysed and preferentially localize within GC276. 
Functionally, CD25- and CD25+ Tfr cells had similar suppressive capacity, as both subsets 
suppressed IgG1 production by B cells in vitro276. To specifically address the impact of IL-
2 on Tfr cells, Ritvo and colleagues, used Foxp3GFP reporter mice infected with adeno-
associated virus coding for IL-2 (to maintain continuous high levels of IL-2) prior to OVA 
immunization277. The frequency of Tfr cells was decreased in the presence of IL-2, 
suggesting a negative impact of IL-2 on Tfr cells277. CXCR5hiPD-1hiGFP+ Tfr cells 
expressed Bcl-6 and lack CD25 expression, suggesting that throughout Tfr cell 
differentiation Bcl-6 is progressively upregulated while CD25 is downregulated277. Thus, 
Ritvo and colleagues claimed that all Tfr cells lack CD25 expression, but they did not 
provide an explanation for the existence of CXCR5+CD25+ Treg cells. Interestingly, using 
the same CXCR5hiPD-1hiGFP+ strategy to identify Tfr cells, Linterman and colleagues found 
that Tfr cells express CD25 (although at lower levels compared to conventional Treg cells) 
in their pioneering work255. Although, Tfr cells clustered with Tfh cells when their 
transcriptomic profile were analysed, Ritvo and colleagues found that Tfr cells preferentially 
expand when insulin (a self-antigen) was used as the immunizing antigen277. These findings 
are consistent with a similar TCR repertoire between Tfr and Treg cells264.  Thereby, Tfr 
cells acquire a Bcl-6-depedent transcriptome throughout their differentiation process but 
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retain a thymic-derived Treg cell self-biased TCR repertoire. CD25+ Tfr and CD25- Tfr cells 
were also found in PR8 influenza virus infected mice278. However, while previous studies 
have shown that Tfr cells quickly develop following soluble protein immunization, under 
physiological conditions (influenza infection further validated with LCMV infection), Tfr 
cells only accumulated during the late phase of the primary response (day 30–60)260,254,255,278. 
Botta and colleagues found that most Bcl-6+CXCR5+  Tfr cells were CD25lo and when sorted 
as such they had a very distinct gene profile compared to conventional Treg cells278. 
Importantly, they consistently demonstrated that Tfr cells were derived from CD25+ Treg 
cells, as virtually no progeny derived from CD25loFoxp3+ T cells (adoptively transferred 
with equivalent numbers of CD25hiFoxp3+ T cells into Tcrb-/- T cell-deficient mice) 
upregulated Bcl-6 and CXCR5278. The progeny of CD25hiFoxp3+ T cells which differentiate 
into Tfr cells concurrently downregulated CD25 (Figure 1)278. In a similar system, they also 
confirmed that Foxp3- T cells cannot differentiate into Tfr cells following influenza 
infection278. To mechanistically address the impact of IL-2 in Tfr cell differentiation, Botta 
and colleagues treated influenza infected mice with recombinant IL-2. Under IL-2 treatment 
Tfr cells failed to develop in a Blimp-1 dependent manner278. They generated mixed bone 
marrow chimeras using WT and Prdm1flox/floxLckcre (Blimp-1-deficient) donors to 
demonstrate that Tfr cells quickly developed from Blimp-1-deficient cells as early as 10 days 
following influenza infection even in the presence of recombinant IL-2, suggesting that 
Blimp-1 limits Tfr cell differentiation and mediates the negative impact of IL-2 on this 
population278. Given that IL-2 was shown to inhibit Bcl-6 expression by upregulating Blimp-
1 in Tfh cells, it is tempting to assume that IL-2 enriched conditions also block Tfr cell 
differentiation through a Blimp-1-dependent mechanism (Figure 2)279. Although, IL-2 
seems to inhibit Tfr cell differentiation, the absence of IL-2/STAT5 signalling may lead to 
Foxp3 downregulation28. Therefore, the maintenance of Foxp3-expressing Treg cells in the 
absence of IL-2/CD25 (IL-2Rα) must be accomplished by other homeostatic mechanisms. 
Indeed, Tfr cells express high amounts of intermediate-affinity IL-2 receptor (CD122/IL-
2Rβ) which may be sufficient to prevent Foxp3 downregulation278. Interestingly, some tissue 
resident Treg cells do not require IL-2 for their homeostatic control (and downregulate 
CD25) but instead rely on continued signalling through ICOS280. 
 
At the transcriptomic level, there are also similarities and differences in Tfr and Tfh cell 
differentiation (Figure 2).  
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As referred above, Bcl-6 is the master regulator for both subsets58–60,256,254,255. Two of the 
original groups describing Tfr cells demonstrated BCl-6 requirement for Tfr cell generation, 
using different approaches with Bcl-6-deficient mice254,255. Linterman and colleagues used 
mixed Bcl6+/+:Bcl6-/- bone marrow chimeras to prove that cells lacking Bcl-6 expression did 
not give to Tfr cells following SRBC immunization (in these mice normal GC formation was 
observed)255. On the other hand, Bcl-6 was also shown to be essential for Tfr cell generation, 
as Bcl6-/- mice had a significant reduction in Tfr cells following immunization with KLH in 
CFA254. A key difference on the transcription factors present in Tfr and Tfh cells is the 
balance between Bcl-6 and Blimp-1. While Bcl-6-deficiency resulted in a virtually complete 
absence of Tfr cells, Blimp-1-deficiency increased Tfr cells, suggesting Blimp-1 limits the 
size of Tfr cell population255,281. This intricate balance seems to be required to position Tfr 
cells between the phenotype of Tfh and Treg cells.  
 
 
Figure 2: Signalling and transcriptomics of Tfr cells.  
While, a balance between Bcl-6 and Blimp-1 is critical for the establishment of full transcriptional 
profile Foxp3+ Tfr cells, store-operated Ca2+ entry (by ORAI and STIM1 and STIM2) are required 
for upregulation of chemokine receptor CXCR5, via NFAT2. IL-21 (secreted by Tfh cell) inhibit 
Tfr cell differentiation through IL-21R / STAT3 signalling, maintaining Tfh and Tfr cells regulated 
by a IL-21-dependent feedback mechanism. IL-2/STAT5 signalling inhibits Bcl-6-dependent Tfr 
cell program through Blimp-1 upregulation, therefore, environment IL-2 consumption is required 
to promote Tfr cell development. At the same time Bcl-6 upregulation also decreases CD25 (IL-
2Rα) enforcing Tfr cell program. Additionally, ICOS signalling promotes interaction between 
p85α and intracellular osteopontin (OPN), followed by translocation of OPN to the nucleus, where 
OPN protects Bcl-6 from ubiquitin-dependent proteasome degradation. Signalling via mTOC 
complex 1 (mTORc1), in a STAT3-dependent manner, is also crucial for integration of diverse 
signals promoting Tfr cell differentiation. 
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Initial CXCR5 expression on Tfh cells requires Ascl2 exppression98. So far, Ascl2 
expression on Tfr cells was not reported. On the contrary, CXCR5 expression in Tfr cells 
requires the expression of a Ca2+-responsive molecule, called transcription factor nuclear 
factor of activated T cells 2 (NFAT2, also known as NFATc1)282. Indeed, conditional 
knockout mice for NFAT2 in CD4+ T cells have a specific reduction of Tfr cells followed 
by an overall amplification of GC reactions and increased frequencies of Tfh cells upon 
different immunizing antigens (namely NP-KLH, OVA and SRBC)282. Taking advantage of 
adoptive cell transfer experiments (in which WT and NFAT2-deficient CD4+ T cells were 
co-transferred to Rag-/- mice) and Naft2flox/flox mice crossed to Foxp3IRES-Cre mice, the effect 
of NFAT2 was found to be Tfr cell-intrinsic282. Mechanistically, NFTA2 directly binds to 
Cxcr5 promoter, inducing Tfr cell differentiation from thymic Treg cells by upregulating 
CXCR5282.  
 
Moreover, stromal interaction molecule 1 (STIM1) and STIM2, which mediate the activation 
of membrane Ca2+ channels on T cells upon TCR stimulation (a pathway known as store-
operated Ca2+ entry, or SOCE), leading to activation of transcription factors of the NFAT 
family, were also found to be important for Tfr cell differentiation283,284. In conditional 
double knockout mice of STIM1 and STIM2 in CD4+ T cells (Stim1flox/floxStim2flox/flox mice 
crossed to Cd4Cre mice), Tfr cells were significantly reduced. However, it is noteworthy that 
the Tfr cell population, even in unimmunized WT mice, was much larger than originally 
reported258,256,254,255,283. Using Rag-deficient mice reconstituted by 1:1 mixed bone marrow 
chimeras of WT and Stim1flox/floxStim2flox/floxCd4Cre, Vaeth and colleagues proposed an 
intrinsic requirement for SOCE in Tfr cell differentiation283. STIM1 and STIM2-deficient 
Treg cells (sorted from Stim1flox/floxStim2flox/floxFoxP3-YFPCre hemizygous female mice) 
showed an impaired expression of Bcl-6283.  
 
Tumor necrosis factor receptor (TNFR)-associated factor 3 (TRAF3), and signal transducer 
and activator 3 (STAT3) were also found to play a role in Tfr cell differentiation285,286. When 
Chang and colleagues investigated the role of TRAF3 in homeostasis and function of Treg 
cells, using Traf3flox/flox mice crossed to Foxp3Cre mice, they found an amplified GC 
formation along with absence of Tfr cell expansion (but normal levels of Tfh cells) following 
SRBC immunization286. These findings suggested TRAF3 is critical for Tfr cell induction 
upon antigen stimulation. This signal adaptor has a broad spectrum of biological functions 
which are cell type-specific. TRAF3 binds to TCR/CD28 complex and to many other 
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receptors expressed by Treg cells, namely TNFR2 and GITR287. This provides evidence for 
the potential dependency of Tfr cell differentiation from inflammatory signals, such as TNF. 
Similarly, Wu and colleagues used Stat3flox/flox mice crossed to Cd4Cre to establish that 
STAT3 was necessary for Tfr cells, as Tfr cells were almost absent in those mice following 
SRBC immunization285.  
 
The p85α-osteopontin axis was also found to be required for Tfr cell differentiation, 
providing a link between ICOS-induced PI3K signalling and Bcl-6 upregulation in this cell 
population288. Using adoptive cell transfers, Leavenworth and colleagues demonstrated that 
TCR-deficient mice transferred with WT naïve T cells and osteopontin (OPN)-deficient Treg 
cells had substantial fewer CXCR5+PD-1+CD25hi Tfr cells (which was associated with 
expanded GC B cells and higher anti-KLH antibody titres) following immunization with 
KLH in CFA288. Further mechanistic studies allowed these authors to propose that upon 
ICOS stimulation intracellular OPN interacts with p85α (a component of PI3K complex), 
which promotes nuclear translocation of OPN. In the nucleus, OPN stabilizes Bcl-6 
expression through interference with the ubiquitin-mediated degradation of Bcl-6288.  
 
Recently, Xu and colleagues addressed the role of mTOR signalling in Tfr cell fate 
decisions289. The mTOR signalling (through two functionally distinct complexes mTORC1 
and mTORC2) controls various cellular processes, including cell growth, proliferation, and 
survival, by sensing and integrating environmental cues, taking part in T cell fate 
decisions290. Specifically, the IL-2/mTORC1 signalling axis appears to inhibit Tfh and Treg 
cell differentiation (although mTORC1 is important for the suppressor function of Treg 
cells), whereas mTORC2 was reported to be essential for Tfh cell differentiation182,291–293. 
Upon OVA-CFA immunization, Tfr cells expressed the highest amounts of phosphorylated 
S6 and 4E-BP1 (the key mTORC1 targets), compared to Tfh and CXCR5- Treg cells, 
suggesting a differentiating role of mTORC1 in Tfr cells289. Importantly, mTORC1 
signalling induced de novo Tfr cell differentiation from thymic-derived Treg cells, as 
rapamycin (a selective inhibitor of mTORC1 pathway) treated conventional Treg cells 
showed a reduction conversion to Tfr cells post OVA-CFA immunization, when adoptively 
transferred into WT recipient mice289. Consistently, Rptorflox/+Foxp3Cre mice (which harbour 
a selective but partial reduction of mTORC1 signalling in Treg cells to avoid the impact of 
complete loss of mTORC1 signalling on their homeostatic proliferation) had a reduced 
proportion and absolute numbers of Tfr cells after NP-OVA in CFA immunization289. 
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Moreover, mTORC1 signalling is also important for Tfr suppressive capacity, as when 
rapamycin-treated Tfr cells formed upon LCMV infection were adoptively transferred with 
WT Tfh cells (also sorted from LCMV infected mice) into SAP-deficient mice (which fail 
to generate functional Tfh and Tfr cells upon infection), they failed to regulate GC reactions. 
Indeed, SAP-deficient mice transferred with rapamycin-treated Tfr cells showed an 
substantial expansion of GC B and plasma cells, indicating that mTORC1 signalling is 
required for differentiation of Tfr cells, as well as for their suppressive functions upon 
infection289. The gene set enrichment analysis of gene signatures in WT and Rptor-/- Tfr cells 
(sorted from Raptorflox/floxCD4Cre mice after OVA-CFA immunization) implied mTORC1 
signalling played an important role in many features of Tfr cell lineage, as the Tfr cell gene 
signature was substantially reduced in mTORC1-deficient Tfr cells289. Using a sequential 
set of vector-transduced Rptor-/- Treg cell experiments, Xu and colleagues also proposed that 
mTORC1 signalling mediates Tfr cells conversion from conventional Tregs through a 
STAT3-TCF-1-dependent Bcl-6 upregulation289. 
 
Finally, members of the helix-loop-helix family (E and Id proteins) also contribute to Tfr 
cell fate decision294,295. Miyazaki and colleagues observed a spontaneous Th2 cell-mediated 
fatal inflammation in mice lacking Id2 and Id3 expression in Treg cells. In these 
Id2flox/floxId3flox/floxFoxp3Cre mice spontaneous formation of IgG1 and IgE producing GC and 
expansion of IL-4, IL-5 and IL-13-secreting Tfh cells was associated with an increased 
proportion of CXCR5+PD-1+ Treg cells in lymphoid organs294. Despite expression of some 
follicular markers, this cell population did not fully differentiate into Bcl-6+ Tfr cells. As 
upon in vitro exposure to TCR-mediated signalling Treg cells downregulated Id3 and E2A-
bound sites were found to be associated with putative enhancer regions across the Cxcr5 
loci, the authors proposed that upon TCR-mediated signalling, Id2 and Id3 levels decline 
permitting E-protein binding activity and induction of a Tfr cell prone transcription 
signature. Later on, Id2 and Id3 abundance is required to modulate Bcl-6 and Blimp-1, 
ultimately leading to the development o 
f a mature Tfr cell population294. Thus, it is likely that a default Tfr-cell program is induced 
in Treg cells upon TCR-mediated activation, leading to full differentiated Tfr cells whenever 
additional signals are present, namely B-cell interactions and (probably) low exposure to IL-
2. 
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Although, the same type of cellular interactions seems to trigger both Tfr and Tfh cells 
differentiation, kinetic studies of the accumulation of both populations after immunization 
revealed that Tfr cells appear in the GC at later time points reaching their maximum 
frequency around 5 days later than Tfh cells do260,256,277,278,296,297. This unsynchronized 
accumulation of Tfr and Tfh cells may be required for the initial establishment of the GC, 
where few Tfh and GC B cells need to rapidly expand without the suppressive action of Tfr 
cells. On the contrary, once the GC has reached a significant size, Tfr cells would be 
important for the control of the GC reaction and its outcome. Despite their accumulation 
upon antigen stimulation, the individual contribution of Tfr cells to the total CXCR5+ T cell 
population decrease with time, suggesting a disproportionate expansion of Tfr and Tfh cells 
during adaptive immune responses297.  
 
3.3.2. Mechanisms of Tfr Cell Function 
 
Tfr cells constitute a regulatory T cell subset specialized in the regulation of the GC response. 
By directly modulating Tfh cell proliferation, B cell metabolism and cytokines secreted by 
Tfh cells in secondary lymphoid organs, Tfr cells modify GC outcomes at several levels: a) 
control of GC size; b) selection of antigen specific Tfh and B cell clones; and c) modulation 
of class switch and affinity maturation of antibodies (Figure 3).  
 
Figure 3: Mechanisms of Tfr cell-mediated regulation of humoral responses.  
Tfr cells regulate T – B interactions within GC mainly by physical interference at the 
immunological synapse, which is required for the survival feedback loop between GC B cells and 
Tfh cells. CTLA-4 is a key molecule of Tfr cell function at immunological synapse, as it directly 
blocks CD80/CD86 co-stimulatory signals. Using these mechanisms, Tfr cells impair GC B cell 
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metabolism (mainly by decreasing glucose uptake and usage) and induce the downregulation of 
GC B cell effector molecules, such as Pou2af1 (required for GC B cell formation), Xbp1 (required 
for antibody secretion) and Aicda (required for class switch recombination). On the other side of 
the immunological synapse, Tfr cells limit IL-21 and IL-4 secretion by Tfh cells capacity is also 
modulated y the presence of Tfr cells. Granzyme B, IL-10 and TGF-β secretion by Tfr cells may 
also account for their regulatory capacity.  
 
The precise molecules that underpin such effects are largely unknow, but undoubtedly 
encompass CTLA-4-mediated suppression (see below). Hypothetically, other molecular 
mechanisms may be involved in Tfr cell function, namely secretion of IL-10 and TGFβ, 
induction of cell death by granzyme-mediated apoptosis, and cell contact by unknow 
mechanisms (Figure 3). 
 
Control of GC Outcomes 
The initial studies ascribed control of GC size and of immunoglobulin class and antibody 
affinity to Tfr cell population256,254,255. Indeed, Tfr cells are critical to control GC size and 
immunoglobulin production, as Tcrα-/- mice transferred with OT-2 cells (from mice without 
Treg cells) plus CXCR5-deficient Treg cells had greater GC volumes and higher serum titres 
of OVA-specific IgM and IgG2a, following OVA-Alum immunization256. Using a similar 
adoptive cell transfer experiment, Chung and colleagues showed that mice lacking either 
CXCR5 or Bcl-6-expressing Treg cells had expanded GC B cells and a higher proportion of 
NP-specific GC B cells following NP-KLH-CFA immunization. Moreover, in the absence 
of Tfr cells higher amounts of high-affinity NP-KLH-specific IgG1 and IgG2 antibodies 
were observed254. However, the impact of Tfr cells in selection of antigen specific cells and 
antibody affinity maturation is controversial. In mixed bone marrow chimeras (1:1 ratio of 
Sh2d1a-/-Foxp3DTR or Sh2d1a+/+Foxp3DTR cells), Linterman and colleagues observed an 
increase in Tfh and GC B cells, but a reduced proportion of NP-specific GC B cells (but no 
differences in antigen-specific antibodies) when mice lacking Tfr cells were immunized with 
NP-KLH in alum255. Curiously, in secondary immune responses (NP-KLH boost at day 24 
after primary immunization), high-affinity NP-specific antibody titres were lower in Treg 
and Tfr cell depleted mice, suggesting that kinetics and modulation of GC reaction by Tfr 
cells is different in primary and secondary immune responses255. These reported differences 
in GC outcomes may be, at least partially, assigned to the nature of adjuvants used298–300. 
Curiously, in murine models of influenza vaccination (where adjuvants are not used and 
antigens are not proteins) virtually no Bcl-6+ Tfr cells were generated at the peak of GC 
reaction (days 7 – 15), albeit Tfr cell were detected at later time points (day 30)278,301. 
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Additionally, the methods used to induce Treg cell depletion might also explain these 
conflicting results, as excessive IL-2 signalling after Treg depletion was shown to restrain 
antigen-specific Tfh cell responses206,301. 
 
Whereas these pioneer reports showed contradictory results in the absence of Tfr cells, more 
recent studies support the concept that Tfr cells restrain generation of antibodies specific to 
the immunizing antigen while favour the emergence of B cell clones secreting high affinity 
antibodies259,269,278,302,303. In a recent study, an increased percentage of NP-specific GC B 
cells and NP-specific IgG2a and IgE titres was observed when Treg cells were not allowed 
to generate Tfr cells. By diphtheria toxin administration, these Foxp3DTR mice showed a 
persistent Tfr cell depletion at the peak of GC response in parallel with Treg cell recovery269. 
Interestingly, Wing and colleagues proposed that while antigen-specific Treg cells might 
suppress the relevant response, polyclonal Treg cells are critical for the maintenance of 
immune homeostasis. Indeed, upon transient Treg cell depletion on the time of immunization 
an increased proportion of antigen-specific Tfh cells was observed, while an overall 
reduction of antigen-specific GC B cells (as well as increased anti-dsDNA autoantibody 
levels) was noticed when Treg cells were sustainably depleted269. Sage and colleagues 
showed that when Cd28-/- mice (which cannot generate Tfh and Tfr cells) were transferred 
with a pool of CXCR5+ICOS+ Tfh and Tfr cells (sorted from NP-OVA in CFA immunized 
Ctla4flox/floxFoxp3ERT-Cre) and submitted to tamoxifen-induced depletion of Tfr cells an 
overall increase in Tfh cells and NP-specific antibodies (with lower affinity) was noticed259. 
In these experimental conditions, the emergence of low affinity antibodies might be due to 
a less stringent B cell competition imposed by a facilitated Tfh cell-dependent B cell help in 
the absence of CTLA-4-suficient Tfr cells. Another study reported that Bcl-6flox/floxFoxp3Cre 
conditional knockout mice (specifically lacking Tfr cells) had normal GC size and GC B cell 
numbers, but exhibited high serum titres of antigen-specific IgA responses (and lower titres 
of antigen-specific IgG), suggesting that besides antigen specificity of antibodies produced 
within GC, Tfr cells modulate class-switch303. Finally, in the gut microenvironment, 
Kawamoto and colleagues demonstrated that Tfr cells are required in GCs of Peyer’s patches 
to normalize the microbiota diversity, as transfer of Treg cells lacking Bcl-6 expression 
failed to induce normal bacterial diversity in T cell-deficient (Cd3e-/-) mice302. Previous work 
of this group elucidated for the IgA dependency of gut microbiota and immune 
homeostasis304–307. Thus, they tested whether IgA production is impaired in the absence of 
Tfr cells. Indeed, IgA-producing B cells were decreased in small intestine lamina propria 
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(but not in Peyer’s patches), directly linking gut Tfr cells with IgA production and microbiota 
homeostasis302.  
 
These regulatory mechanisms have been further studied in murine models of autoimmunity 
diseases, where Tfr cells were directly implicated in ensuring tolerance to self-antigens and 
preventing autoimmunity273,278,282,283. The loss of Tfr cells in Stim1flox/floxStim2flox/floxCd4Cre 
mice (described above) was followed by a massive increase in Tfh cells, accumulation of 
GC B cells, and fatal autoimmunity manifestations, such as elevated concentrations of serum 
autoantibodies (anti-dsDNA, anti-La, anti-Ro52, and anti-Ro60) and autoantibody-induced 
glomerulonephritis283. Tfr cell requirement for restraining antigen-specific GC responses in 
vivo was confirmed by Vaeth and colleagues. Using a LCMV infection model, they reported 
an amplified production of anti-LCMV antibodies when Tfr cells are absent (due to SOCE 
deficiency) in the recipient mice of transferred LCMV-specific (SMARTA) CD4+ T cells283. 
In an independent set of experiments, the same group found that Nfat2flox/floxCd4Cre mice 
were more prone to develop the clinical hallmarks of SLE after induction of a SLE-like 
disease (by immunization with chromatin isolated from syngeneic-activated 
lymphocytes)282. Curiously, in murine models of chronic graft-versus-host disease (another 
disease known for the pathogenic importance of GC responses), CXCR5-exppressing Treg 
cells were required to treat this disease308. Botta and colleagues found that in the absence of 
Tfr cells (either by treating influenza infected mice with recombinant IL-2 treatment or by 
infecting Bcl-6flox/floxFoxp3 conditional knockout mice) self-reactive anti-nuclear antibody 
producing plasma cells emerged from influenza-induced GC reactions278. These findings 
suggest that during GC reactions, IL-2 consumption acts as a rheostat that, while facilitating 
specific Tfh cell responses, selectively prevents Tfr cell development at the peak of the GC 
response. Thus, the selective use of Tfr cells (or IL-2 to fine-tune Tfr cell responses) to target 
diseases after the establishment of pathogenic GC reactions might be regarded as a new 
research direction.  
 
The outcome of GC reactions is also modulated by age-induced alteration in Tfh and Tfr cell 
numbers and function309. In a study by Sage and colleagues, an increased proportion of Tfr 
cells (with increased Tfr/Tfh ratio) in aged (compared to young) mice following NP-OVA 
in CFA immunization was observed. Aged mice harboured reduced titres of NP-specific 
antibodies309. The authors used different approaches to address whether defective Tfh and/or 
Tfr cell functions contributed to this observation. They cocultured young and aged Tfr with 
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young Tfh and B cells sorted from NP-OVA immunized mice and further stimulated the 
cells in vitro with NP-OVA. Both young and aged Tfr cells suppressed class switch by B 
cells and Tfh cell proliferation309. To validate these findings, they adoptively transfer young 
and aged Tfr cells along with young Tfh cells to CD28-deficient mice (which cannot generate 
Tfh and Tfr cells). After 10 days of NP-OVA in CFA immunization, antigen-specific 
antibody titres were comparable between recipients of young and aged Tfr cells. While, aged 
Tfr kept their suppressive capacity, aged Tfh cells showed less antigen-specific stimulatory 
capacity309. Thus, defective antigen specific antibody responses in aging resulted, at least in 
part, from the combination of defective Tfh cell function and higher proportions of Tfr cell 
in aged mice.  
 
GC reactions are orchestrated in secondary lymphoid organs in physiological conditions. 
The recent identification of circulating Tfr cells (see above) add an additional layer of 
complexity over the mechanisms of Tfr cell function, as compartments of the immune 
system might evoke different Tfr cell responses196,197,223,258,260,310. Sage and colleagues 
designed in vitro systems to address the function of Tfr cells derived from lymph nodes and 
blood. They first induced immune responses in vivo by immunizing mice with NP-OVA in 
CFA. Then, they sorted B, Tfh and Tfr cells from those immunized mice and stimulated 
them in vitro with anti-CD3 and anti-IgM258,260. Circulating Tfr cells had lower capacity to 
suppress B cell activation and class switch recombination in cocultures with Tfh and B 
cells258. Although, Sage and colleagues did not directly compare blood and lymph node Tfr 
cell function in vivo, they observed that blood Tfr cells were able to suppress B cell activation 
and production of antigen-specific antibodies (while Treg cells were not)260. For that they 
took advantage of adoptive cell transfers of blood Tfr cells (sorted from NP-OVA in CFA 
immunized mice) to Cd28-/- or Tcra-/- mice (which do not generate follicular T cells)260. 
Likewise, when blood Tfr cells from NP-OVA in CFA immunized CD45.2 mice were 
transferred to CD45.1 mice, blood Tfr (CD45.2-expressing cells) cells were readily seen in 
recipient lymph nodes and GC 7 days after NP-OVA immunization258. Hence, blood Tfr 
cells are phenotypically distinct from lymph node Tfr cells, but rapidly gain access to GC 
and suppress antigen-specific B cell responses upon immunization258,260.  
 
Control of Cytokine Milieu and Cell Metabolism 
Sage and colleagues extensively studied Tfr cell function directly on Tfh and B cells using 
several in vitro systems (described above)258–260,272. In these systems, Tfh cells cultured in 
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presence of Tfr cells expressed lower levels of Ki-67, downregulated IFN-γ, IL-21, IL-10 
and TNF-α, and produced less IL-4 and IL-21258,272. In another study, equivalent results were 
observed in Bcl-6-deficient Treg cells. In those mice, Tfh cells upregulated IFN-γ, IL-21, 
and IL-10 upon SRBC immunization303. 
 
At least part of the suppressive mechanism of Tfr cells seems to involve the modulation of 
metabolic pathways (specifically, oxidative phosphorylation, glycolysis and one-carbon 
metabolism), and metabolic checkpoints (such as MTORc1) in Tfh and GC B cells272. Sage 
and colleagues used the same in vitro systems described above to show that neither Tfh or 
B cells lost their transcriptomic signature or activation potential in the presence of Tfr cells, 
but did not express their effector molecules272. Indeed, B cells were still able to express early 
activation markers (such as CD69) and to proliferate in presence of Tfr cells. Additionally, 
the lack of specific effector molecules on Tfh and B cells was not due to cell exhaustion or 
anergy272. The effector molecules of B cells downregulated in presence of Tfr cells were 
Pou2af1 (required for GC B cell formation), Xbp1 (required for antibody secretion) and 
Aicda (required for class switch recombination)137,272,311–313. The modulation of B cells 
persisted in the absence of Tfr cells and was associated with epigenetic changes. However, 
the suppressive state induced by Tfr cells was reversible, as IL-21 addition was able to 
overcome the suppressive effect of Tfr cells by increasing B cell metabolism and by directly 
inhibiting Tfr cells (as described above) (Figure 2)272. While, the exact way Tfr cells induce 
these metabolic changes in Tfh and B cells is speculative, Sage and colleagues proposed that 
Tfr cells may physically interrupt bidirectional costimulation and linked recognition during 
Tfh cell – B cell immunological synapses (which are required for effector functions of both 
cells) (Figure 3)272. Alternatively, Tfr cells may use metabolic disruption mechanisms used 
by Treg cells, such as generation of pericellular adenosine through the action of ectoenzymes 
CD39 and CD73 or transfer of the potent inhibitory second messenger cAMP into effector 
T cells through membrane gap junctions209–213. The suppression actions of adenosine are of 
particular interest in the context of humoral responses, as adenosine can inhibit IL-6, a 
cytokine required for Tfh cell differentiation61,78,212. Curiously, a recent report found that 
adenosine A2a receptor agonists can limit GC and Tfh cell responses following 
immunization, suggesting adenosine may indeed be a mediator of Tfr cell effector functions 
in humoral responses314. 
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Molecular Mechanisms of Tfr Cell Function 
CTLA-4 has a widely known function in maintaining immune homeostasis and mediating 
Treg cell function155,214–216. Indeed, mice selectively lacking CTLA-4 expression on Treg 
cells succumbed to a spontaneous lymphoproliferation with fatal T cell-dependent 
autoimmune disease214,217. Briefly, CTLA-4 works in a cell-extrinsic manner by capturing 
ligands (namely CD80 and CD86) from the surface of APCs, thereby limiting CD28 
engagement. In a highly endocytic behaviour, CTLA-4 can strip APCs of costimulatory 
ligands, traffic them to lysosomes for degradation, and then recycle to repeat215,216,315.  
 
As CTLA-4 expression on Tfr cells was comparable to its expression on activated highly 
suppressive Treg cells (as described above), two independent groups extensively studied the 
role of CTLA-4 in Tfr cell function259,269. Tamoxifen-induced CTLA-4 depletion on Treg 
cells at the time of immune challenge was used by Sage and colleagues to demonstrate that 
GC B cells, Tfr and Tfh cells expanded simultaneously (but with relative greater increase in 
Tfr cells) following immunization with NP-OVA in CFA259. While, transendocytosis and 
downregulation of CD80 and CD86 has been proposed to be one mechanism by which 
CTLA-4 controls immune responses, these authors did not observe any difference on 
CD80/CD86 staining in B cells upon CTLA-4 depletion259,315. Importantly, CTLA-4-
deficient Tfr cells were less capable to suppress class-switch recombination to IgG1, and 
Tfh cell proliferation259. Concordantly, Wing and colleagues showed that in the absence of 
CTLA-4 in Treg cells a massively enhanced GC and Tfh cell responses occurs. In these 
CTLA-4flox/floxFoxp3Cre hemizygous male mice, Treg and Tfr cells were also increased 
suggesting that in the absence of CTLA-4 even high proportions of regulatory T cells are 
unable to restrain humoral responses269. To circumvent a large scale inflammatory milieu, 
the authors also studied CTLA-4wt/floxFoxp3Cre hemizygous male mice. In this context, 
antigen-specific Tfh and B cells (but not NP-specific IgG titres) were increased following 
NP-OVA in alum immunization. To address the mechanisms of CTLA-4 on humoral 
responses, the authors took advantage of female mice homozygous for CTLA-4flox and 
heterozygous for Foxp3Cre to sort CTLA-4-sufficient and CTLA-4-deficient Treg and Tfr 
cells from otherwise healthy mice. Contrary to the in vivo experiments reported by Sage and 
colleagues, CTLA-4-deficient Treg and Tfr cells failed to downregulate CD86 and CD80 on 
activated B cells in vitro269. Additionally, they found that upon CTLA-4 blockage IL-4 
producing Tfh cells increased269. Thus, the authors proposed that CTLA-4 expressed on Tfr 
cells restrains IL-4 secretion by Tfh and blocks CD80/CD86 costimulatory signals on B 
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cells, limiting antigen-specific humoral responses269. Thus, CTLA-4 has been regarded as 
one key mediator of Tfr cell regulation of humoral responses (Figure 3).  
 
Despite most of Tfr cell suppressive capacity is lost in the absence of CTLA-4, it is expected 
that these cells employ multiple and complementary regulatory mechanisms (such as TGF-
β, IL-10 and granzyme B secretion), like other Treg subsets (Figure 3) 28,152,153,155,196,257,297. 
The role of IL-10 and TGF-β in Tfr cell-mediated suppression is largely unknow. The few 
attempts to study the role of IL-10 in Tfr cell function produced mixed results. While, Tfr 
cells produce IL-10 gene transcripts, IL-10 production assessed in supernatants of cocultures 
with Tfh and B cells was reduced when Tfr cells were added, suggesting that Tfr cells might 
not be able to rise the IL-10 concentration near Tfh cell – B cell synapses258,255. Moreover, 
it is unlikely that IL-10 mediates Tfr cell suppression within GC, as IL-10-deficient mice 
have relative normal levels of antibodies and mice with IL-10-deficient Treg cells did not 
developed systemic autoimmunity200,316,317. Tfr cells also express granzyme B (although in 
lower levels than Treg cells), thus granzyme B-mediated cytolysis might be another 
regulatory mechanism employed by Tfr cells, as it was already described for Treg cells (see 
above)164,255. 
 
Division of Labour Between Treg and Tfr Cells 
Although the main biological aspects of Treg cells have been broadly established, it is still 
unclear how different Treg cell subsets integrate to underpin immune tolerance and 
regulation of humoral responses. Many studies demonstrated that in the absence of Foxp3+ 
Treg cells uncontrolled and spontaneous humoral responses arise318–321. Whether those 
findings resulted from the absence of all Treg cell subsets or uniquely from the absence of 
CXCR5+ Tfr cells is not known. Nevertheless, humoral suppressive capacity has been 
claimed to be assigned uniquely to Tfr cells. This concept arose from Sage and colleagues 
observations that conventional (non-Tfr) Treg cells lack the capacity to suppress Tfh cell 
proliferation, B cell activation, and class switch recombination258. Likewise, conventional 
Treg cells did not fully abrogate the secretion of IgG (contrary to Tfr cells)272. To validate 
these in vitro findings, Sage and colleagues transferred Tfh and Tfr (or Treg) cells (sorted 
from NP-OVA in CFA immunized mice) to Tcra-/- mice. In these lymphopenic conditions 
and using 1:2 non-physiological Treg/Tfh ratio, they claimed conventional Treg cells were 
not able to block NP-specific IgG secretion by B cells260. Conversely, two independent 
groups found a comparable decrease in Tfh cell proliferation when co-cultured with Tfr and 
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conventional Treg cells254,269. Hence, while a direct comparison of Tfr and conventional Treg 
in physiological conditions is lacking, Tfr cells presumably acquire their unique humoral 
suppressive capacity when they co-opt Tfh cell differentiation program. The suppression of 
Tfh cell proliferation is probably not unique to Tfr cells, as it might be a general Treg cell 
feature. It is noteworthy that migration toward CXCL13 enriched B cell zones is only 
possible for CXCR5-expressing cells. Therefore, one critical aspect that might distinguish 
Tfr from conventional Treg cells in vivo is the exceptional ability of Tfr cells to get access 
to GCs. 
 
3.3.3. Tfr Cells in Humans 
 
As described above, Tfr cell biology has been mainly studied in murine models. However, 
there is a growing concern that laboratory mice do not reflect many relevant aspects of the 
human immune system322. Therefore, studies directly performed in humans are vital to 
understand Tfr cell biology in the complex human immune system.  
 
So far, it has been shown that, Tfr cells in human lymph nodes do not require B cells for 
their maintenance, as depletion of CD20+ B cells by rituximab did not decrease the number 
of CD57+CXCR5+Foxp3+CD127- Tfr cells323. Similarly to murine findings, there is evidence 
suggesting some divergence in human Tfr and Tfh cells differentiation: a primary 
immunodeficiency defined by PI3KR1 gain-of-function mutation did not affect the 
frequency of tonsil Tfr cells, while it significantly reduced the frequency of Tfh cells324.  
 
The restricted access to human tissues forced the search for putative Tfr cells in human 
blood. Several studies confirmed circulating CXCR5+ T cells as the counterparts of tissue 
Tfh cells, arising from lymphoid tissue cells before reaching the GC, in spite of low Bcl6 
expression53–56,120. It is well known that some human blood Treg cells express CXCR5 
among other CXC chemokine receptors325. Thus, many studies have been using circulating 
CXCR5+Foxp3+ T cells to define Tfr cells in humans (see below). Surprisingly, no study 
specifically addressed whether blood CXCR5+Foxp3+ T cells are truly circulating GC Tfr 
cell counterparts. Although circulating memory Tfr cells were observed after immunization 
protocols in mice258,260, CXCR5 and Foxp3 transient upregulation upon human T cell 
activation challenge the assumption that human blood CXCR5+Foxp3+ T cells are Tfr 
cells49,235,326–328. Dhaeza and colleagues found that blood CXCR5+PD-1+CD25+CD127- T 
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cells increased on day 7 following influenza vaccination (showing a positive correlation with 
plasma antibodies titers for influenza), and suppressed T cells in vitro upon αCD3/CD28 
stimulation329. Although this report has correlated blood CXCR5+PD-1+CD25+CD127- T 
cells with influenza vaccination responses, they did not provide any evidence of an intrinsic 
humoral regulatory capacity. The results described in the first part of the results of this thesis 
addressed this specific issue providing the first evidence of the biology and ontogeny of 
human blood CXCR5+Foxp3+ T cells from a Tfr cell perspective330. 
 
Based on these limited studies some aspects of Tfr cell biology are now being clarified 
(Table 4).  
 
Table 4: Biology of Tfr cells in Mice and Men 
Adapted from Maceiras at al331 
 Mice Men 
   
Membrane 
markers 
CD25, CXCR5, PD-1, ICOS, CTLA-4 CD25, CXCR5, PD-1, ICOS (?) 
   
Transcription 
factors 
Foxp3, Bcl-6, Blimp-1, NFAT2 Foxp3, Bcl-6 
   
Immune 
compartments 
Lymph node, spleen, blood 
Tonsil, lymph node, spleen, blood, 
ectopic lymphoid structures 
   
Cell of  
origin 
Thymic Treg cells Not directly studied 
   
Differentiation 
signals 
MHCII, CD28, ICOS, PD-1, SAP, IL-
21, SOCE, TRAF3, STAT3 
IL-21. Other molecules not directly 
studied. 
   
Functions 
 Control Tfh and GC B-cell 
numbers by inducing a suppressive 
state and inhibiting proliferation 
 Impair IL-4 and IL-21 production 
by Tfh cells 
 Reduce the levels of antibodies 
produced (namely IgM and IgG) 
and class switch recombination 
 Control antibodies’ quality 
 Impair Tconv and Tfh cell 
proliferation 
 Impair IL-4 and IL-21 production 
by Tfh cells 
 Impair immunoglobulin (namely 
IgA) production by B cells 
   
TCR Repertoire 
Tfr cells have an oligoclonal TCR 
repertoire, different from Tfh cell 
repertoire, and similar to the repertoire 
of Treg cells. 
Unknown 
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3.3.4. Tfr Cells in Different Human Diseases 
 
Despite the speculative role of human blood CXCR5+Foxp3+ Tfr cells as a specialized subset 
of Treg cells in regulating humoral responses, recently many groups reported altered Tfr cell 
composition in peripheral blood of patients with several diseases (Table 5). 
 
Table 5: Foxp3+ Tfr cells in Human Diseases 
Adapted from Maceiras at al331 
Reference Clinical Condition Tissues Tfr cells Major findings 
Faghih et 
al, 2014332 
Breast cancer 
Lymph 
nodes 
CXCR5+ 
Foxp3+ 
Bcl6+ 
CD4+ 
No impact on Tfr cell frequency. 
Wallin et 
al, 2014323 
Kidney transplant 
recipients 
undergoing therapy 
with Rituximab 
Lymph 
nodes 
CD57+ 
CXCR5+ 
Foxp3+ 
CD127- 
CD4+ 
Rituximab had no impact on Tfr cells.  
Tfr cells reduced IgA production by B 
cells (in vitro). 
Wang et 
al, 2014333 
Chronic hepatitis B 
(HBV) and C 
(HCV) 
Blood 
CXCR5+ 
Foxp3+ 
CD4+ 
Tfr cells increased during HBV and 
HCV infection. Tfr cells positively 
correlated with HBsAg titres and viral 
load. 
Chen et al, 
2015334 
S. japonica 
infection 
Blood 
CXCR5+ 
Foxp3+ 
CD4+ 
Tfr cell frequency increased during S. 
japonica infection. 
Colineau 
et al, 
2015335 
HIV-1 infection Spleen 
Foxp3+ 
CXCR5+ 
CD45RA- 
CCR7- 
CD4+ 
Tfr cell frequency increased during HIV 
infection. 
De Bruyne 
et al, 
2015336 
Food alergy Blood 
CXCR5+ 
CD45RO+ 
Foxp3+ 
CD25+ 
CD4+ 
No impact on Tfr cell frequency. 
 
Dhaeze et 
al, 2015329 
Multiple sclerosis 
(MS) 
Blood 
CXCR5+ 
PD-1+ 
CD25+ 
CD127- 
CD4+ 
Tfr cell frequency increased upon 
influenza vaccination, positively 
correlating with specific antibody titres.  
Tfr cell frequency was decreased in MS, 
showing less suppressive capacity. 
Miles et 
al, 2015337 
HIV-1 infection 
In vitro 
Lymph 
nodes 
Tonsil 
cells 
CD25+ 
CD127- 
CXCR5+ 
CD3+ 
CD8- 
Tfr cell expanded upon HIV infection 
(TGF-β dependent). Tfr cells reduced 
ICOS+IL-21+IL-4+ Tfh cells. 
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Shan et al, 
2015338 
Ankylosing 
spondylitis (AS) 
Blood 
CXCR5+ 
Foxp3+ 
CD4+ 
Tfr cells were increased in AS, 
increasing further upon therapy. Tfr cells 
negatively correlated with serum IgA 
titres. 
Di Fonte 
et al, 
2016324 
PI3KR1 gain-of-
function (c.1425 + 
1G>T) 
Tonsil 
CXCR5+ 
Foxp3+ 
CD4+ 
No impact on Tfr cell frequency. 
Moody et 
al, 2016339 
HIV-1 infection Blood 
CXCR5+ 
CD25+ 
Foxp3+ 
CD4+ 
Tfr cells were increased in HIV infected 
patients  
Xu et al, 
2016340 
Kidney allograft 
rejection 
Kidney 
CXCR5+ 
Foxp3+  
Tfr cells were rarely present in kidney 
tertiary lymphoid structures. 
Vaeth et 
al, 2016283 
ORAI1 p.R91W Blood 
CD45RO+ 
Helios+ 
Foxp3+ 
CD4+ 
SOCE signalling defects impaired Tfr 
cell frequency. 
Wen et al, 
2016341 
Myasthenia gravis 
(MG) 
Blood 
CXCR5+ 
Foxp3+ 
CD4+ 
Tfr cells were decreased in MG, 
inversely correlating with disease 
severity. Treatment with steroids re-
establish the frequency of Tfr cells. 
Chen et al, 
2017342 
Kidney allograft 
rejection 
Blood 
Kidney 
CXCR5+ 
ICOS+ 
Foxp3+ 
CD127- 
CD4+ 
Tfr cells were decreased in patients with 
antibody-mediated rejection. Tfr cells 
inhibited B cell proliferation and IgA and 
IgG production. Sirolimus induced a 
decrease in Tfr cell frequency. 
Cobb et al, 
2017343 
HCV Liver 
CXCR5+ 
PD-1+ 
Foxp3+ 
CD25+ 
CD4+ 
Liver Tfr cells were increased in HCV 
infected patients. Tfr cell expansion was 
induced by TGF-β-containing exosomes 
derived from HCV-infected hepatocytes. 
Tfr cells restrained Tfh cell proliferation. 
Cunill et 
al, 2017344 
Common Variable 
Immunodeficiency 
(CVID) 
Blood 
CXCR5+ 
CD25+ 
CD127- 
CD4+ 
Tfr cells were reduced in CVID patients 
with < 2% of IgD-CD27+ B cells. Tfr 
cells suppressed conventional T cell 
proliferation. 
Fonseca et 
al, 2017330 
Sjögren’s syndrome 
(SS) 
Healthy  
Blood 
CXCR5+ 
Foxp3+ 
CD25+ 
CD4+ 
Tfr cells were increased in SS patients 
with serum autoantibodies. Blood Tfr 
cells are immature cells, not fully 
licensed with humoral suppressive 
function (in vitro). Blood Tfr cells 
emerge prior to B cell interactions.  
Miller et 
al, 2017345 
HIV-1 infection 
In vitro 
Tonsil 
cells 
CXCR5+ 
CD25+ 
CD127- 
CD3+ 
CD8- 
Tfr cells expressed CCR5 and Ki-67 at 
baseline.  Tfr cells were the most 
permissive cell type for R5-tropic HIV1 
infection. 
 
Autoimmune diseases 
So far, very few studies addressed Tfr cells in human autoimmunity. Blood CXCR5+PD-
1+CD25+CD127- Tfr cells were found reduced in MS patients329. In addition, blood Tfr cells 
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from MS patients were less suppressive than equivalent cells sorted from healthy controls, 
using CD25-CD127+ T cells as responders in vitro329. This work suggests that blood Tfr cells 
might be functionally defective in autoimmunity. However, the functional assays performed 
in this study did not address the putative specialization of Tfr cells in suppressing humoral 
responses. An additional study also found a decreased frequency of blood CXCR5+Foxp3+ 
Tfr cells in untreated patients with MG, recovering to normal levels after corticosteroid-
based treatment341.  
 
However, not all studies of CXCR5+Foxp3+ T cells in autoimmunity are concordant. A 
higher frequency of blood CXCR5+Foxp3+ Tfr cells was found in patients with AS, 
increasing even further after treatment with the TNF blocker, Etanercept338. The blood 
frequency of Tfr cells did not correlate with MS nor AS disease severity, questioning the 
direct role of blood CXCR5+Foxp3+ T cells in autoimmune pathogenesis. In SLE, Xu and 
colleagues described a reduced frequency of blood CXCR5+CD25+CD127- Tfr cells, 
although, they did not use Foxp3 for identifying those cells346. Blood Tfr cell population, 
which was enriched for PD-1+ICOS+ cells, negatively correlated with anti-dsDNA 
antibodies, disease activity score, and serum IL-21 concentration, but not with total IgG or 
frequency of blood plasmablasts. Interestingly, patients with relapsing SLE showed an 
increase in Tfr cell frequency after treatment346. While, this work suggests that Tfr cells are 
decreased in blood of patients with chronic systemic autoimmune diseases, it is noteworthy 
that treatment regimens at baseline were not considered during data analysis. Whether 
reduced Tfr cells in blood was due to SLE or to immunosuppressant drugs is not known. 
 
Overall, those studies showed that blood Tfr cells are reduced in human autoimmune 
diseases. As their relationship with disease activity, autoantibody production, and treatment 
regimens was not consistent in the different studies, the biological role of Tfr cells in 
autoimmunity remains elusive.  
 
HIV and Other Infectious Diseases 
HIV-1 infected patients (not receiving highly active antiretroviral therapy) have an increased 
frequency of GC Foxp3+CD4+ Tfr cells337, spleen Foxp3+CXCR5+CD45RA-CCR7-CD4+ 
Tfr cells335, and blood CXCR5+CD25+Foxp3+CD4+ Tfr cells339. Tfh cells (defined as 
CXCR5+CD45RA-CCR7-CD4+ T cells for spleen and as PD-1+CXCR3-CXCR5+ CD4+ T 
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cells for peripheral blood) were also increased, suggesting that Tfr and Tfh cell expansion 
can occur simultaneously in cases of antigen persistence.  
 
In vitro studies using tonsil cells spinoculated with X4 and R5 HIV-1 have shown Tfr cell 
expansion (with increased CTLA-4, LAG3 and IL-10 expression) upon HIV infection in a 
TGFβ-dependent manner337. It remains to be determined whether induced Treg cells are 
physiologically present in vivo as functionally competent suppressive cells in humans, Miles 
and colleagues confirmed (in line with murine studies described above) that CXCR5+CD25- 
Tfh cells did not acquire Foxp3 expression upon in vitro stimulation, even in the presence 
of TGFβ171,328,337,347,348. These authors also demonstrated that in HIV-1 infected tonsil cells, 
a predominance of indoleamine-2,3-dioxygenase producing plasmacytoid DCs, known for 
their role in Treg cell generation, were increased, indicating specific DCs subsets may be 
more proficient in promoting Tfr cell fate27,349–351. In the context of in vitro HIV-1 infection, 
Tfr cells impaired ICOS expression and proliferation of Tfh cells, as well as their IL-21 and 
IL-4 secretion capacity337. Tfr cells were also found to be the most permissive CD4+ T cell 
subset to R5-tropic HIV-1 infection both in vitro and in vivo345. Again, with tonsil cells 
spinoculated with X4 and R5 HIV-1, Miller and colleagues demonstrated that 
CXCR5+CD25+CD127-CD3+CD8- Tfr were the most permissive cells for R5-tropic HIV-1 
internalization. This finding was not due to acquisition of Tfr cell markers upon HIV-1 
infection, but owed to expansion of pre-existent Tfr cells337,345. Additionally, they showed 
that Tfr cells from lymph nodes of HIV-1 infected patients had the highest number of HIV-
1 copy number per ng of total RNA345. They claimed high proliferative rate and high CCR5 
expression of Tfr cells could drive this permissivity345. In blood, the presence of broad 
neutralizing antibodies did not impact the frequency of Tfr cells, although patients with high 
titres of neutralizing antibodies displayed a higher expression of PD-1 in Tfr cells339. 
Although increased PD-1 signalling has been shown to inhibit Tfr cell function in mice260, 
it is still highly speculative to correlate the presence of broad neutralizing antibodies with 
putative Tfr cell exhaustion.  
 
Blood CXCR5+Foxp3+ Tfr cells were also found increased in HBV and HCV chronically 
infected patients, showing a significant correlation with blood viral load in both infections. 
Another group studied Tfr cells in cell suspensions obtained from HCV infected livers343. 
CXCR5+PD-1+CD25+Foxp3+ Tfr cells, as well as Tfh cells, were increased in the liver of 
HCV infected patients. Then, Cobb and colleagues used in vitro co-cultures with human 
Introduction 
58 
 
hepatoma cell lines to demonstrate that HCV-infected hepatocyte induced Tfr cell expansion 
(with higher IL-10 and CTLA-4 expression)343. They claimed HCV-infected hepatocytes 
were able to expand highly suppressive Tfr cells, yet they did not compare Tfr cells derived 
from HCV-infected hepatocytes co-cultures with Tfr cells derived from non-infected control 
cultures343. Curiously, when Cobb and colleagues blocked TGF-β on exosomes derived from 
HCV-infected hepatocytes the Tfr cell expansion effect was lost343.  In recent years, the 
modulation of immune system by exosomes (and extracellular vesicles), and its therapeutic 
potential, became one area of active research202. Thus, the work of Cobb and colleagues 
(although performed in very artificial systems) disclosed one putative mechanism by which 
exosomes may regulate humoral immune responses in the context of HCV infection. An 
increased frequency of blood CXCR5+Foxp3+CD45RA- Tfr cells was also found in 
helminthic infection by Schistosoma japonica334.  
 
Primary Immunodeficiencies 
Many human monogenic primary immunodeficiencies are associated with defective B cell 
responses. It is the case of STAT3, IL-10R, CD40L, NEMO, BTK, and ICOS mutations 
where, as anticipated, there is a decreased frequency of Tfh cells119. Although, frequency of 
blood CXCR5+Foxp3+ Tfr cells were not yet studied in these pathologic conditions, patients 
with less than 2% of IgD-CD27+ B cells in the setting of Common Variable 
Immunodeficiency (CVID) have a reduction of blood CXCR5+CD25hiCD127low Tfr cell 
frequency, in line with a reduction of total Treg frequency in peripheral blood344. While, this 
study suggests a relationship between IgD-CD27+ B cells and blood Tfr cells, the clinical 
heterogeneity and largely unknown molecular mechanisms driving CVID preclude a definite 
conclusion about blood Tfr cell ontogeny352. Specifically, gene defects known to cause 
CVID (such as, genes encoding CTLA-4, ICOS, IL-21, and IL-21R) can directly affect Tfr 
cell differentiation and function (Figure 1 and 2)259,269,270,352.  
 
Recently, the SOCE (store-operated calcium entry) pathway in T cells has been implicated 
in Tfr cell differentiation in humans. Patients with severe combined immunodeficiency-like 
disease due to inherited loss-of-function mutations in ORAI1 and STIM1 (genes that abolish 
SOCE) have a significant reduction in blood CD45RO+Helios+Foxp3+ Tfr-like cells283. In 
another recent study, IL-21R-deficiency patients have been shown to have a significant 
increase in frequency of blood Foxp3+CXCR5+PD-1+ Tfr cells. In contrast, a marked 
decrease in circulating CXCR5+PD-1+ Tfh cells was observed in IL-21R-deficiency 
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patients270. Taken together, these recent studies suggest that human Tfh and Tfr cells have 
different, sometimes reciprocal, requirements for their differentiation.  
 
Transplantation 
In renal transplant patients with acute and chronic rejection, very rare CXCR5+Foxp3+ Tfr 
cells were found within graft tissues. Xu and colleagues claimed Tfr cells (as well as Treg 
cells) were not responsible for tolerance in ectopic lymphoid structures (ELS) found in the 
graft tissues, as the presence of Tfr cells was not associated with longer duration of graft 
function340. More recently, blood CXCR5+ICOS+Foxp3+CD127- Tfr cells and tissue (renal 
allograft sections) CXCR5+Foxp3+ Tfr cells were associated with antibody-mediated 
rejection in renal transplant patients342. Using unspecified in vitro conditions, a decreased 
frequency of recovered Tfr cells was found when peripheral blood lymphocytes (sorted from 
healthy donors) were cultured under the presence of Sirolimus (compared to Cyclosporine 
and Tacrolimus)342. This finding is not consistent with NFAT2-dependency of Tfr cell 
differentiation, as Sirolimus blocks mTOR and not NFAT (like Cyclosporine and 
Tacrolimus do)282,283,353. Chen and colleagues speculated that Tfr cells directly inhibited B 
cell proliferation and IgG and IgA production in a CTLA-4, IL-10 and TGF-β-dependent 
manner342. Curiously, the author did not define the stimulation conditions for B cell 
proliferation and activation. In contrast, the same researches, in another set of experiments 
concluded Tfr cells from patients with antibody-mediated rejection had no functional 
defect342. 
 
 
4. T – B Cross-Talk in Autoimmunity 
 
The concept of autoimmunity was first predicted by Nobel laureate Paul Ehrlich at the start 
of the twentieth century with the definition of “horror autotoxicus”. His experiments led him 
to conclude that the immune system is normally focused on responding to foreign agents and 
has an inbuilt tendency to avoid attacking self-tissues. However, the occasional failure to 
distinguish friends from foes results in a coordinated attack of self-tissues resulting in 
autoimmune diseases. The perplexing issue of what allows the immune system to attack self-
tissues is still an active focus of research. At a biochemical level, no structural difference 
exists between self and foreign antigens. Autoreactive immune cells can, and do, arise 
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against any tissue, yet the prevalence of autoimmunity remains low because additional 
molecular, cellular and contextual cues control immune responses towards self-antigens. 
 
More than 80 distinct autoimmune diseases have been described and many of these are 
associated with the development of autoantibodies. Indeed, detection of autoantibodies in 
patients’ serum is used in the clinical diagnosis of many autoimmune diseases. Some studies 
suggested that autoantibodies share a common ontogeny with conventional antibodies that 
are formed during T cell-dependent responses to foreign antigens or indeed as a consequence 
of somatic hypermutation in GCs15,354,355. Several strains of mice that typically develop 
autoimmune diseases exhibit spontaneous GC formation providing further evidence that GC 
reactions are involved in the pathogenesis of autoimmune diseases143. Moreover, in organ-
specific autoimmune diseases, in which expression of the target self-antigen is often tissue 
restricted, organized ELS (also called tertiary lymphoid organs) harbouring abnormal self-
centred GC reactions, form at the site of tissue pathology (see below)143,356,357.  
 
Thus, B – T crosstalk is a ubiquitous phenomenon in immune responses driving 
autoantibody-mediated autoimmune diseases. In the last years, targeting various critical 
molecules involved in pathological pathways of autoimmune diseases has led to disease 
modulation. However, most of these new immune therapies target cytokines or individual 
cell subsets in non-rate-limiting processes. While, few therapies, such as anti-TNF 
monoclonal antibodies, have markedly ameliorated some autoimmune disease progression, 
most of the available drugs have little benefit and/or serious adverse effects in autoimmune 
diseases358. Targeting continuous self-centred B – T crosstalk might selectively disrupt 
autoantibody formation and prevent B-cell lymphomagenesis143,356,357,359.  
 
4.1. Dysregulation of Germinal Centre Responses 
 
Pathological autoantibodies are mainly dependent on GC reactions, as the majority are high 
affinity IgG antibodies143. The stochastic nature of somatic hypermutation makes the 
generation of autoreactive B cell clones an almost certain by-product of routine GC 
responses to foreign antigens15,360,361. If these autoreactive B cell clones are not effectively 
eliminated or at least regulated, there can be long-term consequences in the form of 
autoimmune diseases143. Therefore, dysregulated GC responses are an important component 
in the pathogenesis of autoimmunity disorders.  
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A wide range of murine studies have identified several mechanisms responsible for breaking 
GC tolerance in autoimmunity143. On the B cell side, TLR7 and TLR9 signalling, induced 
by the large amounts of self-DNA and RNA exposed by apoptotic GC B cells can overcome 
the need for cognate Tfh cell help, thereby driving the selection of autoantibody-producing 
B cell clones362–364. Failure of pro-apoptotic instructions (defined by downregulation of Bcl-
2 and Bcl-XL, and upregulation of BIM) in low affinity and autoreactive B cells may also 
promote their maintenance and development365–368. Finally, altered regulation of BCR 
signalling in GC B cells by low-affinity Fc receptors (FcγRIIB), which work by coupling 
the BCR to an inhibitory pathway, was also found to account for autoantibody-mediated 
disorders369–371. Insufficient disposal of apoptotic bodies by DNaseI, receptor tyrosine kinase 
MER, transglutaminase 2, complement component C1q and peroxisome proliferator-
activated receptor-δ compromise the clearance of apoptotic cells leading to autoantibody 
formation372–376. On the Tfh cell side, overexpression of OX40L, TLR7 or Tfh cell intrinsic 
Roquin mutations contribute to aberrant positive selection of autoreactive B cell clones in 
murine models of autoimmune diseases377–380. The abnormal positive selection of 
autoreactive GC B cells may also be perpetuated by deficient CD95/CD95L signalling381–
383. Additionally, excessive production of IL-21 may further contribute to GC longevity and 
emergence of autoantibody responses in those animal models273,274,379.  
 
Although, the role of somatic hypermutation and antigen-driven affinity maturation is well 
established in mouse and human autoimmunity, the actual contribution of defective GC-
based checkpoints to the generation of autoantibody-mediated disorders is very difficult to 
establish in humans143. Nevertheless, multiple lines of evidence, namely from studies with 
SLE patients, support the role for abnormal GC reactions in the pathogenesis of human 
autoimmune diseases. First, the use of CD40L-specific antibodies ameliorates SLE disease 
severity and autoantibody titres, suggesting a follicular origin of autoantibodies384,385. 
Moreover, defective free apoptotic bodies clearance in SLE patients was associated with the 
induction of pathogenic autoantibodies386,387. Notably, the study of autoreactive 9G4 B cells 
have demonstrated that GCs in healthy individuals are competent in censoring these cells. 
By contrast, a high proportion of tonsil GCs from patients with SLE showed expansion of 
9G4 B cell clones388,389. These findings suggest that defective GC-based tolerance 
checkpoints take part in the pathogenesis of human autoimmune diseases143. Lastly, an 
increasing number of studies have shown aberrant Tfh cell responses in patients with 
different autoimmune diseases143,390–392.  
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Autoimmunity of follicular origin poses a considerable challenge because once the long-
lived autoreactive B cells have been generated, treatments that disrupt GCs might fail. As 
the treatment of human autoimmune diseases often occurs years after the onset of the 
pathogenic process, combined therapeutic approaches targeting ongoing autoreactive GC 
reactions and the autoreactive long-lived B cell compartment may be an ideal option for 
those patients. However, to accomplish this aim, a GC “tune down” approach would be 
necessary in order to reduce the risk of autoimmunity while preserving foreign antigen-
specific responses. Following the discovery of Tfr cells as GC “fine tune” regulators (as 
described above), targeting Tfr cell responses may constitute a novel and highly selective 
approach to the treatment of autoantibody-mediated autoimmune diseases. Yet, the still 
embryonic knowledge about Tfr cell biology in humans halts these advances. 
 
4.2. Ectopic Lymphoid Structures  
 
Tissues harbouring the target antigens of chronic immune responses are usually infiltrated 
by cellular effectors of the immune system, mainly T cells and macrophages, but also APCs, 
B cells, and plasma cells. These cellular elements often organize themselves anatomically 
and functionally as in secondary lymphoid organs, leading to de novo and ectopic formation 
of B cell follicles and T cell areas (ELS). This phenomenon is termed lymphoid neogenesis 
or tertiary lymphoid organ formation356,357,393. The architecture organization of ELS 
resemble the follicular compartment seen in secondary lymphoid organs, ranging from 
simple aggregates of B and T cells to highly ordered structures. The most complex ELS 
develop high endothelial venules (specialized postcapillary venous swelling that enable 
access to lymphocytes expressing L-selectin) and networks of stromal-derived FDCs356,357. 
Importantly, AID expression with evidence of in situ B cell affinity maturation and clonal 
selection characterizes these highly organized ELS357. However, contrary to secondary 
lymphoid organs, ELS lack afferent lymphatics, thus their formation is presumably driven 
by antigen diffusing from the surrounding inflammatory milieu143. 
 
The formation of ELS is not exclusive to autoimmune diseases, as it has also been described 
in chronic infections, graft rejection and cancer356. Following the demonstration of in situ 
pathogenic autoantibody production in ELS by Armengol and colleagues, compelling 
evidence supports the importance of ELS in human autoimmune diseases, namely in 
Rheumatoid Arthritis (RA), SS, SLE, MS, Primary Sclerosing Cholangitis, Primary Biliary 
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Cirrhosis, Hashimoto’s Thyroiditis, and MG356,357,394. 
 
4.2.1. Development of Ectopic Lymphoid Structures 
 
The mechanisms that regulate formation, maintenance and function of ELS are largely 
shared with those involved in the organogenesis, maintenance and function of secondary 
lymphoid organs395,396. In inflamed tissues, stromal/mesenchymal cells may acquire 
lymphoid tissue organizer cell-like properties, such as secretion of IL-7, RANKL and 
CXCL13. Indeed, some studies found that even in the absence of secondary lymphoid 
organs, the expression of chemokines in non-lymphoid organs is essential for local B and T 
cell responses and for the development and organization of ELS397–399. Those activating 
signals induce the migration of lymphoid tissue inducer and initiator cells. The interaction 
between membrane-bound heterotrimeric LTβ (LTα1β2) expressed by these cells with LTβ 
receptor expressed by mesenchymal cells triggers the subsequent development of ELS via 
CXCL13, CCL19 and CCL21 secretion356,357,396. At this stage, the formation of the 
lymphotoxin-lymphoid chemokine feedback loop is also required for the development of 
high endothelial venules400. Following this homeostatic chemokine release, an increasing 
number of CCR7+ (which engage CCL19 and CCL21) T cells, as well as other T and B cell 
subsets, will progressively infiltrate the ELS356,357,395,401. In the specific inflammatory milieu 
driving ELS in autoimmune diseases, IL-17/IL-23 pathway was also found to contribute for 
ELS formation and maintenance356,357. Both IL-17 producing adult innate lymphoid cells 
(ILC3 cells) and Th17 cells were found to contribute to ELS development402,403. In addition 
to IL-17, IL-22 was reported to be required for the development of ELS that formed in 
salivary glands in a mouse model of virus-induced lymphoid neogenesis (which displays 
several features of SS). In that experimental model, IL-22 promoted CXCL13 secretion by 
exocrine gland stroma cells, thereby inducing ELS development404. Consistently, another 
report found that IL-22-deficient mice were protected from ELS development and 
autoimmunity through reduced B-cell recruitment to salivary glands405. 
 
The presence of ELS is often a transient feature of inflamed tissues, thus, the mechanisms 
that control their maintenance during disease may have greater clinical significance. Some 
reports have implicated Tfh cell responses and IL-21 in ELS development in patients with 
RA and SS406,407. While, known mechanisms of Tfh cell function in humoral responses 
formed in lymphoid organs may prompt the assumption that Tfh cells are key mediators of 
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maintenance and acquisition of GC features by ELS, this is still too speculative. However, 
other T helper cell subsets can contribute to GC reactions within ELS. Indeed, a IL-21-
producing CXCR5-PD-1+ T cell population (called peripheral T helper cells) was found 
within ELS formed in synovial tissues of RA patients and proposed to be uniquely poised to 
promote B-cell responses and antibody production within inflamed non-lymphoid tissues408. 
Recently, IL-27-deficient mice were found to develop a more severe form of antigen-induced 
arthritis, characterized by the development of multiple ELS. In parallel, levels of IL-27 in 
synovial tissue from patients with AR correlated inversely with ELS development409. These 
findings suggest that IL-27 may be a negative regulator of ELS formation and/or 
maintenance357. Whether other negative regulators, such as Tfr cells, also play a role in ELS 
maintenance and function is not known. 
 
4.2.2. Autoantibody Formation in Ectopic Lymphoid Structures 
 
Some studies have shown, conclusively, that ELS in inflamed tissues retain the necessary 
molecular machinery to support in situ antibody diversification within ectopic GC 
reactions356,357. Microdissection of ectopic GCs isolated from synovium of patients with RA 
and salivary glands of patients with SS has demonstrated that ELS were populated by B cell 
clones with highly somatically hypermutated antibodies410–412. Indeed, intra-tissue AID-
dependent clonal diversification and differentiation into antibody-producing cells can occur 
within ectopic GC in non-lymphoid organs413–415. Besides their engagement with 
autoantibody production, ELS have been implicated in the perpetuation of autoimmunity 
within the target organ356,357. While some studies questioned the importance of ELS for 
autoantibody production, based on the presence of ELS in seronegative (no autoantibody 
detection in serum) RA patients, a large body of evidence corroborated the pathogenic role 
of ELS in autoantibody production413,416. Using a human-mouse chimeric model, Humby 
and colleagues demonstrated that only the engraftment of ELS-positive synovial tissue from 
RA patients resulted in the release of human class-switched anti-citrullinated autoantibodies 
(the hallmark of RA), as compared to ELS-negative synovial tissues413,417–420. Autoreactivity 
towards SS-associated autoantigens, such as ribonucleoproteins Ro/SSA and La/SSB, was 
also detected in plasma cells which were infiltrating ELS in salivary glands of SS patients418–
420.  
 
Notably, many of the regulatory mechanisms that ensure tolerance within GC reactions in 
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secondary lymphoid organs are not seen in ELS induced in autoimmune settings143,356. Le 
Pottier and colleagues demonstrated that autoreactive 9G4 B cells were not excluded from 
ELS found in salivary glands of SS patients415. Although, the mechanisms driving 
accumulation of autoreactive B cells in ELS are not fully understood, some reports have 
implicated a role for Epstein-Barr virus (EBV)356,418,421–423. EBV is a γ-herpesvirus which is 
usually acquired silently early in life and carried thereafter as an asymptomatic infection of 
the B lymphoid compartment424. ELS from patients with MS, MG, RA and SS frequently 
harbour latent EBV infection, where EBV-transformed B cells and plasma cells display 
autoreactivity to disease-specific autoantigens, such as citrullinated fibrinogen in RA and 
ribonucleoprotein Ro/SSA in SS418,421–423. 
 
Overall, the above evidence strongly supports that ELS encompass an additional and/or 
alternative site for autoantibody production by putative dysregulated GC reactions which 
perpetuate pathogenic mechanisms of autoimmune diseases. However, the prevalence of 
ELS with GC features varies among autoimmune diseases356,357. While, around 20% of ELS 
found in exocrine glands of SS patients have GC activity, GC are virtually absent in ELS 
from SLE and Autoimmune Myositis patients, suggesting that ELS account for clinical 
heterogeneity observed in patients with autoimmune diseases411,425–427. The reason 
underlying such variability remains unknown, although genetic predisposition and/or 
environmental factors shape the inflammatory response to give rise to diverse structural 
outcomes within individual tissue microenvironments356,357. 
 
4.2.3. Targeting Ectopic Lymphoid Structures 
 
Besides their role in the pathogenesis of autoimmune diseases, ELS have been reported as 
useful markers of disease severity with prognosis relevance and as new therapeutic targets 
in autoimmunity.  
 
In SS, the presence of ELS in salivary glands is associated with higher levels of circulating 
autoantibodies and systemic manifestations, as well as with the risk of subsequent mucosal-
associated lymphoid tissue (MALT) lymphoma development418,419,428–430. The evidence for 
clinical relevance of ELS in RA is more controversial. While, several studies have reported 
that ELS are associated with increased circulating levels of inflammatory markers, 
autoantibody status and higher disease severity, others reports have failed to find a direct 
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correlation between the presence of ELS and those disease features431,432. In SLE, very few 
studies have also shown an association between the presence of renal ELS and severity of 
lupus nephritis433. 
 
Although, the results are conflicting, ELS have also been studied as predictors of response 
to TNF inhibitors (Infliximab) and anti-CD20 antibodies (Rituximab)434,435. In RA patients 
persistence of ELS after Infliximab treatment emerged as a negative predictor of clinical 
improvement434,435. In SS patients, treated with Rituximab, the median number of CD20+ B 
cells within ELS in parotid gland emerged as a positive predictor of clinical improvement436. 
 
The advances in the understanding of the mechanisms regulating the formation, maintenance 
and function of ELS, and the increased appreciation of their importance in disease 
pathogenesis and response to treatment, have provided a strong rationale for targeting ELS 
in autoantibody-mediated autoimmune diseases for therapeutic purposes. So far, attempts to 
disrupt ELS formation using Baminercept (a fusion protein of human LTβ receptor and 
human IgG1) failed to demonstrate clinical efficacy in RA and SS357. Therapeutic 
approaches targeting T-B cell interactions, rather than solely disrupting ELS, might instead 
fine-tune the function of ectopic GC, thereby representing an attractive new strategy. 
However, to effectively advance the field, it is essential to stratify patients according to the 
presence of ELS and to refine methodologies to study mechanisms regulating ELS biology. 
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Humoral immunity is critical for the clearance of pathogens and is also the basis for 
protection elicited by vaccines. Failure of the immune system to enforce tolerance during 
humoral responses readily leads to the development of autoimmune diseases. Although, the 
identification of most players in the process of autoimmunity have led to development of 
virtuous immune-based therapies in the last decade, none is able to induce complete and 
sustained remission of autoimmune diseases. Moreover, very few immune-based therapies 
target endogenous regulatory mechanisms, especially those used to survey the emergence of 
self-reactive B cells within GCs.  
 
Tfr cells regulate GC reactions presumably patrolling the development of B cell harbouring 
high affinity self-reactive antibodies. While many features of Tfr cell biology remain elusive, 
targeting Tfr cells or Tfr cell-dependent regulatory mechanisms could become a novel 
approach to treatment of autoimmune diseases. This concept relies on the assumption that 
human blood CXCR5+Foxp3+ T cells are circulating Tfr cells, as these are the putative Tfr 
cells easily accessible in humans. 
 
The overall aim of this thesis was to investigate the biology of Tfr cells in human adaptive 
immunity and autoimmunity, by addressing two main questions: 
 
1. Do blood CXCR5+Foxp3+ Treg cells constitute circulating counterparts of germinal 
centre Tfr cells? 
 
Following the identification of Tfr cells as key regulators of humoral responses in murine 
secondary lymphoid organs, many studies categorically assumed CXCR5+Foxp3+ T cells 
in human blood are circulating Tfr cells (as circulating CXCR5+ T cells were 
demonstrated to be circulating counterparts of tissue Tfh cells with memory 
properties52,54–56). However, the formal demonstration of a specialized subset of human 
blood Treg cells engaged with regulation of humoral responses was never achieved. 
Besides the limited access to human secondary lymphoid tissues, Foxp3 and CXCR5 
upregulation by human non-regulatory T cells undergoing activation creates a further 
challenge on the assumption that peripheral blood CXCR5+Foxp3+ T cells are indeed 
bona fide circulating Tfr cells232–235,326. 
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The first part of the results describes several experiments designed to investigate whether 
human blood CXCR5+Foxp3+ T cells are indeed circulating counterparts of bona fide 
Tfr cells. We analysed the phenotype of CXCR5+Foxp3+ T cells in different human 
tissues, namely, blood, cord blood, tonsils and thymus. In addition, we optimized and 
performed various in vitro assays to directly address the function of this cell population. 
Finally, we used blood samples from B cell-deficient patients and from a prospective 
cohort of healthy volunteers undergoing seasonal influenza vaccination to demonstrate 
the intricate relationship between blood CXCR5+Foxp3+ T cells and GC responses.  
 
We found that CXCR5+Foxp3+ T cells are suppressive Foxp3+ Treg cells with migratory 
capacity toward B cell follicles, thus comprising a circulatory compartment of bona fide 
Tfr cells. We also found that CXCR5+Foxp3+ T cells increase after the induction of GC 
responses by vaccination and are absent from neonatal cord blood (an immune setting in 
which GC reactions do not take place), confirming their relationship with humoral 
responses in secondary lymphoid organs. However, as these cells gain access to 
circulation prior to B-cell interaction, they are immature and not yet proficient in 
regulating humoral responses. Therefore, blood Tfr cells are not fully competent Tfr 
cells.  
 
2. Do blood CXCR5+Foxp3+ Treg cells constitute a novel biomarker for autoantibody-
mediated systemic autoimmune diseases? 
 
After the demonstration that blood Tfr cells arise following humoral responses, we 
wondered whether this Treg cell subset is altered in autoimmune diseases, specifically 
those with autoantibody production in ectopic (tertiary) lymphoid structures356,357. We 
hypothesized that blood Tfr cells would be increased in patients with autoimmune 
diseases, rather than decreased, as blood Tfr cells do not represent the humoral 
suppressive potential of the immune system. 
 
Sjögren syndrome (SS) is a systemic autoimmune disease characterized by ectopic 
lymphoid neogenesis in exocrine glands where autoantibodies are produced due to 
dysregulated T – B cell interactions415,420,437–439. 
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Taking advantage of paired blood and tissue (salivary gland biopsies) samples from 
patients referred for clinical evaluation of SS we addressed whether blood Tfr cells could 
be used to identify SS patient with autoantibody production and ectopic lymphoid 
activity. These results are described in the second part of the thesis results. 
 
We found that blood Tfr cells, and specifically the Tfr/Tfh ratio, are increased in SS 
patients. Notably, patients with ectopic lymphoid activity have the highest level of blood 
Tfr/Tfh ratio. These findings led us to propose blood Tfr/Tfh ratio as a novel biomarker 
of ectopic lymphoid activity in SS, a finding with potential clinical implications. 
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1. Patient Recruitment and Human Samples  
 
1.1. Healthy Donor’s Blood Samples 
 
Fresh peripheral blood samples were collected from 42 adult healthy volunteers (recruited 
from a Lisbon Health Centre: USF do Parque), with no known medical condition, no 
vaccination or infection in the past two weeks, and no chronic medication. Fresh buffy-coats 
(blood collection in less than 24 hours) from Instituto Português do Sangue e da 
Transplantação, Lisboa, Portugal were used for in vitro functional assays. All blood samples 
were collected in EDTA coated tubes. 
 
For vaccination studies, we used 32 adult healthy volunteers recruited from the Cambridge 
BioResource as part of the vaccination study during the 2014 – 2015 winter season. 
Participants were excluded if they have had a previous adverse reaction to any vaccination, 
a known allergy to any components of the vaccine, were taking immune modulating 
medication, and women who were pregnant or breastfeeding. Participants were administered 
the inactivated influenza vaccine (split virion) BP vaccine (Sanofi Pasteur) by intramuscular 
injection in the right deltoid. Blood samples were collected in EDTA coated tubes on the 
day of vaccination (prior to administration of the vaccine) and 7 days following vaccination. 
These data were obtained as part of a collaborative work with Michell A Linterman’s 
laboratory at Babraham Institute, Cambridge, UK.   
 
1.2. B-cell Deficient Patients 
 
Fresh blood samples were collected from 5 adult X-linked Agammaglobulinemia (BTK-
deficient) patients before schedule treatment with intravenous immunoglobulin from 
Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa, Portugal. Blood samples 
were collected in EDTA coated tubes. 
 
1.3. Children Blood and Tissue Samples 
 
Thymus tissue was collected from 4 children submitted to cardiac surgery due to congenital 
heart disease who were otherwise healthy, under a collaborative work with Ana E Sousa’s 
laboratory, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de 
Materials and Methods 
76 
 
Lisboa, Lisboa, Portugal and Centro Hospitalar Lisboa Ocidental, Hospital de Santa Cruz, 
Lisboa, Portugal. 
 
Tonsils and fresh peripheral blood samples were collected from 6 healthy children submitted 
to tonsillectomy due to tonsil hypertrophy at Hospital de Santa Maria, Centro Hospitalar 
Lisboa Norte, Lisboa, Portugal. Children with any clinical condition, under any drug 
treatment or submitted to tonsillectomy due to chronic tonsillitis were excluded. 
 
Umbilical cord blood samples were collected from 3 healthy pregnancies during delivery, at 
Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa, Portugal. Blood samples 
were collected in EDTA coated tubes. 
 
1.4. Sjögren Syndrome Patients 
 
We recruited 56 patients referred to the Rheumatology and Metabolic Bone Diseases 
Department of Centro Hospitalar Lisboa Norte, Lisboa, Portugal for minor salivary gland 
(MSG) biopsy due to clinical suspicion of SS. Fresh blood samples were collected on the 
day of MSG biopsy. MSG tissue was divided for routine diagnostic purposes and for flow 
cytometry and microscopy. We excluded patients treated with biologic drugs, disease 
modifying anti-rheumatic drugs (DMARDs) other than hydroxychloroquine or more that 7.5 
mg per day of prednisolone equivalent, diagnosed with an infectious disease or who had 
received any vaccine in the previous month, and those with exclusion criteria for SS (Figure 
4)440. Patients were classified as having primary SS if they fulfilled American European 
Consensus Group (AECG) 2002 classification criteria440, whereas those with sicca 
symptoms and no evidence of an inflammatory rheumatic disease were classified as non-
Sjögren sicca syndrome and used as appropriate controls (Figure 4). Patients with secondary 
SS or with clinical diagnosis of primary SS but not fulfilling AECG criteria were excluded 
from analysis to standardize populations. Disease activity was evaluated by the European 
League Against Rheumatism SS disease activity score (ESSDAI)441. Routine serum 
autoantibodies, c-reactive protein (mg/dL), erythrocyte sedimentation rate (mm) and serum 
electrophoresis gamma-fraction (g/dL) levels closest to MSG biopsy were used. Blood 
samples were collected in EDTA coated tubes.  
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Figure 4: Flowchart of Sjögren syndrome patient recruitment and selection.  
DMARDs, disease modifying anti-rheumatic drugs; TNF, tumor necrosis factor; AECG, 
American-European Consensus Group criteria for Sjögren’s syndrome. 
 
1.5. Ethical Issues 
 
Studies were approved by the Lisbon Academic Medical Center Ethics Committee 
(reference number 505/14). Informed consent was obtained from all adult volunteers, parents 
or legal guardians. The influenza vaccination study protocol was approved by the Health 
Research Authority, National Research Ethics Service Committee South Central, Hampshire 
A, UK (REC reference:14/SC/1077). 
 
2. Cell Isolation and Flow Cytometry 
 
PBMCs were isolated from blood samples by Ficoll-gradient medium (Histopaque-1077, 
Sigma-Aldrich) using SepMate tubes (StemCell Technologies). Lymphocytes from tonsils 
and thymocytes were also isolated by Ficoll-gradient medium after mechanical disruption. 
Before cell sorting, PBMCs from Buffy-coats were enriched for CD4+ T cells using 
MojoSort Human CD4 T Cell Isolation Kit (BioLegend). The CD4+ fraction was used for 
cell sorting of CD4+ T cell subsets. The CD4- fraction was used for cell sorting of naïve B 
cells (supplementary Figure 1a for sorting strategy).  
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To study human MSG biopsies, we first optimized the experimental protocol to ensure that 
enzymatic digestion of tissue had negligible impact on cellular markers. A cell suspension 
was prepared from salivary gland tissue for flow cytometry analysis. The salivary gland was 
cut into small fragments and incubated at 37ºC with Liberase TM 0.1 mg/mL plus DNAse I 
0.1 mg/mL in RPMI medium for 20 minutes. After washing, fragments were incubated again 
for 10 minutes with the same enzyme solution. After washing, fragments were vigorously 
pipetted and filtered to obtain a homogenous cell suspension. 
 
For flow cytometry cells were stained with anti-Bcl-6 (K112-91, BD Biosciences), anti-
CCR6 (G034E3, BioLegend), anti-CCR7 (#150503, R&D Systems), anti-CD127 
(eBioRDr5, eBioscience), anti-CD19 (HIB19, BioLegend), anti-CD25 (BC96, eBioscience), 
anti-CD27 (LG.7F9, eBioscience), anti-CD3 (OKT3, eBioscience), anti-CD31 (WM-59, 
eBioscience), anti-CD38 (HB-7, BioLegend), anti-CD4 (OKT4, BioLegend), anti-CD45 
(HI30, BioLegend), anti-CD45RA (HI100, eBioscience), anti-CD45RO (UCHL1, 
BioLegend), anti-CD57 (HNK-1, BioLegend), anti-CD62L (DREG-56, BioLegend), anti-
CD69 (FN30, BioLegend), anti-CD8 (RPA-T8, eBioscience), anti-CTLA-A (L3D10, 
BioLegend), anti-CXCR3 (G025H7, BioLegend), anti-CXCR5 (J252D4, BioLegend), anti-
Foxp3 (PCH101, eBioscience), anti-HLA-DR (G46-6, BD Biosciences), anti-ICOS 
(C398.4A, BioLegend), anti-IgD (IA6-2, BioLegend), anti-Ki67 (Ki-67, BioLegend), anti-
PD-1 (EH12.2H7, BioLegend). For Bcl-6, CTLA-4, Foxp3, and Ki67 intracellular staining, 
Foxp3 Fix/Perm Kit (eBioscience) was used according to manufacturer’s instructions. For 
cell viability staining, Live/Dead Fixable Aqua Dead Cell Stain Kit (Life Technologies) was 
used. Cell Trace Violet Cell Proliferation Kit (Life Technologies) was used for cell 
proliferation assessment. Cell sorting was performed in Aria IIu and Aria III instruments 
(BD Biosciences). Flow cytometry analysis was performed in a LSR Fortessa instrument 
(BD Biosciences) and further analyzed with FlowJo v10 software (TreeStar). 
 
3. Functional Assays 
 
3.1. Suppression Assays and in vitro Cultures 
 
For in vitro suppression assays 25 x 103 CXCR5-CD25-CD127+CD4+ conventional T cells 
or 25 x 103 CXCR5+CD25-CD127+CD4+ Tfh cells were plated with CXCR5-CD25+CD127-
CD4+ Tregs cells or CXCR5+CD25+CD127-CD4+ Tregs cells in 1:1 ratio. Cells were 
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cultured with 1 μg/mL anti-CD3 (OKT3, eBioscience) in the presence of 105 irradiated (2500 
rad) allo-PBMCs. After 5 days, cells were harvested and responder cells were analyzed for 
CTV dilution by flow cytometry. For TCR stimulation assays 25 x 103 CXCR5-
CD25+CD127-CD4+ Tregs cells and CXCR5+CD25+CD127-CD4+ Tregs were plated with 1 
µL/well of anti-CD3/anti-CD28 MACSiBead particles (T Cell Activation Kit, Miltenyi 
Biotec).  
 
For co-culture in vitro suppression assays 25 x 103 CXCR5+CD25-CD127+CD4+ Tfh cells 
were plated with CXCR5-CD25+CD127-CD4+ Tregs cells or CXCR5+CD25+CD127-CD4+ 
Tregs cells in 1:1 ratio, in presence of 30 x 103 CD27-IgD+CD19+ naïve B cells. Cells were 
cultured with 1 μg/mL SEB (Sigma-Aldrich). After 5 days, responder Tfh cells were 
analyzed for CTV dilution, B cells for CD38 upregulation, and Tregs for follicular and 
activation markers.  
 
For immunoglobulin measurement 25 x 103 CXCR5+CD25-CD127+CD4+ Tfh cells were 
plated with CXCR5-CD25+CD127-CD4+ Tregs cells or CXCR5+CD25+CD127-CD4+ Tregs 
cells in 1:1 ratio, in presence of 30 x 103 CD27-IgD+CD19+ naïve B cells. Cells were cultured 
with 1 μg/mL SEB (Sigma-Aldrich) + 10 ng/mL SEA (Toxin Technology) + 10 ng/mL SEE 
(Toxin Technology) + 10 ng/mL TSST-1 (Toxin Technology). After 10 days, supernatants 
were collected and immunoglobulin concentration determined by ELISA.  
 
Cultures were performed in U-shape 96 wells plates in RPMI medium (RPMI 1640, Life 
Technologies) supplemented with 10% heat-inactivated Fetal Bovine Serum (Life 
Technologies), 1% HEPES (Sigma-Aldrich), 1% Sodium Pyruvate (Life Technologies), 1% 
PenStrep (Life Technologies), and 0.05% Gentamicin (Life Technologies) and in 37ºC, 5% 
CO2 incubator conditions. 
 
3.2. ELISA 
 
IgA, IgM, and total IgG concentration were determined in supernatants from T-B co-culture 
(as described above) by ELISA using Human ELISA Ready Set Go Kit, according to the 
manufacturer’s instructions (eBioscience). 
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3.3. Migration Assays 
 
For in vitro chemotaxis assays 75 x 103 CXCR5-CD25-CD127+CD4+ conventional T cells, 
CXCR5+CD25-CD127+CD4+ Tfh cells, CXCR5-CD25+CD127-CD4+ Tregs cells and 
CXCR5+CD25+CD127-CD4+ Tregs cells, sorted from buffy-coats, were loaded on top wells 
of HTS Transwell 96-well permeable supports (5μm pore size) (Corning). Plain RPMI 
medium (RPMI 1640, Life Technologies) or medium supplemented with 0.2 μg/mL 
CXCL13 (Peprotech) was added to the bottom wells of the plate. After 4 hours of incubation 
(37ºC, 5% CO2), filters were removed and cells that migrated to the lower chamber were 
counted in a LSR Fortessa instrument (BD Biosciences) and further analyzed with FlowJo 
v10 software (TreeStar). Chemotaxis index was calculated as the ratio of cells migrating 
toward CXCL13 and cells randomly migrating. 
 
4. Real-time RT-PCR 
 
Total RNA was extracted, and reverse transcribed from FACS-sorted CXCR5-CD25-
CD127+CD4+ conventional T cells, CXCR5+CD25-CD127+CD4+ Tfh cells, CXCR5-
CD25+CD127-CD4+ Tregs cells and CXCR5+CD25+CD127-CD4+ Tregs from buffy-coats, 
using RNeasy Micro Kit (Qiagen) according to manufacturer’s instructions. cDNA was 
generated using SuperScript III reverse transcriptase (Life Technologies), according to 
manufacturer instructions. Real-time PCR was set up with Power SYBR Green PCR Master 
Mix (Applied Biosystems) and performed on ViiA 7 Real-Time PCR System (Applied 
Biosystems), according to manufacturer’s instructions. The expression of each gene was 
normalized to housekeeping genes (B2M, ACTB or G6PD) and calculated by change-in-
threshold method (ΔCT), using QuantStudio Real-Time PCR software v1.1 (Applied 
Biosystems). The following primers (Invitrogen) were used: Foxp3, 5’-
GCAAATGGTGTCTGCAAGTG-3’ (forward) and 5’-GCCCTTCTCATCCAGAAGAT-3’ (reverse); 
CXCR5, 5’-CTGGAAATGGACCTCGAGAA-3’ (forward) and 5’-
GCAGGGCAGAGATGATTTTC-3’ (reverse); Bcl-6, 5’-TTCCGCTACAAGGGCAAC-3’ (forward) 
and 5’-CGAGTGTGGGTTTTCAGGTT-3’ (reverse); B2M, 5’-TATGCCTGCCGTGTGAACCAT-3’ 
(forward) and 5’-CGGCATCTTCAAACCTCCATG-3’ (reverse); ACTB, 5’-
CTCTTCCAGCCTTCCTTCCT-3’ (forward) and 5’-AGCACTGTGTTGGCGTACAG-3’ (reverse); 
G6PD, 5’-CCAAGCCCATCCCCTATATT-3’ (forward) and 5’-CCACTTGTAGGTGCCCTCAT-3’ 
(reverse). 
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5. Microscopy 
 
5.1. Human Tonsils 
 
After paraffin removal and antigen retrieval by heat (HIER pH 9, Leica Biosystems) 3 µm 
sections of formalin-fixed paraffin-embedded human tonsil were stained with anti-human 
CXCR5-Alexa-Fluor 488 (J252D4, BioLegend), anti-human CD4 (SP35, CellMarque) and 
anti-human Foxp3 (PCH101, eBioscience) primary antibodies. Alexa-Fluor 488 (anti-
mouse), Alexa-Fluor 546 (anti-rabbit) and Alexa-Fluor (anti-Rat) were used as secondary 
antibodies, respectively. DAPI was used as nuclei counterstaining. Images were acquired 
with ZEN 2012 software on a Zeiss LSM 710 confocal point-scanning microscope (Carl 
Zeiss, Oberkochen, Germany) using a dry plan-apochromat 20x objective (200x 
magnification) and with a numerical aperture of 0.80. Images were further analyzed using 
Image-J FiJi software.  
 
5.2. Minor Salivary Gland Biopsies 
 
MSG were fixed in 10% buffered formaldehyde, embedded in paraffin wax and sectioned 
into 3 µm sequential sections. Sections were stained after deparaffinisation, pretreatement 
with Ultra CC1 (Ventana Medical Systems, USA), antigen retrieval and endogenous 
peroxidase blocking using Benchmark machine. Sections were immunohistochemically 
stained with anti-human CD20 (L26, DAKO), anti-human CXCR5-Alexa-Fluor 488 
(J252D4, BioLegend), and anti-human Foxp3 (236A/E7, eBiosciences). The sections were 
then treated with a peroxidase-labelled secondary antibody and visualized with the 
chromogen DAB solution and/or universal AP Red. Hematoxylin was used as 
counterstaining. Images were acquired with NanoZoomer-SQ (Hamamatsu, Japan) using a 
20x objective with a numerical aperture of 0.75. Images were further analyzed using 
NDP.view software. Number of CXCR5 and Foxp3 double positive cells were counted 
manually. Routine hematoxylin and eosin staining was used to define histological diagnosis 
in MSG: Normal, section with no pathological findings; LI, sections with unspecific 
lymphocytic infiltration; and focal sialadenitis (FSA), sections with ≥1 dense aggregate of 
≥50 lymphocytes per 4 mm2 of tissue located in perivascular or periductal locations442. 
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6. Statistical analysis 
 
Unpaired Student T-test, one-way ANOVA with post-test Turkey’s multiple comparison, 
and two-way ANOVA with post-test Bonferroni’s multiple comparison were used as 
described. Normality of data was assessed by Shapiro-Wilk test. Variance across groups was 
assessed with Levene’s and Brown–Forsythe’s tests and, where different, Welch correction 
of T-test or Mann Whitney U test were preferred. Pearson correlation and linear regression 
were also conducted for some data. For categorical variables Fisher’s exact test was used. 
Logistic regression and receiver operating characteristic (ROC) analysis were conducted to 
study the association of Tfr/Tfh ratio with SS and FSA and the cut-off with the best 
discriminative value was determined. Results are presented as mean ± SD. P values of less 
than 0.05 were considered statistically significant. GraphPad Prism v5 and Stata v.12.1 were 
used for statistical and graphical analysis. Correlation heatmaps were computed in R studio 
v3.1.2. 
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Human Blood CXCR5+Foxp3+ Treg Cells Are Immature Tfr 
Cells Not Fully Licensed with Humoral Suppressive Function 
 
 
Introduction 
 
GC responses are crucial for the generation of high affinity antibodies during T-dependent 
immune responses. Within the GC resides a specialized subset of CD4+ T cells – the Tfh 
cells – which are essential for GC development and function63,443. It is now clear that Tfh 
cells play a central role in productive vaccine responses, while defects in their formation or 
function can contribute to immunodeficiency or autoimmunity390,392. More recently, the 
discovery of Tfr cells, a subset of suppressive regulatory T cells that participate in the GC, 
added an additional layer of complexity in the biology of GC responses257,256,254,255.  
 
Tfr cells, generally defined by Bcl-6+CXCR5+PD-1+ICOS+Foxp3+, are a distinct subset of 
thymic Foxp3+ Treg cells present in lymphoid tissues. Like the Tfh cell differentiation 
pathway, Tfr cell-commitment require both dendritic cell and B cell interactions, as well as 
CD28, SAP, ICOS, and PD-1 signaling258,260,255. A tight balance between expression of 
transcription factors Bcl-6 and Blimp-1 regulates the differentiation of Tfr cells255. Tfr cells 
have specialized functions in controlling the magnitude of GC responses and in limiting the 
outgrowth of non-antigen-specific B cell clones256,255. However, the precise mechanisms of 
Tfr cell suppression remain elusive, although CTLA-4 and regulation of metabolic pathways 
seem to play a key role259,269,272.  
 
Although, Tfh and Tfr cells are characterized by their location in lymphoid tissues an 
increasing number of studies have described putative circulating counterparts of these cells 
in peripheral blood. This is particularly relevant for studying the biology of these cells in 
humans, as access to secondary lymphoid tissues can be limiting. Human blood CXCR5+ T 
cells have been established as memory Tfh-like cells, based on their ability to recapitulate 
bona fide Tfh cell functions: human blood CXCR5+ T cells can promote plasmablast 
differentiation, AID expression and class switch recombination by naïve B cells. However, 
they are phenotypically distinct from tissue Tfh cells and do not express the transcriptional 
repressor Bcl-652,55,56. Furthermore, an immunization leading to GC and antibody responses 
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correlates with an increase in the frequency of circulating ICOS+ Tfh cells, suggesting that 
they indicate ongoing Tfh cell responses in secondary lymphoid tissues52,54,55,120,123. Human 
circulating Tfh cells comprise a heterogeneous population concerning their phenotype and 
the quality of help they provide to B cells52,54. 
 
In mice, CXCR5+Foxp3+ Tfr-like cells were found in peripheral blood after immunization, 
and shown to represent a circulating counterpart of tissue Tfr cells258,260.  
 
Although, CXCR5-expressing Treg cells and GC Foxp3-expressing T cells have been found 
in humans254,323,325, so far, no study have addressed the biological significance of these 
putative circulating Tfr-like cells in humans. Human tonsil CD25+CD69- T cells have been 
shown to directly suppress B cell responses, but the relationship of these putative Treg cells 
to Bcl-6+CXCR5+PD-1+ICOS+Foxp3+ Tfr cells is unclear444,445. Peripheral blood CXCR5+ 
Treg cells are being studied as circulating Tfr cells in many different human diseases, despite 
the biological relevance of these cells being unclear329,333,338,341,446. Additionally, Foxp3 
upregulation by non-regulatory human T cells and transient CXCR5 expression by T cells 
undergoing activation challenge the assumption that peripheral blood CXCR5+ Treg cells 
are indeed bona fide circulating Tfr cells235,326.  
 
Here, we found that human blood Tfr cells, defined as CXCR5+Foxp3+ T cells, are generated 
in peripheral lymphoid tissues as humoral immune responses are established. However, in 
contrast to tissue Tfr cells and conventional CXCR5- Treg cells, circulating Tfr cells have a 
naïve-like phenotype. Our data demonstrate that blood Tfr cells are generated following the 
initial steps that lead to GC responses being distinct from tissue Tfr cells.  
 
 
Results 
 
Blood and tissue Tfr cells present different follicular and regulatory markers 
 
To test whether CXCR5+Foxp3+ Tfr cells in human peripheral blood are circulating 
counterparts of tissue Tfr cells, we studied peripheral blood from a cohort of 42 healthy 
volunteers between 22 and 92 years old (mean age 46.76 ± 18.14 years old, 30 females and 
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12 males). We found that CXCR5 was expressed by 18.57 ± 6.55% of total Tregs (defined 
as CD4+CD25+Foxp3+ T cells) (Figure 5A). The frequency and number of CXCR5+Foxp3+ 
Tfr cells did not change with aging (Figure 5B, C). 
 
 
Figure 5: Identification of blood Tfr cells.  
(A) CXCR5+ Tfr cells constitute 18.57 ± 6.55% of Tregs (left) and 0.93 ± 0.56% of total CD4+ T 
cells (middle), representing 9985 ± 9043 cells per mL of blood (right) (n = 42, adult healthy 
donors). (B) Variation of blood Tfr cells frequency (left) and absolute number per ml of blood 
(right) accordingly to age (age range: 22 – 92 years old). (n = 42, linear regression). (C) Variation 
of blood Tfh cells (left) and total Tregs (right) frequency accordingly to age (age range: 22 – 92 
years old) (n = 42, linear regression). Error bars represent SEM. 
 
As CXCR5 is used to identify human circulating Tfh cells, we compared the phenotype of 
circulating CXCR5+Foxp3+ Tfr cells with that of circulating Tfh cells and CXCR5- 
conventional Treg cells. Peripheral blood CXCR5+Foxp3+ T cells share characteristics with 
both circulating Tfh cells and CXCR5- Treg cells (Figure 6A-C). Bcl-6 expression was not 
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detected in any population by real-time PCR (Figure 6D), consistently with previous reports 
showing that blood Tfh cells do not express Bcl-653–56,120.  
 
 
Figure 6: Blood Tfr cells show expression of follicular and regulatory markers.  
(A) Expression of Foxp3, CD25, CD69, CTLA-4, CXCR5, ICOS, PD-1 Bcl-6, and CD57 by Tfh 
cells (blue), CXCR5- Tregs (black) and Tfr cells (red), in adult. Naïve CD4+ T cells were used as 
control (gray). Representative plots from 42 healthy volunteers. (B) MFI of Foxp3, CD25, CD69, 
CTLA-4, CXCR5, ICOS, PD-1 Bcl-6, and CD57 by Tfh cells (blue), CXCR5- Tregs (black) and 
Tfr cells (red) in adult blood (**p<0.01, ***p<0.001, n = 6, one-way ANOVA with post-test 
Turkey’s multiple comparison) (C) Isotype controls for intracellular Bcl-6 and Foxp3 staining by 
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flow cytometry. (D) Relative expression of Bcl-6 by sorted Tconv, Tfh cells, CXCR5- Tregs and 
Tfr cells from blood, by real-time RT-PCR. Gene expression normalized to housekeeping genes 
(B2M, G6PD and ACTB) (n = 2, each with technical duplicates, Student t-test). CD38hiIgD- 
germinal center B cells sorted from human tonsils were used as positive control. Error bars 
represent SEM. 
 
Taking advantage of routine tonsillectomies performed due to tonsil hypertrophy in 
otherwise healthy children, we compared the cell phenotype of paired blood and tissue 
samples from the same child (Figure 7A, B).  
 
 
Figure 7: Blood Tfr cells are distinct from their tissue counterparts.  
(A) Gating strategy for identification and analysis of Tconv, Tfh cells, CXCR5- Tregs and CXCR5+ 
Tregs in human tonsils. (B) Expression of Foxp3, CD25, CD69, CTLA-4, CXCR5, ICOS, PD-1 
Bcl-6, and CD57 by Tfh cells (blue), CXCR5- Tregs (black) and Tfr cells (red), in children blood 
(top rows) and in tonsils (bottom rows). Naïve CD4+ T cells were used as control (gray). 
Representative plots from 6 healthy children. 
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We found that circulating Tfh cells were phenotypically distinct from their tissue 
counterparts, in line with previous reports, especially regarding their PD-1, ICOS and Bcl-6 
expression (Figure 7B)52,56. In an analogous way, circulating CXCR5+Foxp3+ Tfr cells were 
also ICOS-PD-1-Bcl-6-CD57-, and consequently distinct from tonsil Tfr cells (Figure 7B). 
Our results are consistent with murine studies showing that blood and tissue Tfr cells are 
phenotypically distinct258. Notably, ICOS was not differentially expressed by Treg cells and 
Tfr cells in tonsils (Figure 7B). We also confirmed that tissue CXCR5+Foxp3+ T cells are 
localized within GCs, therefore, corresponding to Tfr cells (Figure 8A, B). Curiously, we 
observed different Tfr/Tfh ratios in the blood and tonsils (Figure 8C). 
 
 
Figure 8: CXCR5+Foxp3+ T cells are localized within GCs in human secondary lymphoid 
organs.  
(A) Immunofluorescence microscopy of formalin-fixed paraffin-embedded human tonsils stained 
for DAPI (blue), CXCR5 (yellow), CD4 (red) and Foxp3 (green). Top, middle and bottom outlined 
areas indicate top, middle and bottom enlarged areas on the right, respectively. Data are 
representative of tonsil sections from 5 healthy children. (B) Negative control for 
immunofluorescence microscopy, merge (left) and composite of the four immunofluorescence 
channels (right). After paraffin removal and antigen retrieval by heat sections of formalin-fixed 
paraffin-embedded human tonsil were stained with Alexa-Fluor 488 (anti-mouse), Alexa-Fluor 
546 (anti-rabbit) and Alexa-Fluor (anti-Rat) secondary antibodies, without primary antibodies. 
DAPI was used as nuclei counterstaining. Unspecific binding of secondary antibodies and cross-
reactivity between secondary antibodies were excluded. (C) Blood Tfr/Tfh ratio in adult blood, 
children blood (tonsil donors) and in tissues (tonsils). Black and red dots represent blood and tonsil 
results, respectively (n = 42 for adults and n = 6 for children, Student t-test). Error bars represent 
SEM.  
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CXCR5+Foxp3+ Tfr cells are a distinct subset of suppressive Foxp3+ T cells 
 
It has been described that CXCR5 expression can transiently occur upon human T cell 
activation49,326,327. Moreover, human T cells can also transiently express Foxp3 upon in vitro 
TCR stimulation in a TGF-β dependent manner235,328. To address whether ex vivo 
CXCR5+Foxp3+ Tfr cells were bona fide regulatory cells, we sorted that cell population, as 
well as CXCR5- conventional Treg cells (Figure 9A,B).  
 
 
Figure 9: Sorting strategy for human blood Tconv, Tfh, CXCR5- Treg, Tfr cells, and naïve 
B cells.  
(A) Sorting strategy for FACS-sort of CXCR5+CD25-CD127+CD4+ Tfh cell, CXCR5-CD25-
CD127+CD4+ Tconv cell, CXCR5+CD25+CD127-CD4+ Tfr cells, CXCR5-CD25+CD127-CD4+ 
Treg cells, and CD27-IgD+CD19+ naïve B cell populations from peripheral blood (buffy-coats). 
(B) Purity of FACS-sorted CXCR5+CD25+CD127-CD4+ Tfr cells, CXCR5-CD25+CD127-CD4+ 
Treg cells. 
 
We cultured CXCR5- Treg and Tfr cells with CTV-labelled conventional T cells. 
Proliferation of responder cells was analysed after 5 days of soluble αCD3 stimulation 
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(Figure 10A). Blood CXCR5+Foxp3+ T cells significantly reduced conventional T cell 
proliferation (Figure 10B, C), clearly demonstrating their regulatory function.  
 
 
Figure 10: Blood Tfr cells are a distinct subset of suppressive Treg cells.  
(A) Schematic representation of in vitro suppression assay. FACS-sorted 25 x 103 CXCR5-CD25-
CD127+CD4+ Tconv cells were co-cultured with 25 x 103 CXCR5-CD25+CD127-CD4+ Tregs or 
CXCR5+CD25+CD127-CD4+ Tfr cells under stimulation by anti-CD3 (1 μg/mL), in presence of 
105 irradiated (2500 rad) allo-PBMC. After 5 days cells responder cells were analysed for CTV 
dilution by flow cytometry. (B) Proliferation of Tconv cells without Tregs or in the presence of 
either CXCR5- Tregs or Tfr cells. Representative plots (left) and pooled data (right) (n = 3, each 
with technical triplicates, One-way ANOVA with post-test Turkey’s Multiple Comparison). (C) 
Suppression curve of CXCR5- Tregs and Tfr cells in different ratios, using the same conditions 
described in Fig. 3A, B) (n = 1, with technical triplicates, Two-way ANOVA). Error bars represent 
SEM. 
 
Stability of Foxp3 expression is required for the suppressive function of Tregs cells171. In 
order to determine whether blood Tfr cells have stable Foxp3 expression, we stimulated 
sorted Tfr cells and CXCR5- Treg cells with anti-CD3/CD28 microbeads for 5 days, in the 
absence of exogenous IL-2. In the absence of IL-2 Treg cells do not survive well in culture. 
Under these conditions, both CXCR5- Tregs and Tfr cells retain a similar frequency of 
Foxp3+ cells, albeit lower than in the beginning of the culture (Figure 11A). Interestingly, 
the frequency of recovered live Foxp3-expressing cells was slightly higher for sorted Tfr 
cells as compared to CXCR5- conventional Treg cells. Next, we analysed the relative 
expression of Foxp3 and CXCR5 in sorted conventional T cells, Tfh cells, Tfr and CXCR5- 
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Treg cells from human blood, by real-time PCR. Although Foxp3 protein expression was 
lower in Tfr cells than in CXCR5- Treg cells (Figure 6A, B), Foxp3 gene expression was 
similar between the two subsets (Figure 11B). In addition, circulating Tfh cell and Tfr cells 
also showed comparable CXCR5 gene expression (Figure 11B). 
 
 
Figure 11: Stability of blood Tfr cells.  
(A) Stability of Foxp3 expression by sorted CXCR5- Tregs and CXCR5+ Tfr cells after 5 days of in 
vitro culture under αCD3/αCD28 (1 μL/well) stimulation. Percentage (left) and cell number (right) 
(n = 5, each with technical triplicates, Student t-test). (B) Relative expression of Foxp3 and CXCR5 
by sorted Tconv, Tfh cells, CXCR5- Tregs and Tfr cells from blood, by real-time RT-PCR. Gene 
expression normalized to housekeeping genes (B2M, G6PD and ACTB) (n = 2, each with technical 
duplicates, Student t-test). Error bars indicate SEM. 
 
To investigate whether activation of blood Tfr cells triggers upregulation of Foxp3, CD25 
and CTLA-4, a phenomena known to be associated with increased Treg cell suppressive 
function171, we analysed the phenotype of sorted CXCR5+ and CXCR5- Treg cells after 5 
days of culture in presence of αCD3/CD28 microbeads. We found an upregulation of Foxp3 
and CD25 by Tfr cells, while CTLA-4 was increased in both populations (Figure 12A). The 
levels of expression of these markers by blood Tfr cells after activation resembled those from 
tissue Tfr cells (compare with Figure 7B). Importantly, CXCR5 upregulation was not 
detected in sorted CXCR5- Treg cells showing that CXCR5+ Tfr cells are a distinct subset 
of human blood Treg cells. 
 
Blood Tfr cells do not preferentially suppress humoral responses 
 
In order to address the function of blood Tfr cells we first investigated if this population 
could directly suppress Tfh cells. Using a similar in vitro assay used to prove the regulatory 
capacity of blood Tfr cells (Figure 10A), but with sorted Tfh cells as responders, we found 
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that blood Tfr cells strongly suppressed Tfh cell proliferation, however without a specific 
advantage when compared with CXCR5- Treg cells (Figure 13A).  
 
Figure 12: CXCR5 upregulation by blood Treg cells is not induced by TCR or CD28 
signalling.  
(A) Expression of Foxp3, CD25, CTLA-4 and CXCR5 by sorted CXCR5- Tregs and Tfr cells at 
baseline (d0) and after 5 days of in vitro culture under αCD3/αCD28 (1 μL/well) stimulation. 
Representative histograms (top rows) and pooled data (bottom row), from 3 independent 
experiments, each one with technical triplicates. Pooled data are based on MFI of Foxp3, CD25, 
CTLA-4 and CXCR5 of sorted CXCR5- Tregs and Tfr cells at baseline (d0) and after 5 days of in 
vitro culture under αCD3/αCD28 (1 μL/well) stimulation (*p<0.05, **p<0.01, ***p<0.001, n = 3, 
one-way ANOVA with post-test Turkey’s multiple comparison). Error bars indicate SEM. (ns = 
not significant). 
 
 
Figure 13: Blood Tfr cells suppress Tfh cell proliferation.  
(A) Proliferation of CXCR5+CD25-CD127+CD4+ Tfh cells without regulatory T cells or in the 
presence of either CXCR5- Tregs or Tfr cells after 5 days of in vitro culture as described in Figure 
10A. Representative plots (left) and pooled data (right) (n = 3, each with technical triplicates, One-
way ANOVA with post-test Turkey’s Multiple Comparison). Error bars indicate SEM. (ns = not 
significant). 
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Next, to directly assess the impact of blood Tfr cells on B cell activation, we used in vitro 
T-B co-cultures in presence of SEB superantigen (Figure 14A). After 5 days of culture, B 
cells upregulated CD38 and downregulated IgD only in presence of Tfh cells (Figure 14B). 
Both CXCR5- and CXCR5+ Treg cells impaired the generation of CD38+IgD- GC-like B 
cells. Consistent with our results from suppression assays with Tfh cells (Figure 13A), Tfh 
cell proliferation was inhibited by CXCR5- and CXCR5+ Treg cells (Figure 14B). However, 
in these conditions, blood Tfr cells were less potent compared to conventional CXCR5- Treg 
cells in suppression Tfh cell proliferation (Figure 14C). As expected Tfh cells showed better 
proliferation responses in co-culture with B cells. 
 
 
 
Results I 
 
96 
 
Figure 14 (previous page): Blood Tfr cells do not show specialized humoral regulatory 
capacity.  
(A) Schematic representation of suppression co-culture assay. FACS-sorted 25 x 103 
CXCR5+CD25-CD127+CD4+ Tfh cells (or CXCR5-CD25-CD127+CD4+ Tconv cells) were co-
cultured for 5 days with 25 x 103 CXCR5+CD25+CD127-CD4+ Tregs (or CXCR5-CD25+CD127-
CD4+ Tregs) under stimulation by SEB (1 μg/mL) and in the presence of 30 x 103 CD27-
IgD+CD19+ naïve B cells. (B) Upregulation of CD38 and downregulation of IgD by naïve B cells 
(top) and proliferation of Tfh cells by CTV dilution (bottom) without Tregs or in the presence of 
either CXCR5- Tregs or Tfr cells. Representative plots (left) and pooled data (right) (n = 5, each 
with technical triplicates, One-way ANOVA with post-test Turkey’s Multiple Comparison). (C) 
Suppression curve of CXCR5- Tregs and Tfr cells in different ratios, using the same conditions 
described in Fig. 4B, C) (n = 1, with technical triplicates, Two-way ANOVA). (D) ELISA 
determination of for IgA, IgM and total IgG in supernatants after 10 days of in vitro co-culture 
performed as described in (A), but using SEB (1μg/mL) + SEA (10g/mL) + SEE (10ng/mL) + 
TSST-1 (10ng/mL) as superantigen stimulation. (n = 3, each with technical triplicates, One-way 
ANOVA with post-test Turkey’s Multiple Comparison). (E) In vitro migration of 75 x 103 sorted 
Tconv, Tfh, CXCR5- Tregs, and Tfr cells towards a CXCL13 gradient (2 μ/mL), expressed by 
chemotaxis index (n = 3, each with technical triplicates, One-way ANOVA with post-test Turkey’s 
Multiple Comparison). Error bars indicate SEM. (ns = not significant). 
 
To further address the function of blood Tfr cells on humoral responses we analysed class 
switch recombination by naïve B cells 10 days after superantigen stimulation. We found that 
blood Tfr cells, although able to reduce activation of naïve B cells and proliferation of Tfh 
cells as shown before, did not significantly limit class switch recombination by B cells, as 
no impact on IgA nor IgG production was observed (Figure 14D). On the contrary, CXCR5- 
Treg cells efficiently suppressed humoral responses (Figure 14D).  
 
CXCR5/CXCL13-dependent migration to GC is critical for suppression of humoral 
responses by Tfr cells256,254 and plasma CXCL13 levels have been correlated to ongoing GC 
responses in humans447. To prove that blood Tfr cells were capable to migrate towards a 
CXCL13 gradient we conducted in vitro chemotaxis assays with sorted populations from 
human peripheral blood. We found that, although the CXCR5 MFI of peripheral Tfh and Tfr 
cells was slightly different (Figure 6A, B), both populations shared their ability to migrate 
towards a CXCL13 gradient, showing functional capacity of blood Tfr cells to enter 
CXCL13 enriched tissues (Figure 14E). 
 
Blood Tfr cells have a distinctive naïve-like phenotype  
 
To explain the surprising observation that blood Tfr cells do not suppress antibody 
production we hypothesized that this population could represent thymus-derived precursors 
of Tfr cells not yet fully committed to regulate humoral responses. Indeed, we found that 
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blood Tfr cells were predominantly CD45RO-Foxp3lo resting Treg cells (Figure 15A), 
expressing high levels of CD45RA, CCR7, CD62L, CD27 and low levels of HLA-DR, 
reminiscent of a naïve phenotype (Figure 15B).  
 
 
Figure 15: Blood Tfr cells are immature (resting-like) cells.  
(A) Backgate of CXCR5- and CXCR5+ Tregs accordingly to CD45RO and Foxp3 expression. (B) 
Expression of CD45RO, CD45RA, CCR7, CD62L, HLA-DR and CD27 by Tfr cells (red) and 
CXCR5- Tregs (black) in blood. (c) Expression of Ki-67 by CXCR5+ Tregs and CXCR5- Tregs in 
blood (n = 22, Student t-test). (D) CD45RO+CCR7- effector-memory (EM), CD45RO+CCR7+ 
central-memory (CM) and CD45RO-CCR7+ naïve subsets of Tfr cells and CXCR5- Tregs in adult 
blood. Representative plots (left) and pooled data (right) (n = 22, Student t-test). Tfh cells are 
represented in blue, CXCR5- Tregs in black and Tfr cells in red. (E) Expression of CD45RO and 
CD45RA in adult blood by total Tfh cells and Tfr cells (left) and by CCR7+CD45RO- naïve Tfh 
cells (nTfh cells) and by CCR7+CD45RO- naïve Tfr cells (nTfr cells) (right). Representative plots 
from 22 healthy donors. Bars represent SEM. (ns = not significant). 
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Virtually, all blood Tfr cells were quiescent Ki-67- non-proliferating cells when analyzed ex 
vivo (Figure 15C). Moreover, circulating Tfr cells were virtually devoid of CD45RO+CCR7- 
effector-memory cells in striking contrast to CXCR5- Treg cells, a phenotype more similar 
to circulating Tfh cells (Figure 15D). While the vast majority of blood Tfh cells were 
CD45RO+CCR7+ central-memory cells, consistently with previous reports52,54–56, a 
significant proportion of Tfr cells were CD45RO-CCR7+ naïve cells (Figure 15D). 
Furthermore, the few CD45RO- Tfh cells did not express high levels of CD45RA indicating 
that those cells were not really naïve, in contrast to Tfr cells.  (Figure 15E). Therefore, blood 
Tfr cells constitute a pool of naïve resting cells.  
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Figure 16 (previous page): Blood Tfr cells are generated in the periphery after mature 
adaptive immune responses.  
(A) Variation of CD45RO-CCR7+ naïve Tfr and CXCR5- Treg cells frequency in blood 
accordingly to age (n = 22, linear regression). (B) Variation of CD45RO-CD31+ naïve Tfr cells 
and CXCR5- Treg cells frequency in blood accordingly to age (n = 22, linear regression). (C) 
Expression of CD31 by Tfh and Tfr cells in adult blood of healthy donors. Representative plots 
(left) and pooled data (right) (n = 22, Student t-test). (D) Expression of CXCR5 by Foxp3+CD4+ 
thymocytes (n = 4). (E) Expression of CXCR5 by cord blood Foxp3+CD4+ T cells (n = 3). (F) 
Expression of CD45RO, CCR7, CXCR5, PD-1, and ICOS by cord blood Foxp3+ Treg cells (n = 
3). Bars represent SEM.  
 
To test whether blood Tfr cells were indeed thymus-derived precursors of tissue Tfr cells we 
analysed the frequency of these cells accordingly to age. Contrary to thymic derived naïve 
Tregs, CD45RO-CCR7+ naïve Tfr cells did not significantly decrease with increasing age 
(Figure 16A). In addition, the expression of CD31, a marker used to identify recent thymic 
emigrants in human blood245,247,448, was not specifically enriched in that population (Figure 
16B, C). Although these observations suggest blood Tfr cells are not a thymic population, 
this was not conclusive. Therefore, we directly examined CXCR5-expressing T cells in the 
human thymus and neonatal cord blood. There was not a population of CXCR5+ Treg cells 
detected in any of those tissues (Figure 16D-F). Although, CXCR5-expressing Tregs were 
not found in cord blood, some Foxp3+ cells expressed CD45RO, suggesting that additional 
activation signals not present before birth are required to shape a CXCR5 phenotype in 
circulating Treg cells. Consistent with our previous data, ICOS+ Tregs were detected in cord 
blood, indicating that ICOS cannot be used as a specific follicular marker in circulating 
human Treg cells (Figure 16F). 
 
Blood Tfr cells emerge from lymphoid organs before B-cell interaction 
 
Having demonstrated that circulating Tfr cells did not egress from the thymus, we 
investigated whether Tfr cells recirculate from secondary lymphoid tissues before being fully 
committed to tissue Tfr cells. We compared both CXCR5+ and CXCR5- Treg cell subsets 
from children paired blood and tissue (tonsils) concerning their effector-memory, central-
memory and naïve composition. We found that CD45RO+CCR7- effector Tfr cells were 
present in lymphoid tissues but not in blood, suggesting that effector Tfr cells are selectively 
retained in tissues, similarly to effector Tfh cells (Figure 17A). Therefore, it is unlikely that 
blood CD45RO- Tfr cells derive from the fully mature tissue Tfr cells that express CD45RO, 
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as the few CD45RA-re-expressing end-stage memory CD4+ T cells do not become CD45RO- 
(Figure 15E)449,450.   
 
 
Figure 17: Tissue Tfr cells are effector cells.  
(A) CD45RO+CCR7- EM, CD45RO+CCR7+ CM and CD45RO-CCR7+ naïve subsets of Tfr cells 
and CXCR5- Tregs in children blood (top) and in tissues (bottom). Representative plots (left) and 
pooled data (right) (n = 6, Student t-test). Tfh cells are represented in blue, CXCR5- Tregs in black 
and Tfr cells in red. CXCR5+ subsets in tonsils were defined as CXCR5+ICOS+ cells (Figure 7A). 
Bars represent SEM.  
 
To directly assess the functional differences between tissue and blood Tfr cells we performed 
functional assays with sorted Tfr cells from tonsils. While it was possible to sort blood Tfr 
populations with high purity (Figure 9B), similar purities cannot be achieved from tonsils, 
with the Tfr cells representing a minority of the sorted cells (Figure 18A, B). In fact, many 
Foxp3-negative T cells from the tonsil expressed high levels of CD25 and low CD127. 
Nevertheless, we performed suppressive assays with those Treg cells sorted from tonsils. 
We found that tonsil Tfr cells (together with a large number of contaminants, as Foxp3+ Tfr 
cells comprised only 10% of the total sorted cells) had a suppressive potency similar to 
conventional Treg cells, which had fewer contaminants (Figure 18C). Although, we cannot 
formally exclude a role of Foxp3-negative contaminant cells for the suppression attributed 
to tonsil Tfr cells, it is clear that, overall, the tonsil Tfr population had at least comparable 
suppressive function as Treg cells. 
 
 
 
Results I 
 
101 
 
 
Figure 18: Sorting strategy for human tonsil Tconv, Tfh, CXCR5- Treg and Tfr cells.  
(A) Sorting strategy for FACS-sort of CXCR5+ICOS+CD25-CD127+CD4+ Tfh cell, CXCR5-ICOS-
CD25-CD127+CD4+ Tconv cell, CXCR5+ICOS+CD25+CD127-CD4+ Tfr cells, CXCR5-ICOS-
CD25+CD127-CD4+ Treg cells from human tonsils. CD27-IgD+CD19+ naïve B cell populations 
from human tonsils were sorted as described in Figure 9A. (B) Purity of FACS-sorted 
CXCR5+ICOS+CD25+CD127-CD4+ Tfr cells, CXCR5-ICOS-CD25+CD127-CD4+ Treg cells. (C) 
Proliferation of Tfh cells by CTV dilution (bottom) without Tregs or in the presence of either 
CXCR5- or Tfr cells (at different ratios), using the same conditions described in Figure 14A. 
Representative plots (top and right) and pooled data (centre) from one experiment with technical 
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triplicates, One-way ANOVA with post-test Turkey’s Multiple Comparison). (ns = not 
significant). 
 
Our data suggest that blood Tfr cells are generated in secondary lymphoid tissue prior to full 
differentiation towards mature Tfr cells. It has been known that full differentiation of 
follicular T cells requires a two-step process with an initial activation mediated by DCs and 
a subsequent B cell interaction in the B-T border. We investigated whether blood Tfr cells, 
given their immature phenotype could be generated before the B cell interactions required 
for acquisition of terminal differentiation. To investigate this issue, we analyzed peripheral 
blood from X-linked Agammaglobulinemia (BTK-deficient) patients, with a complete 
absence of CD19+ cells. We observed a striking decrease in blood Tfh cells in those patients, 
in line with previous reports (Figure 19A)119. However, frequency of blood Tfr cells were 
not decreased in B-cell deficiency patients (Figure 19A).  
 
 
Figure 19: Blood Tfr cells emerge prior to B-cell interactions.  
(A) Blood Tfh and Tfr cells from X-linked Agammaglobulinemia (BTK-deficient) patients, 
compared to sex and age-matched healthy donors. Representative plots (left) and pooled data 
(right) (n = 5, Student t-test). (B) CD45RO+CCR7- effector-memory (EM), CD45RO+CCR7+ 
central-memory (CM) and CD45RO-CCR7+ naïve subsets of Tfr cells and CXCR5- Tregs in 
peripheral blood of BTK patients. Representative plots of 5 BTK patients. Error bars represent 
SEM. 
 
Results I 
 
103 
 
These observations are conclusive in establishing that blood Tfr cells enter the circulation 
before B-cell contact, while most of blood Tfh cells require B cell interactions. To 
investigate whether CD45RO+ and CD45RO- blood Tfr cells could discriminate between Tfr 
cells recirculating before and after B-cell interaction, we analysed these two populations in 
peripheral blood of patients with B-cell deficiency. No differences were found, suggesting 
that Tfr cells upregulate CD45RO irrespective of B-cell interaction (Figure 19B).  
 
We therefore hypothesized that blood Tfr cells are generated in secondary lymphoid tissue 
and enter the circulation before full differentiation towards tissue Tfr cells (Figure 20A). To 
test our model in vivo, we analysed samples from healthy adults undergoing influenza 
vaccination. Previous studies have shown a positive correlation between circulating Tfh cell 
subsets and antibody responses following influenza vaccination in healthy adults56,120,123. 
We, therefore, analysed the impact of vaccination in circulating Tfr cells. Consistent with 
our hypothesis we found that circulating Tfr cells increased on day 7 following influenza 
vaccination (Figure 20B). This observation is in line with our prediction that during ongoing 
GC responses Tfr cells are generated and some exit from the tissue to the peripheral blood. 
 
 
Figure 20: Blood Tfr cells are lymphoid tissue derived Tfr precursors.  
(A) Model of CXCR5+ follicular helper and regulatory cells T cells generation and recirculation 
in humans, upon antigen stimulation. Tfh cells in red and Tfr cells in blue. (B) Frequency of 
peripheral blood Tfr cells on the day of influenza vaccination (d0) and 7 days later in healthy 
volunteers. Schematic representation and representative plots (left) and pooled data (right) (n = 
32, paired Student t-test). 
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Discussion 
 
Our comprehensive evaluation of human Tfr cells supports a model in which blood Tfr cells 
are generated following the initial steps that lead to GC responses in secondary lymphoid 
tissues, exiting the tissue prior to interactions with B cells that are required for complete 
differentiation towards tissue resident Tfr cells. 
 
Although some studies have quantified blood CXCR5+ Treg cells as circulating Tfr cells in 
different diseases, the human biology of CXCR5+ Treg cells remains elusive329,333,334,338,341. 
Moreover, most of the literature describe studies where what is defined as blood Tfh cells 
contain both Tfh and CXCR5+ Tfr cells, while many other studies identify as Treg cells a 
mixture of bona fide conventional Treg cells together with CXCR5+ Tfr cells. As such, 
results may be confounded by combining effector and regulatory cell populations.  
 
We found that Tfr cells in tonsils have follicular and regulatory markers and were found 
within GC, whereas blood Tfr cells do not express ICOS, PD-1, or Bcl-6, apparently 
diverging these cells from follicular imprinting. Previous studies have described low ICOS 
and PD-1 expression, and no Bcl-6 expression in human blood Tfh cells 52. In mice, blood 
Tfr cells have also lower expression of ICOS 258. It was also reported that murine circulating 
Tfr cells can bypass the B cell zone and do not gain full activation as part of a memory 
programmed state258.  In line with these studies, the absence of ICOS, PD-1 and Bcl-6 from 
human blood CXCR5+ Tfr cells does not exclude their follicular ontogeny.  
 
Our results show key differences between mice and humans regarding the function of blood 
CXCR5+ Tfr cells: while murine blood Tfr cells appear to be specialized in suppressing 
antibody production (despite their lower suppressive capacity when compared to tissue Tfr 
cells)258–260,272, human blood Tfr cells do not have the ability to fully suppress humoral 
responses. Nevertheless, we found that blood Tfr cells specifically migrated towards 
CXCL13 gradient, suggesting these cells have the capacity to reach the follicles. 
Importantly, CXCR5- conventional Tregs did not upregulate CXCR5 upon in vitro 
activation, further confirming CXCR5-expressing Tfr cells as a distinctive Treg cell subset.   
Moreover, our results from vaccination cohorts show that blood Tfr cells are indicative of 
ongoing humoral activity. 
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We also found that blood Tfr cells have a prominent naïve phenotype. However, they are 
absent from the thymus and cord blood (where activated Treg cells can already be found). 
These observations provide compelling evidence that activation signals generated in 
peripheral lymphoid organs are required to shape a CXCR5+ phenotype on human Foxp3+ T 
cells. Conversely, tissue Tfr cells are almost all CD45RO+ antigen experienced effector cells. 
Taken together, these observations led us to hypothesize that blood Tfr cells leave lymphoid 
tissues as immature cells, prior to B cell interaction in T-B border, and full differentiation 
into Tfr cells. This view was supported by the presence of blood Tfr cells in peripheral blood 
of patients lacking B-cells due to genetic defects. This finding provides an explanation for 
the incomplete suppressive function of blood Tfr cells. 
 
Given that circulating Tfr cells have an immature phenotype, it is not surprising that blood 
Tfr cells are not fully endowed with suppressive function, because the suppressive capacity 
of conventional Treg cells have been ascribed predominantly to those cells with a more 
mature phenotype. The TCR repertoire of Tfr cells is different from Tfh and probably 
skewed towards auto-antigens264, it is possible that circulating Tfr cells represent a pool of 
cells ready to be recruited into subsequent GC responses as they retain the ability to migrate 
towards CXCL13. An important limitation of our study is the difficulty to isolate tissue Tfr 
cells for functional assays, as CD25 and CD127 are not reliable to identify tonsil Foxp3-
expressing cells. Therefore, we were not able to directly address whether more mature Tfr 
cells sorted from GC show a specialized humoral suppressive capacity in humans. 
 
In conclusion, our data support a model in which CXCR5+Bcl6- T cells egress from 
secondary lymphoid tissues during antigen-driven immune responses. While, the frequency 
of blood Tfh cells is reduced in the absence of B cells, Tfr cells do not require interactions 
with B cells. Thus, the acquisition of a CXCR5+Foxp3+ phenotype in the tissues precedes 
access to the follicle, where the cells acquire a fully mature phenotype. Consequently, 
circulating Tfr cells represent lymphoid tissue derived Tfr precursors not yet endowed with 
full B-cell and humoral regulatory function.  
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Blood Tfr/Tfh Ratio Marks Ectopic Lymphoid Structure 
Formation in Primary Sjögren Syndrome 
 
 
Introduction 
 
Sjögren’s syndrome is characterized by lymphocytic infiltration of salivary and lachrymal 
glands, leading to xerostomia and keratoconjunctivitis sicca437,439,451.  However, like in other 
autoimmune diseases, disease heterogeneity remains a hurdle to the development of better 
therapeutic approaches. Disease manifestations are mediated by complex mechanisms 
involving innate type I IFN signature and autoantibodies produced during dysregulated 
adaptive immune responses451. ELS143,356,357 found in salivary and lachrymal glands are a 
major site of autoantibody production415,420,451. These B – T lymphocyte aggregates define 
focal sialadenitis (FSA), the histological hallmark of SS, and have prognostic 
significance419,430. Nevertheless, many patients fulfil classification criteria for SS with 
almost normal salivary gland histology, which highlights the clinical heterogeneity of this 
disease. Whether clinical heterogeneity could be explained by different immunopathogenic 
mechanisms is unknown. However, it is reasonable to hypothesize that patients with FSA, 
especially those with ectopic GC formation, constitute a subgroup of patients more suitable 
for therapies targeting T – B interactions.   
 
Dysregulated GC reactions in secondary and tertiary lymphoid organs underlie the 
generation of self-reactive autoantibodies and many aspects of autoimmune diseases143,357. 
GC reactions are orchestrated mainly by T follicular helper (Tfh) and T follicular regulatory 
(Tfr) cells. Tfh cells provide cognate help to B cells, thus promoting their clonal selection 
and affinity maturation63. Conversely, Tfr cells regulate and limit the GC reaction assuring 
antigen-specific antibodies are produced257,256,254,255,331. While the precise mechanisms of Tfr 
cell functions are not fully understood, unbalanced Tfh and Tfr cell responses may prompt 
antibody-mediated autoimmune diseases.   
 
In the previous section, I described that blood Tfr cells are immature and not yet fully 
specialized in suppressing humoral responses330. However, the relationship between blood 
and tissue Tfr cells remains elusive in patients with immune-mediated diseases. Herein we 
Results II 
 
108 
 
investigated the potential role of blood Tfr and Tfh cells as biomarkers of ectopic lymphoid 
activity in the target organ of SS.  
 
 
Results 
 
Blood activated PD-1+ICOS+ Tfh cells correlate with SS disease activity 
 
To address the impact of Tfr and Tfh cells in human autoimmunity, we studied primary 
Sjögren syndrome from a cohort of 56 patients referred for MSG biopsy due to clinical 
suspicion of SS, together with a cohort of age and sex-matched healthy donors (Figure 4, 
Table 6, 7).  
 
Table 6: Summary of demographic characteristics of primary Sjögren syndrome 
(SS), non-Sjögren sicca syndrome (non-SSS) patients, and healthy donors 
 
Primary SS 
n = 16 
Non-SSS 
n = 16 
Healthy donors 
n = 16 
p-value 
    
Age, y 52.3 ± 17.7 47.3 ± 14.9 48.3 ± 19.7 ns 
Gender (f / m), n 15 / 1 15 / 1 11 / 5 ns 
Disease duration, y 4.8 ± 6.5 - - N/A 
ESSDAI 3.8 ± 5.0 - - N/A 
Extraglandular involvement, n 
(%) 
12 (75) - - N/A 
Prednisolone (≤5mg/d), n (%) 5 (31) 0 - 0.0434 
Hydroxychloroquine, % 3 (19) 0 - ns 
ANA positive, n (%) 15 (94) 2 (13) - <0.0001 
Anti-SSA positive, n (%) 15 (94) 0  <0.0001 
Anti-SSA/Ro52 titer, UQ 7824 ± 15430 - - N/A 
Anti-SSA/Ro60 titer, UQ 8728 ± 6079 - - N/A 
Anti-SSB positive, n (%) 10 (63) 0  <0.0001 
Anti-SSB titer, UQ 1206 ± 4236 - - N/A 
RF positive, n (%) 8 (50) 1 (6)  0.0024 
RF titer, UI/mL 45.7 ± 26.1 18.7 ± 0.0 - N/A 
CRP, mg/dL 0.53 ± 0.58 0.52 ± 0.78 - ns 
ESR, mm 43.7 ± 25.6 22.1 ± 16.3 - 0.010 
γ-fraction, g/dL 1.76 ± 0.58 1.07 ± 0.31 - 0.002 
MSG histology, n (%) 
Focal sialadenitis 
Unspecific inflammation 
Normal 
 
7 (44) 
6 (38) 
3 (19) 
 
0 
5 (31) 
11 (69) 
 
- 
- 
- 
 
0.0068 
ns 
0.0113 
     
Legend: NA, not applicable; ns, not significant    
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Table 7: Demographic and clinical characteristics of Sjögren syndrome (SS) and non-
Sjögren sicca syndrome (non-SSS) patients 
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Figure 21: Primary Sjögren’s syndrome patients have an increased blood Tfr/Tfh ratio.  
(A) Frequency and absolute number (per mL of blood) of CD4+ T cells in peripheral blood of 
primary S Sjögren’s syndrome (SS, n=16) and healthy donors (HD, n=16). (B) Identification of 
CD25+Foxp3+ Treg, CXCR5+CD45RO+CD25-Foxp3- Tfh, and CXCR5+CD25+Foxp3+ Tfr cells in 
peripheral blood of SS (n=16) and HD (n=16). Unpaired Student T-test with Welch’s correction 
for variance. Representative plots (left) and pooled data (right). (C) Frequency (top) and absolute 
number (per mL of blood) (bottom) of Tfh, Treg, CXCR5- Treg, and Tfr cells in peripheral blood 
of SS patients (n=16) and HD (n=16). Unpaired Student T-test. (D) Mean fluorescence intensity 
of CXCR5 and Foxp3 in peripheral blood Tfh and Tfr cells in SS (n=16) and HD (n=16). Unpaired 
Student T-test. (E) Blood Tfr/Tfh (left) and CXCR5- Treg/Tfh (right) ratios in SS (n=16) and HD 
(n =16). Unpaired Student T-test. Bars on scatterplots represent SEM. 
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Primary SS patients were lymphopenic, a common feature of human systemic autoimmune 
diseases (Figure 21A)452. Unexpectedly, we found a striking increased frequency of blood 
Tfr cells in SS as compared to age-matched healthy donors (Figure 21B, C). Interestingly, 
while primary SS patients had decreased absolute number of all CD4+ T cell subsets, in line 
with their CD4+ T cell lymphopenic state, the absolute number of Tfr cells were not different 
when compared to healthy donors (HD), suggesting that the Tfr cell subset is indeed over-
represented in these patients (Figure 21C). The increased frequency of the CXCR5+ Treg 
cell subset was specifically increased providing an explanation for the high Treg cell 
frequency observed in SS patients (Figure 21C). At the protein level, we did not find 
differences in CXCR5 and Foxp3 expression on Tfr cells from SS patients and HD (Figure 
21D). While, Tfh cells from SS patients expressed lower CXCR5, we did not test whether 
Tfh cells from SS patients have different homing properties (Figure 21D). Primary SS 
patients showed a significantly increase in the blood Tfr/Tfh ratio compared to HD (Figure 
21E). The increase in this ratio was specifically attributed to an increase of Tfr cells, as no 
differences were found on CXCR5- Treg cells/Tfh ratio (Figure 21E).  
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Figure 22 (previous page): Circulating Tfh cell subsets are not altered in primary Sjögren 
syndrome.  
(A) Frequency of PD-1+ICOS+ Tfh cells in peripheral blood of SS (n=14) and HD (n=13). 
Unpaired Student T-test with Welch’s correction for variance. Representative plots (left) and 
pooled data (right). (B) Frequency of PD-1+CXCR3- Tfh cells in peripheral blood of SS (n=14?) 
and HD (n=13). Unpaired Student T-test. Representative plots (left) and pooled data (right). (C) 
Distribution of CCR6+CXCR3- Tfh17-like cells, CCR6-CXCR3+ Tfh1-like cells, and CCR6-
CXCR3- Tfh2-like cells in peripheral blood of SS (n=16) and HD (n=16). Unpaired Student T-
test. (D) Distribution of CCR6+CXCR3- Th17 cells, CCR6-CXCR3+ Th1 cells, and CCR6-CXCR3- 
Th2 cells in peripheral blood of SS (n=16) and HD (n=16). Unpaired Student T-test. Bars on 
scatterplots represent SEM. 
 
We did not find a significant increase of activated PD-1+ICOS+ Tfh cells or PD-1+CXCR3- 
GC-like Tfh cells in SS patients (Figure 22A, B)52,54–56,120. Contrary to previous reports453, 
SS patients had a normal distribution of Tfh1, Tfh2 and Tfh17-like cells (Figure 22C, D).  
 
To investigate whether follicular T cell subsets correlated with autoantibodies, inflammatory 
markers and disease activity we conducted correlation heatmaps. We found that blood 
Tfr/Tfh ratio and PD-1+ICOS+ Tfh cells significantly correlated with the presence of anti-
SSA/Ro60 (r=0.580, p=0.0298) and anti-SSA/Ro52 (r=0.558, p=0.047), respectively 
(Figure 23A, B). While most correlations were barely significant, we found a very strong 
association between frequency of activated PD-1+ICOS+ Tfh cells and disease activity 
(ESSDAI, r=0.855, p=0.0008) (Figure 23A, B). Interestingly, blood Tfr/Tfh ratio and PD-
1+ICOS+ Tfh cells consistently correlated in opposite directions with the variables analysed, 
albeit not always reaching statistical significance (Figure 23A). 
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Figure 23 (previous page): Blood PD-1+ICOS+ activated Tfh and Tfr/Tfh ratio marks distinct 
features of primary Sjögren syndrome.  
(A) Heatmap representation of correlation between peripheral blood Tfh cells, PD-1+ICOS+ Tfh 
cells, PD-1+CXCR3- Tfh cells, Tfr cells, and Tfr/Tfh ratio and serum autoantibodies titers 
(antinuclear antibodies (ANA), anti-SSA/Ro52, anti-SSA/Ro60, anti-SSB), rheumatoid factor 
(RF, IU/mL), serum electrophoresis gamma-fraction (γ-fraction, g/dL), C-reactive protein (CRP, 
mg/dL), erythrocyte sedimentation rate (ESR, mm/1st hour) and disease activity measured by 
European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index (ESSDAI), in 
SS patients (n = 16, Pearson coefficient, r). (B) Correlation between peripheral blood Tfr/Tfh ratio 
and serum anti-SSA/Ro60 titers (left); correlation between blood PD-1+ICOS+ Tfh cells and serum 
anti-SSA/Ro52 (centre) and ESSDAI (right) (n = 16, linear regression with interpolated 95% 
confidence interval curves). On linear regression plots, dashed line represents interpolated 95% 
confidence interval. 
 
Blood Tfr/Tfh ratio identifies pathological lymphocytic infiltration in SS target organ 
 
As the Tfr/Tfh ratio may predict the outcome of GC reactions257,260, we hypothesized that 
patients with autoimmune diseases with abnormal GC reactions leading to autoantibody 
production may have an altered Tfr/Tfh ratio. As GC reactions take place in lymphoid tissues 
and ectopic (or tertiary) lymphoid structures, we studied MSG tissue biopsies from patients 
with primary SS and controls with non-Sjögren sicca syndrome (Figure 4, Table 6, 7).  
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Figure 24 (previous page): Optimization of salivary gland enzymatic digestion.  
(A) Impact of different enzymes in membrane markers used for identification of cellular 
components of minor salivary gland tissue infiltrates, including CXCR5-expressing T cells. 
Human tonsil fragments from healthy children were used for optimization. Liberase TM (0.1 
mg/mL), DNAse I (0.1 mg/mL), Collagenase P (0.1 mg/mL). All enzymes led to significant 
duction of CXCR5 on PD-1+CD4+ T cells. Representative plots of 2 independent experiments. (B) 
CXCR5 and ICOS expression by salivary gland CD4+ B cells and CD19+ T cells after enzymatic 
digestion by Liberase TM (0.1 mg/mL) plus DNAse I (0.1 mg/mL), confirming the loss of CXCR5 
staining. Representative plots of 14 MSG biopsies. (C) Microscopy of formalin-fixed paraffin-
embedded MSG stained for CXCR5 (brown, right), with correspondent negative control (left) by 
immunohistochemistry. Data are representative of MSG sections from 4 SS patients. 
 
Loss of CXCR5 receptor following enzymatic digestion due to a tissue-intrinsic factor (as 
the same enzymatic digestion did not limit detection of CXCR5 expression on lymphocytes 
isolated from human tonsils and CXCR5 was detected in salivary gland tissue by 
immunohistochemistry) excluded direct analysis of tissue Tfh and Tfr cells (Figure 24A – 
C).  
 
Primary SS patients had an increased frequency and absolute number (per mg of tissue) of 
non-epithelial CD45+ cells and CD19+ B cells (Figure 25A – C). As around 90% of PD-
1+ICOS+ T cells in lymphoid tissues were CXCR5+ Tfh cells, we assessed salivary gland 
infiltration by PD-1+ICOS+ T cells (Figure 25D, E). We found a striking increased 
frequency and absolute number of infiltrating PD-1+ICOS+ T cells in SS patients (Figure 
25E). Although, it is likely that this cell population comprise tissue Tfh cells, we cannot 
exclude the existence of CXCR5-PD-1+ICOS+ T cells, described as a specific type of helper 
T cells within ELS of RA patients408. In both cases, our findings suggest that MSG tissue 
from primary SS patients host active T-dependent humoral responses. 
 
To validate our results, we compared MSG analysis by flow cytometry with routine 
histological diagnosis of the same biopsies. Infiltration by CD19+ B cells was found in all 
SS patients irrespectively of salivary gland morphology. Yet, only patients with ELS/FSA 
had a significantly higher infiltration by B cells as compared to MSG of patients with non-
Sjögren sicca syndrome (Figure 25F, G). 
 
When we compared blood Tfh and Tfr populations with lymphocytic MSG infiltration of 
patients with SS, we found a strong correlation between blood Tfr/Tfh ratio and the presence 
of ELS in exocrine glands. Indeed, blood Tfr/Tfh ratio was positively correlated with tissue 
infiltration by CD4+ T cells (r=0.8475, p=0.0039), PD-1+ICOS+ T cells (r=0.8400, 
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p=0.0180), and CD19+ B cells (r=0.6748, p=0.0462) (Figure 26A, B). Moreover, blood Tfr 
cells were also positively correlated with tissue CD19+ B cells (r=0.6690, p=0.0488) and a 
positive trend was seen regarding other local populations (Figure 26A). Interestingly, 
despite not significant, blood Tfh cells and Tfh cell subsets negatively correlated with tissue 
infiltration by all inflammatory cells analysed, showing an opposite trend to blood Tfr cells 
and Tfr/Tfh ratio (Figure 26A). Taken together, these data suggest that blood Tfr cells and 
Tfr/Tfh ratio indicate pathological lymphocytic infiltration in the target organ of SS.  
 
To test whether increased blood Tfr cells and Tfr/Tfh ratio observed in patients is due to 
selective exclusion of Tfr cells from FSA lesions we directly accessed CXCR5+Foxp3+ Tfr 
cells infiltration in MSG biopsies by microscopy. We found a substantial number of 
CXCR5+Foxp3+ Tfr cells within CD20+ FSA in MSG of SS patients (Figure 26C). As tissue 
infiltration by CD20+ B cells is considered the first step of ELS formation404, our findings 
suggest that Tfr cells are not excluded from ELS in inflamed SS exocrine glands. 
 
Blood Tfr/Tfh ratio as a marker of SS and focal sialadenitis 
 
As blood Tfr/Tfh ratio was increased in SS patients compared to healthy donors and 
associated with MSG lymphocytic infiltration we wondered whether this ratio could aid in 
the identification of patients with SS and FSA, a major diagnostic marker of SS428,430,442. 
 
Figure 25 (next page): Characteristics of minor salivary gland biopsies of primary Sjögren’s 
syndrome patients.  
(A) Frequency and absolute numbers (per mg of tissue) of CD45+ hematopoietic cells in minor 
salivary gland biopsies (MSG) of SS patients (n=14) and non-Sjögren sicca syndrome (non-SSS) 
patients (n=6). Representative plots (left) and pooled data (right). Unpaired Student T-test. (B) 
Frequency and absolute numbers (per mg of tissue) of CD4+ T cells and CD19+ B cells in MSG 
biopsies of SS (n=14) and non-SSS (n=6). Representative plots (left) and pooled data (right). 
Unpaired Student T-test with Welch’s correction for variance. (C) Weight of salivary gland tissue 
removed during MSG biopsy in SS patients (n=14) and non-SSS patients (n=6). (D) CXCR5 and 
Bcl-6 expression by ICOS+PD-1+CD4+ T cells from human tonsils. Representative plots (left) and 
pooled data (right) (n=6). (E) Frequency and absolute numbers (per mg of tissue) of PD-1+ICOS+ 
T cells in MSG biopsies of SS (n=10) and non-SSS (n=6). Representative plots (left) and pooled 
data (right). Unpaired Student T-test with Welch’s correction for variance. (F) Frequency of CD4+ 
T cells, CD19+ B cells, and PD-1+ICOS+ T cells in MSG biopsies of SS (n=14) and non-SSS (n=6), 
according to histological diagnosis (normal, no infiltration by lymphocytes; LI, unspecific 
lymphocytic infiltration; FSA, focal sialadenitis). Two-way ANOVA with post-test Bonferroni’s 
Multiple Comparison. (G) Microscopy of formalin-fixed paraffin-embedded MSG stained for 
CD20 (brown) in a SS patient with FSA (right) and a SS patient with no pathologic findings 
(normal, left). Bars on scatterplots represent SEM. 
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Figure 26: Blood Tfr/Tfh ratio identifies pathological lymphocytic infiltration in Sjögren’s 
syndrome target organ.  
(A) Heatmap representation of correlation between peripheral blood Tfh cells, PD-1+ICOS+ Tfh 
cells, PD-1+CXCR3- Tfh cells, Tfr cells, and Tfr/Tfh ratio (rows) and salivary gland infiltration by 
CD45+ hematopoietic cells, CD4+ T cells, ICOS+PD-1+CD4+ T cells and CD19+ B cells (columns), 
in primary SS patients (n=14, Pearson coefficient, r). (B) Correlation between peripheral blood 
Tfr/Tfh ratio with salivary gland infiltration by CD45+ hematopoietic cells, CD4+ T cells, 
ICOS+PD-1+CD4+ T cells and CD19+ B cells (n=14, linear regression). (C) Identification of 
CXCR5+Foxp3+ Tfr cells (arrows on extreme right image) within FSA containing CD20+ B cells 
in MSG biopsies of primary SS patients by immunohistochemistry. Extreme left image shows FSA 
containing B cells (CD20 in brown) (x100, digital zoom). The three images on right show double 
immunohistochemistry for CXCR5 (purple/red) and Foxp3 (brown). The squares in each image 
are amplified successively on the right (x100, x200, x400, digital zoom). Representative sections 
(left) and pooled data (right) (n=16). Bars on scatterplots represent SEM. On linear regression 
plots, dashed line represents interpolated 95% confidence interval. 
 
The blood Tfr/Tfh ratio was significantly higher in SS patients compared to healthy donors 
and patients with non-Sjögren sicca syndrome (Figure 27A). This ratio was a significant 
predictor of SS when compared to healthy donors, with an increase of 4.97 in the odds of 
having SS for every decimal increase in the Tfr/Tfh ratio (AUC=0.82, p=0.008) (Figure 
27B, C). Through ROC analysis, we found that a cut-off of ≥0.278 correctly classified 87.1% 
of patients with 100% specificity and 73.3% sensitivity. Compared to non-Sjögren sicca 
syndrome, Tfr/Tfh ratio tended to associate with SS diagnosis (OR=1.93, p=0.099, 
AUC=0.716), with the best cut-off to diagnose SS being a blood Tfr/Tfh ratio ≥0.3009 
(Figure 27B, C). Thus, patients with sicca symptoms and a Tfr/Tfh ratio ≥0.3009 had 13 
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times the odds of having SS, with very high specificity (90.9%) but moderate sensitivity 
(56.3%) (Figure 27C). 
 
Importantly, blood Tfr/Tfh ratio was significantly increased in patients with FSA, compared 
to those with normal histology or mild unspecific inflammation, irrespective of diagnosis 
(Figure 27D). Moreover, it significantly predicted the result of MSG biopsy (FSA vs. no-
FSA), with an increase in the odds of having FSA of 2.03 per each decimal increase (AUC 
0.793, p=0.047) (Figure 27C, E). Values of blood Tfr/Tfh ratio ≥0.302 were significantly 
associated with FSA (OR=10, p=0.022, AUC=0.757), with good sensitivity (71.4%) and 
very good specificity (80%) (Figure 27C). 
 
 
Figure 27: Blood Tfr/Tfh ratio is a marker of primary Sjögren’s syndrome and focal 
sialadenitis.  
(A) Blood Tfr/Tfh ratio in Sjögren’s syndrome (SS, n=16) and non-Sjögren sicca syndrome (non-
SSS, n=11) patients and healthy donors (HD, n =16). Unpaired Student T-test with Welch’s 
correction for variance was used except when variance was not significantly different between 
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groups (non-SSS vs. HD comparison). One-way ANOVA comparison across groups represented 
on top. (B) Receiver operating characteristic (ROC) curve for prediction of SS diagnosis (vs. HD 
and vs. non-SSS) based on Tfr/Tfh ratio. AUC, area under the curve. (C) Odds-ratio (OR), p-value 
and AUC of logistic regression models predicting SS diagnosis (vs. HD and vs. non-SSS) and 
focal sialadenitis (FSA, vs. normal histology or unspecific lymphocytic infiltration, LI) based on 
Tfr/Tfh ratio as a continuous variable or as specific cut-offs. Tfr/Tfh ratio transformed by 1 
decimal place (*101) for better interpretation of the OR. Percentages of sensitivity, specificity and 
correct classification of patients based on given cut-offs. (D) Blood Tfr/Tfh ratio of patients with 
sicca symptoms undergoing minor salivary gland biopsy, with focal sialadenitis (FSA, n=7) and 
normal histology or unspecific lymphocytic infiltration (LI, n=20). Mann-Whitney U test used due 
to skewed distribution of values and non-different variance according to Brown–Forsythe’s test. 
(E) Receiver operating characteristic (ROC) curve for prediction of FSA diagnosis (vs. normal/LI) 
based on Tfr/Tfh ratio. AUC, area under the curve. 
 
 
Discussion 
 
Our results show that blood activated Tfh cells and Tfr/Tfh ratio are associated with disease 
activity and FSA in MSG, respectively, in primary SS. Indeed, there is a striking association 
between high Tfr/Tfh ratio and ectopic lymphoid activity in salivary glands, the target organ 
of this disease. In addition, circulating PD-1+ICOS+ Tfh cells seem to provide a different 
information, indicating disease activity and not FSA. Of note, PD-1+ICOS+ Tfh cells were 
not increased in primary SS, when patients were analysed together, but this cell population 
was increased in patients with high disease activity. 
 
The relationship between circulating PD-1+ICOS+ Tfh cells with ESSDAI was an exciting 
finding. While, many studies have established that circulating activated Tfh cells are 
correlated with disease severity in autoimmunity391,454,455, so far circulating Tfh cells were 
not correlated with ESSDAI. Notably, other Tfh subsets, namely Tfh17-like cells identified 
in other immune-mediated diseases391, were not altered in our cohort of primary SS patients. 
Although, autoimmunity and acute GC reactions induced by vaccination have distinct 
mechanisms, we anticipated a greater relationship between PD-1+ICOS+ Tfh cells with 
serum autoantibodies, given the reported increase of this subset following influenza 
vaccination120,123. Considering that the increase of PD-1+ICOS+ Tfh cells following 
influenza vaccination is only transient, with a peak at day 7 – 10 post vaccination120,123, we 
believe that in primary SS there is a chronic sustained inflammatory state (with ongoing GC 
reactions), which maintains a high frequency of blood PD-1+ICOS+ Tfh cells330. This 
increased inflammatory response will also lead to the clinical and laboratorial manifestations 
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of primary SS, which are adequately captured by ESSDAI, thus further validating the 
usefulness of this tool in clinical practice and research. Moreover, these results suggest that 
PD1+ICOS+ Tfh cells may be directly involved in the pathogenesis of SS, particularly in 
those patients with greater inflammatory activity and high ESSDAI scores. A recent study 
showed that ESSDAI is an independent predictor of lymphoma development in primary 
SS456 thus raising the possibility that increased circulating PD1+ICOS+ Tfh cells are 
somehow related to the same mechanism that will culminate in hematologic malignancy. 
 
The predictive value of Tfr cells, and especially the Tfr/Tfh ratio, regarding the diagnosis of 
primary SS and pathological lymphocytic infiltration in salivary glands may appear 
counterintuitive, given the regulatory role attributed to Tfr cells257,331. However, we have 
recently shown that human blood Tfr cells remain immature and are generated prior to T – 
B interactions required for acquisition of follicle access and full regulatory function330. The 
increased proportion of Tfr cells in peripheral blood of SS patients did not seem to be due to 
anatomic exclusion of Tfr cells from inflamed exocrine glands, as substantial numbers of 
Tfr cells were found within FSA in most patients. Although, we did not perform a detailed 
characterization of FSA regarding their organization as ELS, all patients with FSA had 
organized clusters of CD20+ B cells within those lesions. As tissue infiltration by CD20+ B 
cells is considered the first evidence of ELS development404, we assumed that patients with 
CD20+ FSA had ELS. It is generally assumed that ELS are populated by lymphocytes formed 
outside these structures, in secondary lymphoid organs356,357. Thereby, it is likely that Tfr 
cells result from enhanced differentiation in secondary lymphoid organs due to ongoing 
humoral responses. Our data suggest that accumulation of Tfr cells are not sufficient to 
restore tolerance in exocrine glands (where the first step of SS pathogenesis occur), although 
we did not directly address the presence of Tfr cells in ELS with and without GCs439. A 
recent report claimed salivary gland epithelial cells induce Tfh cell differentiation from naïve 
CD4+ T cells407. While, it is not known whether Tfr cell differentiation can also occur in situ, 
this could possibility provide an alternative explanation for the increased proportion of blood 
Tfr cells in SS. 
 
The blood Tfr/Tfh ratio does seem to be a specific of ELS formation within salivary glands. 
Indeed, we found that Tfr/Tfh ratio could discriminate between SS patients and healthy 
donors with excellent accuracy, with a specific cut-off above which the diagnosis of SS was 
almost certain. Even more important, this ratio was also helpful in predicting a diagnosis of 
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primary SS and the presence of FSA in MSG biopsy in a group of patients investigated for 
sicca symptoms, thus highlighting the potential clinical value of this marker. The proposed 
cut-offs of blood Tfr/Tfh ratio above/equal 0.3009 and 0.302 were strong predictors of SS 
and FSA, respectively, and constitute promising tools for SS clinical evaluation. It should 
be noted that the specificity and sensitivity of Tfr/Tfh ratio to predict FSA and SS was 
remarkably high, in particular given the small number of patients studied. We anticipate that 
greater patient numbers may reinforce the significance of our findings, potentially 
establishing the usefulness of Tfr and Tfh quantification for primary SS patient stratification. 
This is particularly important both for diagnostic and therapeutic purposes as there are major 
unmet needs in these fields in primary SS457. The potential to confirm diagnosis in patients 
who do not fulfil classification criteria, or to identify clusters of patients more prone to 
respond to targeted therapies are some of the applications that such a biomarker could have.  
 
For the results described in this section, we decided to study fresh blood of patients at the 
time of diagnosis who were not under immunosuppressant drugs, to overcome potential drug 
effects on Tfh and Tfr cell subsets. Consequently, the studied cohort of patients was small, 
but uniform and consistent. Other limitations of our study included the fact that paired 
samples for every parameter were, in some cases, not available and the technical difficulty 
in achieving CXCR5 staining in salivary gland cell suspensions, which precluded a direct 
assessment of tissue Tfr cells at a phenotypical and functional level. In addition, we did not 
dissect the organizational complexity of FSA, namely, the presence of high endothelial 
venules, development of CD21+ FDC networks, infiltration by CD138+ plasma cells, and the 
expression of GC-specific proteins such as Bcl-6 and AID357.  It also remains to be shown 
whether alterations of Tfr and Tfh subsets that we describe here are specific for SS or can be 
generalized to other immune-mediated inflammatory diseases, in particular diseases with 
ELS and autoantibody-mediated pathology. 
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Provision of improved hygiene conditions, campaigns of mass vaccination, and eradication 
of mass epidemics were the greatest medical achievements of twentieth-century. The twenty-
first-century medicine is facing new challenges. Modernity inspired people to become more 
demanding, and to hardly accept disappointing results. Even if etiology is well-known, new 
therapies will keep missing the opportunity to directly target disease initiators (other than 
infectious agents), until disease prediction becomes a universal practice. Dysregulated 
immune responses are currently recognized as a cornerstone of disease perpetuation. Thus, 
targeting the immune system to modulate disease, without affecting immunocompetence, is 
probably one of the biggest challenges of modern medicine. 
 
Although, the immune system has an inbuilt tendency to avoid attacking self-tissue, as 
proposed by Paul Ehrlich in 1901, aberrant responses to self do occur458. Half century later, 
Sir Frank Burnet reasoned that somatic mutations in antigen receptors leading to “forbidden” 
clones that were mistakenly not deleted during lymphocyte development can give rise to 
autoimmune diseases427,459. The ability to reprogram the dysregulated immune system 
towards reinstating homeostasis without the need for continuous treatment is the holy grail 
of immunotherapy. Conventional therapies for autoimmunity rely primarily on harsh broad-
spectrum anti-inflammatory and suppressive regimens. The adverse effects of such regimens 
have driven the continuous quest for more specific and less toxic therapies. In the last 20 
years, the use of immunological tools, such as monoclonal antibodies, receptor-
immunoglobulin fusion proteins, vaccines and immune cells, as therapeutic options 
improved our ability to tread the narrow line between treatment efficacy and unacceptable 
collateral damage358. Because immunotherapy manipulates the fundamental components of 
the immune response that underlies both the pathological and the normal immune functions, 
penalty can probably never be entirely separated from success. In addition to the associated 
hazards of immunotherapy, the failure of most immunological approaches that are effective 
in animal models to modulate autoimmune diseases in humans suggests that we do not 
understand many of the principles behind pathogenic mechanisms of those diseases358. To 
minimize the unintended side effects of immunotherapy, we must develop more specific 
methods to target pathogenic cell populations and to identify new disease biomarkers. 
Indeed, as we gain more experience, we are learning to use existing therapies in better ways 
and developing treatments with better efficacy-to-toxicity ratios. Many options are now 
being studied, such as using a combination of therapeutic agents to reduce the dose of each 
individual drug to levels that are not toxic, and to start treatment at early time points, given 
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that a shorter course of treatment is expected to reduce the side effects460. Moving from 
disease biomarkers to biomarkers of specific abnormal immune reactions may be a 
breakthrough to timely treat autoimmune patients with the most appropriate therapeutic 
regimens. 
 
Autoimmunity of follicular origin poses an additional challenge because the therapeutic 
options need to “tune down” GC reactions to reduce the risk of autoimmunity while 
preserving foreign antigen-specific protective responses. Following the discovery of Tfr 
cells as putative GC “fine tune” regulators, targeting Tfr cell responses may constitute a 
novel and highly selective approach for the treatment of autoantibody-mediated autoimmune 
diseases. Yet, the still embryonic knowledge about Tfr cell biology halts these advances, 
particularly in humans. 
 
The main topic of this thesis is human Tfr cells. The overall aim of this work was to study 
human blood CXCR5+Foxp3+ Treg cells from two perspectives. First, we conducted several 
experiments to address whether CXCR5+Foxp3+ T cells constitute a circulating counterpart 
of germinal centre bona fide Tfr cells. While, these cells increased after the induction of GC 
responses by vaccination and are absent from neonatal cord blood (an immune setting in 
which GC reactions do not take place), confirming their relationship with humoral responses 
in secondary lymphoid organs, they fail to fully regulate humoral responses, suggesting these 
cells are not fully competent Tfr cells. These findings may be translated therapeutically as 
far as modulation of blood Tfr cells toward proficient Tfr cells can be experimentally 
achieved. Second, we found that blood Tfr cells, and specifically the Tfr/Tfh ratio, are 
increased in SS patients. Notably, patients with ectopic lymphoid activity have the highest 
level of blood Tfr/Tfh ratio. These findings led us to propose blood Tfr/Tfh ratio as a novel 
biomarker of ectopic lymphoid activity in SS. 
 
 
Human Blood CXCR5+Foxp3+ Treg Cells Are Immature Tfr Cells Not Fully Licensed 
with Humoral Suppressive Function 
 
Our comprehensive evaluation of human Tfr cells supports a model in which blood Tfr cells 
are generated following the initial steps that lead to GC responses in secondary lymphoid 
tissues, exiting the tissue prior to interactions with B cells that are required for complete 
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differentiation towards tissue resident Tfr cells (Figure 20A). Our work was the first to 
address Tfr cell biology and ontogeny in humans. Having demonstrated that Tfr cells are a 
distinct subset of both Tfh and (conventional) Treg cells, we believe human T cell 
immunophenotyping studies will become clearer from now on. Moreover, we showed key 
differences between mice and humans regarding the function of blood Tfr cells: while 
murine blood Tfr cells appear to be specialized in suppressing antibody production (despite 
their lower suppressive capacity when compared to tissue Tfr cells), human blood Tfr cells 
do not have the ability to fully suppress humoral responses. Therefore, our findings also 
advert for the limitations of translating mice knowledge to human therapeutics in this field. 
Animal models have been massively used in life sciences research due to their experimental 
advantages. Their use allows a rigorous and independent study of experimental variables and 
access to tissues not ethically accessible in humans. Yet, several immunological approaches 
that are effective in animal models have failed in humans358. We will probably face a 
turnover in this scientific paradigm in the years to come: instead of using animal models to 
explore new hypothesis, the use of human samples to generate new clinically-relevant 
hypothesis (to be further validated in animal models) will be standard. The adaptive immune 
responses may have critical distinctions between humans and mice322,461,462. For example, 
human Tfh cells require IL-23, IL-12 and TGF-β for their differentiation, in contrast to IL-6 
requirement for murine Tfh cells63,126. Interestingly, the impact of bystander infections on 
basal immune system activation (and on Tfh, Tfr and GC B cell responses, which are 
anticipated to be highly mediated by pathogens) may account for differences reported 
between murine and human immune system461. 
 
The absence in blood Tfr cells of Bcl-6, ICOS and PD-1 expression (which was also reported 
for human blood Tfh cells52) together with their ineffectiveness to fully suppress humoral 
responses can be argued as sufficient evidence to disprove human blood CXCR5+Foxp3+ T 
cells as circulating counterparts of bona fide tissue Tfr cells. However, we found that blood 
Tfr cells specifically migrated toward a CXCL13 gradient, while TCR/CD28 stimulation 
alone was not sufficient to induce CXCR5 upregulation in conventional Treg cells. Together 
with the complete absence of CXCR5+Foxp3+ T cells in neonatal cord blood (where 
activated CD45RO+ICOS+ Treg cells were already present) led us to conclude that CXCR5 
expression is acquired in secondary lymphoid tissue after establishment of mature humoral 
responses, and not simply an activation marker. This conclusion is further supported by the 
immature phenotype of blood Tfr cells and their emergence prior to B-cell interactions, as 
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B-cell deficient patients had normal frequencies of blood Tfr cells. Thereby, the key question 
turns out to be what is the biological relevance of these cells in human blood? Or, 
alternatively, why Tfr cells leave secondary lymphoid organs before having the opportunity 
to exert their function within GCs?   
 
In murine models, adoptively transferred blood Tfr cells have been shown able to migrate to 
secondary lymphoid organs with ongoing GC reactions and to the skin258. In mice parabiosis 
studies, circulating Tfr cells were reported to have memory properties and to outcompete de 
novo formed effector Tfr cells after secondary exposure to antigen258. These findings suggest 
that a major role of blood Tfr cells can be the regulation of secondary GC reactions, raising 
the threshold for B cell activation, thereby limiting inappropriate antibody responses. While, 
these results do not explain the immature phenotype of human blood Tfr cells, they support 
a model in which Tfr cells are formed upon GC-forming immune reactions. Indeed, we 
demonstrated that human blood Tfr cells increase at day seven following influenza 
vaccination. So far, it has been reported that: a) human blood ICOS+CXCR5+ Tfh cells peak 
at day seven upon influenza vaccination and correlate with specific protective 
antibodies120,123,463; b) human blood CXCR5+ Tfh cells are memory-like cells which promote 
antibody responses upon antigen reexposure52,54–56; and c) in mice, lymph node Bcl-
6+CXCR5+ Tfh cells peak between day 7 and day 15 upon intranasally influenza infection, 
but Bcl-6+CXCR5+ Tfr cells only peak at day 30278. Together with our data, it seems 
tempting to hypothesise that Tfh and Tfr cells follow distinct kinetic responses upon 
influenza vaccination: while Tfh cells accumulate in blood and lymph nodes almost 
simultaneously, recirculating as GC-experienced memory Tfh cells, Tfr cells accumulate in 
lymph nodes only after systemic recirculation as immature cells. Whether all Tfr cells follow 
this kinetic profile, or only some cells recirculate is still unknown. We may speculate that 
early recirculation of Tfr cells following adaptive immune responses enforces systemic 
tolerance by unknown mechanisms. 
 
The therapeutically use of Tfr cells to re-establish immune tolerance by fine tuning GC 
reactions is an attractive and promising idea. While, several studies linked the absence of 
Tfr cells to the emergence of autoimmunity in murine models, we still do not understand 
many fundamental aspects of Tfr cell biology. The impact of Tfr cells on the immune system 
is hardly consensual. In different murine models, absence of Tfr cells led to expansion of 
Tfh and GC B cells, as well as increased antibody production256,254,255,278. However, some 
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other groups have shown that the lack of Tfr cells has no impact on GC size and GC B cell 
numbers303. The effect of Tfr cells on antigen-specific B cells and antibody affinity is even 
more complex. Existing evidence suggests that Tfr cells restrains generation of antibodies 
specific to the immunizing antigen while favouring the emergence of B cell clones secreting 
high affinity antibodies259,269,278,302,303. Thus, Tfr cells impose (on GC B cells) a more 
stringent competition for Tfh help, promoting the generation of high affinity antibodies, 
while limiting the expansion of antigen specific B cell clones. As Tfr cells seem to uncouple 
GC B cell expansion and selection, it would be interesting to address the impact of Tfr cells 
on B cell cycling between GC dark and light zones. However, this uncoupling effect by Tfr 
cells may be time-dependent, as suggested by Wing and colleagues269. Further studies using 
specific Tfr cell deletion, or boosting Tfr numbers, at different time points will be critical to 
directly address this issue. It would also be interesting to address the impact of Tfr cells on 
autoreactive self-sustained GC responses, which were recently proposed as the underlying 
mechanisms to epitope spreading observed in autoimmune diseases464. Degn and colleagues 
used the 564Igi murine model (generated by knock in of the heavy chain and kappa light 
chain of an autoreactive B cell clone targeting ribonuclear complexes) to demonstrate that a 
single autoreactive B cell clone drives a TLR7-dependent expansion of other autoreactive B 
cells in spontaneous GCs464,465. Those GC gained independence from the initial 546Igi 
trigger, but evolved toward pauciclonality464. Importantly, these autoreactive GCs were 
ablated by CD40L blockade, suggesting that while autoreactive GCs became independent of 
the initial clone (thereby propagating the disease), they still require T cell help464.   
 
It is likely that boosting Tfr cell responses will facilitate the emergence of high affinity B 
cells clones toward the immunizing antigen. Importantly, this effect may be achieved 
independently of Tfr cell antigen-specificity, as Tfr cells were shown to suppress in an 
antigen-independent manner258,264. It is also possible to anticipate that boosting Tfr cell 
responses will not culminate in gut dysbiosis, as Tfr cells were demonstrated to be required 
for gut IgA production and microbiota homeostasis302. In the setting of autoimmunity, a 
protective function has been ascribed to Tfr cells. In the absence of Tfr cells, some murine 
models developed clinical hallmarks of autoimmunity, such as the production of clinically 
relevant autoantibodies (anti-dsDNA, anti-Ro52, anti-Ro60 and anti-La) and autoantibody-
induced glomerulonephritis273,278,282,283. It is notable that under those conditions, the absence 
of Tfr cells alone appears to be sufficient to induce autoantibody-mediated autoimmunity, 
as several redundant mechanisms maintaining immune tolerance within GCs have been 
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described143. Disappointingly, no study has specifically tested whether the adoptive transfer 
of Tfr cells control ongoing autoimmune diseases. In chronic graft-versus-host disease, an 
autoantibody-mediated disease, CXCR5-expression by Treg cells was shown to be required 
for their protective effect, but the therapeutic potential of Tfr cells remains purely 
speculative308.  
 
Before testing Tfr cell-based immunotherapy in humans it is critical to address whether 
human tissue Tfr cells are intrinsically capable to regulate humoral responses (like their mice 
counterparts). We were unable to sort pure Tfr cells from human tonsils precluding the in 
vitro assessment of their function and a direct comparison between blood and tissue Tfr cells. 
Indeed, only a minority of sorted CXCR5+ICOS+CD25+CD127-CD4+ (the gate used for Tfr 
cells) tonsil cells expressed Foxp3 (Figure 18). This can be due to contamination by 
CD25+Bcl-6lo Tfh cells. In human tonsils, a CD25+Bcl-6lo Tfh cell population, expressing 
IL-21 and c-Maf, was reported to provide help to B cell in a IL-2-dependent manner466. 
Whether this CD25+Bcl-6lo Tfh cell population is unique to human tonsil microenvironment 
or systemically relevant is not known. While, these findings suggest a role for IL-2 signalling 
in GC responses, robust data demonstrated that IL-2 signalling inhibits murine Tfh cell 
differentiation and GC formation83,85,279. Additionally, recent studies claimed that the most 
mature Tfr cells express low CD25 to sustain the Bcl-6-dependent Tfr cell program276–278. In 
this respect, the usage of a stringent CD25hi sorting strategy can be argued as another reason 
for the poor suppressive function of our sorted Tfr cell population. Thus, alternative 
approaches are required to efficiently sort Foxp3+ Tfr cells from human tissues. New Tfr cell 
markers can be tested and different tissues can be used. Our group is now studying new 
sorting strategies for human tissue Tfr cells using, not only new Tfr cell markers (such as 
IL-1R2), but also other secondary lymphoid organs. IL-1R2, the IL-1 receptor decoy, was 
recently reported to discriminate Tfr cells from Treg and Tfh cells in murine studies277. 
Interestingly, IL-1 strongly increases B cell proliferation and induces CD40L and OX40 
expression by T cells, thereby favouring B-T cell interactions in adaptive immune 
responses467–469. The sequestration of IL-1 by IL-1R2-expressing Tfr cells can be 
hypothesised as one additional regulatory mechanism of this Treg cell subset. Although, Tfr 
cells need a balanced Bcl-6- and CD25/IL-2/Foxp3-dependent program, it remains to be 
demonstrated whether there are two subsets of Tfr cells based on CD25 expression, or 
whether true Tfr cells lack CD25 expression276–278. Moreover, no studies yet accessed in situ 
CD25 expression by human GC Tfr cells. The most attractive model to explain the apparent 
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paradox of those two cellular programs was recently proposed by Botta and colleagues. They 
showed that Tfr cells loose CD25 expression throughout their differentiation pathway toward 
fully differentiated GC-resident Tfr cells278. This data is consistent with our model in which 
blood Tfr cells emerge from secondary lymphoid tissues prior to B cell interactions, thereby 
being immature (not fully differentiated) CD25+ Tfr cells.  
 
Blood is the most accessible source of human immune cells, prompting another question: 
how to induce full differentiated Tfr cells from immature blood Tfr cells? Tfr cell 
differentiation has classically been studied in a Tfh cell-biased manner rather than as a 
unique process. Current knowledge has established significant differences between the Tfh 
and Tfr cell differentiation pathways. Specifically, PD-1 and CTLA-4 signalling selectively 
affect Tfr cell differentiation; IL-21 seems to orchestrate a feedback control mechanism in 
humoral responses, favouring Tfh cell differentiation and function while restraining Tfr cell 
differentiation; and mTORC signalling differently affect Tfh and Tfr cell differentiation 
(while IL-2/mTORC1 signalling axis seems to inhibit Tfh cell differentiation, mTORC2 was 
reported to be essential for Tfh cell differentiation)259,260,269,270,272,273,289. Further research 
must now chase detailed requirements for full Tfr cell differentiation. First, the existence of 
a thymic Tfr cell pre-committed Treg cell subset needs to be addressed. Then, it will be 
important to study the antigenic and environmental cues required to induce Tfr cell 
differentiation from the thymic Treg cell pool. Single-cell RNASeq-based technologies are 
revealing a much greater heterogeneity in immune cell populations470. Therefore, the 
absence of follicular markers on thymic Treg cells at the protein level should not be used to 
exclude the possibility of thymic Tfr cell pre-committed Treg cells. On the contrary, the use 
of those technologies may aid in the study of Tfr cell differentiation in human tissues. By 
studying Tfr cells at the single-cell level the evolving transcriptomic changes will be known. 
This knowledge may be used to find candidate genes responsible for the Tfr cell 
differentiation pathway (including its environmental cues) as well as to address whether a 
Tfr cell program is hidden in some thymic Treg cells.  
 
All the described murine studies reported an expansion of (tissue) Tfr cells following 
immunization. In humans, we also demonstrated that blood Tfr cells increase upon influenza 
vaccination. Inflammatory signals augment the differentiation of activated Treg cells from 
resting Treg cells, possibly by enhancing antigen presentation and supplying T cells with 
accessory signals of activation27,280,471–473. Therefore, it is likely that the inflammatory milieu 
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induced by immunization favour the expansion of Tfr cells. Whether this expansion is 
mediated by self or foreign antigens is not known. Although, it is commonly assumed that 
Treg cell TCR repertoire is skewed toward recognition of self-antigens, several studies 
challenged this assumption, demonstrating that TCR is highly diverse174,474. Our group 
showed that although Tfr cells undergo proliferation, their TCR is not specific for the antigen 
driving the GC reaction since the TCR usage has little in common with Tfh cells repertoire 
(but closely resembled the self-skewed TCR repertoire of thymic Treg cells)264. On the 
contrary, under certain conditions, Tfr cells were showed to be specific for the immunizing 
antigen263. However, even under those conditions, antigen-specific Tfr cells did not seem to 
overcome the need of Tfr cells derived from thymic Treg cells. Interestingly, mice 
immunized with insulin (self-antigen) had a higher proportion of tissue Tfr cells (compared 
to OVA immunization)277. Although it is established that, like Treg cells, Tfr cells exhibit a 
TCR-non-specific bystander suppression of effector T cells, further studies should clarify 
the nature of Tfr cell driving antigens, as well as the cytokines required for Tfr cell expansion 
and maintenance, before addressing the methods to modulate Tfr cell responses258,475. A 
thorough study of Tfr cell TCR repertoire (using new computational biology approaches) 
may help defining antigen candidates for driving the differentiation of this cell population. 
Several cytokine combinations may be also tested for in vitro induction of Tfr cells from 
conventional CXCR5- Treg cells. 
 
IL-2 was recently proposed to act as a rheostat during physiological GC responses induced 
by viral infections278. Upon influenza infection, expansion of Treg cells consumed IL-2 from 
lymph node microenvironment facilitating virus-specific Tfh cell responses. The increased 
IL-2/CD25/STAT5 signalling on Treg cells prevented their differentiation toward a Tfr cell 
fate (through Bcl-6 inhibition). As IL-2 signalling decreased during the time course of 
influenza infection, Treg cells undergone a Bcl-6-dependent Tfr cell differentiation pathway. 
Finally, Tfr cells expansion prevented the emergence of self-reactive B cell clones formed 
during infection-induced GC reactions. These results suggest that blocking CD25 may lead 
to augmented Tfr cells responses. However, the impact of IL-2 on different T cell 
populations is extremely complex: IL-2 is essential for the development and maintenance of 
Treg cells, as well as for inducing terminally differentiated effector (Th1 and Th2) T cells, 
whereas strong IL-2 signals inhibit Tfh cell diffentiation83,206. Indeed, the impact of IL-2 on 
Treg and Tfh cells in patients with ongoing autoimmune diseases in not straightforward. In 
a small study, low-dose IL-2 treatment was effective in reducing disease activity in SLE 
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patients. During the 12-week period of this prospective study, a decrease in blood Tfh and 
Th17 cells was observed along with an increased frequency of blood Treg cells476. Whereas, 
Tfr cells were not directly analysed, the results of this study highlight the complexity of IL-
2 axis in disturbed autoimmunity-prone adaptive immune responses.  
 
 
Blood Tfr/Tfh Ratio Marks Ectopic Lymphoid Structure Formation in Primary 
Sjögren Syndrome 
 
We have shown that blood activated Tfh cells and Tfr/Tfh ratio are associated with distinct 
aspects of primary SS pathogenesis. While, high blood Tfr/Tfh ratio is correlated with the 
presence of FSA in salivary glands of SS patients (the target organ of this disease), 
circulating PD-1+ICOS+ activated Tfh cells indicated SS disease activity (but not ELS 
formation).  
 
The predictive value of blood Tfr cells, and especially the blood Tfr/Tfh ratio, regarding the 
diagnosis of primary SS and the identification of pathological lymphocytic infiltration in 
salivary glands may appear counterintuitive. First, Tfr cells were described as regulators of 
GC responses, thus decreased Tfr/Tfh ratios (in both secondary lymphoid organs and blood) 
have been associated with augmented autoantibody production by GC B cells257,260,297,331. 
Second, IL-21 has been reliably implicated in the development of SS477. The reported impact 
of IL-21 on Tfr cell differentiation and proliferation would predict a decreased proportion of 
Tfr cells in IL-21-drived conditions270,272,273.  
 
In systemic autoimmune conditions with disturbed and chronic GC reactions we anticipated 
that Tfr/Tfh ratio would be decreased due to an unproportioned increase in Tfh cells143. 
Consistently, blood Tfr cells were found reduced in the blood of MS, SLE and MG 
patients329,341,346. However, these studies used different markers to identify blood Tfr cells 
and found unreliable relationships between blood Tfr cells and disease activity, autoantibody 
production, and treatment regimens. For example, blood Tfr cells were increased in patients 
with AS338. On the other hand, our observations were done following a comprehensive study 
of human Tfr cells and on a cohort of immunosuppressant drug-naïve patients. Given that 
blood Tfr cells emerge prior to B-cell interactions and only following mature adaptive 
immune responses, the increased proportion of Tfr cells in peripheral blood of primary SS 
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patients may be a consequence of ongoing GC reactions. Indeed, the increased proportion of 
activated PD-1+ICOS+ Tfh cells observed in our SS cohort support the existence of ongoing 
GC reactions in these patients, as those cells were found to correlate with humoral responses 
induced by vaccination120,123.   
 
The current theory explaining the pathogenesis of SS (also termed “autoimmune epithelitis”) 
suggests that salivary gland epithelial cells (SGEC) are central regulators of the autoimmune 
response by acting as atypical antigen-presenting cells and by constitutively expressing a 
plethora of immune-competent molecules, which are implicated in lymphoid cell 
recruitment, homing, activation, differentiation, and proliferation439,451,478–481. Although, the 
trigger for altered SGEC remains speculative, the microenvironment changes induced by 
SGEC lead to development of ELS, in situ autoantibody production, and subsequent epitope 
spreading420,439,451,481,482. Recent evidence supports this hypothesis, as once tolerance has 
been broken for one self-antigen, autoreactive GCs targeting other self-antigens can be 
spontaneously generated464. Whether Tfr and Tfr cells responses in SS are initiated in 
inflamed exocrine glands or in secondary lymphoid organs is still unknown. While, it is 
generally assumed that ELS are populated by lymphocytes formed outside these structures, 
in secondary lymphoid organs, one study reported that SGEC activated CD4+ T cells in vitro 
and mediated their differentiation into Tfh cells356,357,407. We observed in situ 
Foxp3+CXCR5+ Tfr within FSA lesions enriched for CD20+ B cells in SS patients, 
suggesting anatomic exclusion of Tfr cells from inflamed exocrine glands cannot explain the 
increased proportion of this T cell population in peripheral blood of SS patients. In our work 
we hypothesized that CD20+ FSA harboured typical ELS responses, as tissue infiltration by 
CD20+ B cells was shown to occur in the first steps of ELS development404. However, we 
did not dissect ELS-defining features in FSA , such as segregation of T cells and B cells into 
discrete areas, development high endothelial venules, differentiation of networks of FDC, 
accumulation of CD138+ plasma cells, as well as the de novo ectopic expression of genes 
encoding proteins, such as AID and Bcl-6356,357. Nevertheless, it is likely that Tfr cell 
expansion, either in secondary lymphoid organs or in ELS, occurs in primary SS 
pathogenesis. This is further supported by the observation that absolute number of Tfr cells 
in peripheral blood of SS patient did not follow the trend imposed by their lymphopenic 
state. Indeed, the absolute number of blood Tfr cells did not differ between SS patients and 
healthy donors, while all other tested T cell populations were decreased (as measured by 
absolute numbers per mL of blood) in agreement with lymphopenia. 
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To unify our findings with current knowledge of SS pathogenesis one may argue that Tfr 
cells expand as an (insufficient) attempt to restore immune tolerance. Different murine 
models have demonstrated that CTLA-4 deletion led to an increased frequency and absolute 
numbers of Tfr cells (in lymph nodes as well as in blood)259,269. These mice developed 
spontaneous GCs and T-cell-mediated autoimmunity, suggesting that expansion of Tfr cells 
can occur concomitantly with autoimmunity, as far as Tfr cells are defective in CTLA-4-
mediated GC regulation259,269. In humans, monogenic defects involving CTLA-4 and its 
intracellular trafficking regulator (LRBA, lipopolysaccharide-responsive beige-like anchor 
protein) lead to a primary immunodeficiency characterized by recurrent infections and 
autoimmunity (manifested by inflammatory bowel disease, autoimmune endocrinopathies, 
and cytopenias)483–489. Exaggerated Tfh cell responses were recently linked to failure of 
CTLA-4-mediated regulation in CTLA-4 and LRBA deficiencies487,490. In these patients, 
treatment with Abatacept was found to, at least partially, restore immune homeostasis490. 
Abatacept is a fully human fusion molecule of CTLA-4 with IgG-Fc, that binds to CD80/86 
and consequently impairs CD28-mediated T cell co-stimulation. To date, two open-label 
studies have evaluated the efficacy of Abatacept in primary SS patients491,492. Adler and 
colleagues observed histological, cellular and serological changes in response to treatment, 
including a decrease in local Treg cells and serum gammaglobulins492. It is noteworthy, that 
treatment with Abatacept induced a decrease in salivary gland Treg cells. Indeed, other 
studies found that Treg cells were increased in salivary glands from SS, even though these 
tissues harbour dysregulated autoimmune responses493,494. Meiners and colleagues showed 
that Abatacept improves systemic disease activity and patient-reported symptoms, measured 
by ESSDAI and Patient Reported Index (ESSPRI), respectively491. The effects of Abatacept 
on human T cells and on T cell-dependent B cell hyperactivity in primary SS where further 
analysed by Verstappen and colleagues495. In this recent report, Abatacept reduced the 
number, proportion and activation (assessed by PD-1 and ICOS expression) of circulating 
Tfh cells, as well as serum levels of IL-21, serum titres of autoantibodies (anti-Ro52, anti-
Ro60, and anti-La), and number and proportion of blood CD27+CD38+ plasmablasts495. It 
may be hypothesized that a selective defect in CTLA-4-mediated Tfr cell function is acquired 
during SS pathogenesis. Alternatively, an aberrant CXCR5 expression intrinsic to Treg cells 
may explain our findings, as variants in the CXCR5 region have been associated with SS in 
genome-wide association studies496. 
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Many studies have established a strong IL-21 signature in primary SS pathogenesis477,497–
499. Given the reported role of IL-21 on Tfr cell biology it would be anticipated a decrease 
proportion of Tfr cells in SS patients270,272,273. Jandl and colleagues claimed that a decrease 
IL-2 responsiveness, mediated by IL-21-dependent Bcl-6 upregulation (which in turn 
decrease CD25 expression), underlie the Tfr cell inhibition270. However, the impact of 
IL2/IL-21 axis on Tfr cells (and on immune systems) seems far more complex278,500. If a 
decrease CD25 expression on Treg cells was responsible to limit Tfr cell differentiation, as 
suggested by Jandl and colleagues, CD25 downregulation could not be argued as a 
consequence of Tfr cell differentiation, as demonstrated by Botta and colleagues270,278. 
Moreover, recombinant IL-2 treatment would hardly inhibit Tfr cell differentiation, as Botta 
and colleagues also showed278. Importantly, it is still not known whether human Tfr cells 
express IL-21 receptor. Thus, the strong IL-21 signature underlying SS pathogenesis cannot 
be used to overturn our observations. The further assessment of IL-2/IL-21 axis and of 
CTLA-4-mediated Tfr cell responses (together with a detailed characterization of salivary 
gland infiltrating Tfr cells) in SS will probably be of great clinical value. To specifically 
address infiltrating Tfr cells in non-lymphoid tissues new methodological approaches will 
be needed to circumvent the technical limitations with conventional methods. 
 
Consequently, one imperative question is whether blood Tfr cell expansion is a specific 
feature of SS or a common feature of autoimmune diseases. Our group is now addressing 
this specific issue on distinct human autoimmune conditions, from organ specific 
Hashimoto’s thyroiditis to systemic diseases, such as RA and SLE. One possibility is that 
blood Tfr cells are increased in autoimmune diseases in which ELS formation plays an 
important pathogenic role356,357. Indeed, we found that the blood Tfr/Tfh ratio does seem to 
be a specific marker of ELS formation within salivary glands.  
 
From a clinical perspective, our findings may aid in decomposing SS heterogeneity. Within 
a single autoimmune disease, there is considerable variation in clinical manifestations and 
severity427. It is widely accepted that disease heterogeneity is probably the result of intricate 
genetic and non-genetic factors which account for subtle differences in immunopathogenic 
mechanisms. The unpredictable response to target therapies both at disease and patient level 
further highlights autoimmunity heterogeneity. A detailed and global understanding of the 
human immune system could help to identify individual immunotypes501. For example, 
Banchereau and colleagues longitudinally profiled the blood transcriptome to assess SLE 
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molecular heterogeneity502. This analysis enabled patient stratification into seven groups and 
provided an explanation for the failure of clinical trials, as SLE patients are highly 
heterogeneous502. Our results suggest that primary SS can be stratified into four groups: a) 
patients with high disease severity scores (measured by ESSDAI) and increased blood 
activated PD-1+ICOS+ Tfh cells, b) patients with FSA and increased blood Tfr/Tfh ratio, c) 
patients with high disease severity scores and FSA, and d) patients without any of these 
features (Figure 28). Autoimmune epithelitis is only one possible explanation for the 
immunopathology of primary SS. Several studies have also suggested role for 
neuroendocrine mechanisms that is related to the influence of hormones and neuropeptides 
in the function of the exocrine glands503. These alternative mechanisms could explain why 
some patients with primary SS present with severe sicca symptoms with no inflammatory 
histological features. Interestingly, very recently, some human Tfh cells were found to 
contain chromogranin marked granules, normally found in neuronal presynaptic terminal 
storing catecholamines504. Whether neuroendocrine dysfunction have an impact on ELS 
formation and Tfh cell responses in autoimmunity is not known. While, we did not address 
the impact of disease duration in Tfh cell subsets and Tfr cells, the identification of a specific 
pathogenic mechanism (namely “autoimmune epithelitis”) by Tfr/Tfh ratio could be a major 
step in achieving earlier and targeted therapies in primary SS. Importantly, so far, no formal 
correlation was demonstrated between ESSDAI and histopathological findings on salivary 
gland biopsies436,505. However, FSA severity (assessed by focus score) is an important 
predictor for lymphoma development in these primary SS428,442. 
 
 
Figure 28: Proposed model for primary Sjögren’s syndrome patient stratification  
Disease severity (measured by ESSDAI), focal sialadenitis (FSA) on MSG biopsy, activated blood 
Tfh cells and blood Tfr/Tfh ratio define four subgroups of primary Sjögren syndrome patients: a) 
patients with high ESSDAI scores and increased blood activated PD-1+ICOS+ Tfh cells, b) patients 
Discussion 
 
138 
 
with FSA on MSG biopsy and increased blood Tfr/Tfh ratio, c) patients with both disease 
signatures, and d) patients without any of these features  
 
Overall, our findings suggest that immunopathogenic stratification of SS patients could be 
achieved through quantification of blood Tfh and Tfr cell subsets. Blood Tfr/Tfh ratio seems 
to help in predicting the presence of FSA in target tissues of SS pathogenesis. We propose 
the use of blood Tfr/Tfh ratio as a quick, simple and non-invasive test to stratify SS patients 
with autoimmune epithelitis, who will potentially be the best candidates for therapies 
targeting T – B interactions in the context of dysregulated GC responses. 
 
 
Concluding Remarks 
 
Biomedical discovery is classically based on unifying principles of broad applicability. 
Similarly, medical practice has traditionally been based on repeated observations and 
definitions of similarities between patients, that guide treatment decisions on the basis of 
prior experience. It is increasingly clear, however, that the full realization of the promise of 
genetic and genomic discovery will require a paradigm shift embracing complexity, 
heterogeneity, and information-rich decision matrices personalized to individual 
patients506,507. Central to this new era of precision medicine will be the development of drugs 
to attain control of inflammation and prevention of structural tissue damage. For all 
autoimmune diseases, future goals involve earlier intervention, induction of immune 
tolerance, and possibly normalization of immune responses. Critical to this progress will be 
targeting pathways that maintain disease chronicity but are not involved in host defense 
against infection. 
 
By providing a better understanding of human Tfr cell biology we further support the 
importance of the immune system on human pathology both from a fundamental and a 
clinical perspective.  
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A U T O I M M U N I T Y
Human blood Tfr cells are indicators of ongoing 
humoral activity not fully licensed with  
suppressive function
Valter R. Fonseca,1,2 Ana Agua-Doce,1,3 Ana Raquel Maceiras,1,3 Wim Pierson,4 Filipa Ribeiro,1,3 
Vasco C. Romão,1,2 Ana Rita Pires,1 Susana Lopes da Silva,1,2 João Eurico Fonseca,1,2 Ana E. Sousa,1 
Michelle A. Linterman,4 Luis Graca1,3*
Germinal center (GC) responses are controlled by T follicular helper (Tfh) and T follicular regulatory (Tfr) cells and 
are crucial for the generation of high-affinity antibodies. Although the biology of human circulating and tissue 
Tfh cells has been established, the relationship between blood and tissue Tfr cells defined as CXCR5+Foxp3+ 
T cells remains elusive. We found that blood Tfr cells are increased in Sjögren syndrome, an autoimmune disease 
with ongoing GC reactions, especially in patients with high autoantibody titers, as well as in healthy individuals 
upon influenza vaccination. Although blood Tfr cells correlated with humoral responses, they lack full B cell–
suppressive capacity, despite being able to suppress T cell proliferation. Blood Tfr cells have a naïve-like pheno-
type, although they are absent from human thymus or cord blood. We found that these cells were generated in 
peripheral lymphoid tissues before T-B interaction, as they are maintained in B cell–deficient patients. There-
fore, blood CXCR5+Foxp3+ T cells in human pathology indicate ongoing humoral activity but are not fully com-
petent circulating Tfr cells.
INTRODUCTION
Germinal center (GC) responses are crucial for the generation of 
high-affinity antibodies during T-dependent immune responses. Within 
the GC resides a specialized subset of CD4+ T cells—the T follicular 
helper (Tfh) cells—which are essential for GC development and func-
tion (1, 2). It is now clear that Tfh cells play a central role in productive 
vaccine responses, whereas defects in their formation or function can 
contribute to immunodeficiency or autoimmunity (3, 4). More recently, 
the discovery of T follicular regulatory (Tfr) cells, a subset of suppressive 
regulatory T (Treg) cells that participate in the GC, added an additional 
layer of complexity in the biology of GC responses (5–8).
Tfr cells, generally defined by Bcl-6+CXCR5+PD-1+ICOS+Foxp3+, 
are a distinct subset of thymic Foxp3+ Treg cells present in lymphoid 
tissues. Like the Tfh cell differentiation pathway, Tfr cell commitment 
requires both dendritic cell and B cell interactions, as well as CD28, 
SAP (SLAM-associated protein), ICOS (inducible costimulator), and 
PD-1 (programmed cell death–1) signaling (6, 9, 10). A tight balance 
between expression of transcription factors Bcl-6 and Blimp-1 regulates 
the differentiation of Tfr cells (6). Tfr cells have specialized functions in 
controlling the magnitude of GC responses and in limiting the out-
growth of non–antigen-specific B cell clones (5, 6). However, the precise 
mechanisms of Tfr cell suppression remain elusive, although cytotoxic 
T lymphocyte–associated antigen 4 (CTLA-4) and regulation of meta-
bolic pathways seem to play a key role (11–13).
Although Tfh and Tfr cells are characterized by their location in 
lymphoid tissues, an increasing number of studies have described 
putative circulating counterparts of these cells in peripheral blood. 
This is particularly relevant for studying the biology of these cells in 
humans, because access to secondary lymphoid tissues can be limit-
ing. Human blood CXCR5+ T cells have been established as memory 
Tfh–like cells based on their ability to recapitulate bona fide Tfh cell 
functions: Human blood CXCR5+ T cells can promote plasmablast 
differentiation, activation-induced cytidine deaminase expression, and 
class switch recombination by naïve B cells. However, they are pheno-
typically distinct from tissue Tfh cells and do not express the tran-
scriptional repressor Bcl-6 (14–16). Furthermore, an immunization 
leading to GC and antibody responses correlates with an increase in 
the frequency of circulating ICOS+ Tfh cells, suggesting that they 
indicate ongoing Tfh cell responses in secondary lymphoid tissues 
(14, 16–19). Human circulating Tfh cells comprise a heterogeneous 
population concerning their phenotype and the quality of help they 
provide to B cells (14, 17). In mice, CXCR5+Foxp3+ Tfr-like cells were 
found in peripheral blood after immunization and were shown to 
represent a circulating counterpart of tissue Tfr cells (9, 10).
Although CXCR5-expressing Treg cells and GC Foxp3-expressing 
T cells have been found in humans (7, 20, 21), so far, no studies have 
addressed the biological importance of these putative circulating Tfr-like 
cells in humans. Human tonsil CD25+CD69− T cells have been shown 
to directly suppress B cell responses, but the relationship of these puta-
tive Treg cells to Bcl-6+CXCR5+PD-1+ICOS+Foxp3+ Tfr cells is unclear 
(22, 23). Peripheral blood CXCR5+ Treg cells are being studied as circu-
lating Tfr cells in many different human diseases, despite the fact that 
the biological relevance of these cells is unclear (24–28). Additionally, 
Foxp3 up-regulation by nonregulatory human T cells and transient 
CXCR5 expression by T cells undergoing activation challenge the 
assumption that peripheral blood CXCR5+ Treg cells are bona fide cir-
culating Tfr cells (29, 30).
Here, we found that human blood Tfr cells, defined as CXCR5+Foxp3+ 
T cells, are generated in peripheral lymphoid tissues as humoral im-
mune responses are established. However, in contrast to tissue Tfr 
cells and conventional CXCR5− Treg cells, circulating Tfr cells have a 
naïve-like phenotype. Our data demonstrate that blood Tfr cells are 
generated following the initial steps that lead to GC responses being 
distinct from tissue Tfr cells.
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RESULTS
Blood Tfr cells indicate ongoing GC responses
To address the impact of Tfr/Tfh ratio in human autoimmunity, we 
studied Sjögren syndrome (SS), a systemic autoimmune disease char-
acterized by the lymphocytic infiltration of salivary and lachrymal 
glands, with the formation of ectopic lymphoid structures demonstrat-
ing the pathogenic involvement of T-B cell interactions (31, 32). We 
studied a cohort of 25 patients with recently diagnosed SS according 
to American-European Consensus Group (AECG) criteria (33) under 
no immunosuppressive treatment other than prednisolone (less than 
7.5 mg/day or equivalent) or hydroxychloroquine (table S1). Unexpectedly, 
we found a notable increased frequency of circulating Tfr cells in SS 
as compared with age-matched healthy donors (HDs) (Fig. 1A and 
fig. S1, A and B). Whereas SS patients showed fewer Treg and Tfh cells 
per milliliter of blood, in agreement with their lymphopenic state 
(fig. S1C), the absolute number of CXCR5+ Tfr cells was not different 
when compared with HDs (fig. S1B), in line with the increased frequency 
of blood CXCR5+ Tfr cells. The increased frequency of the CXCR5+ 
Treg cell subset was specifically increased, providing an explanation for 
the high Treg cell frequency observed in SS patients (Fig. 1A). SS pa-
tients showed a substantial increase in the Tfr/Tfh ratio compared with 
HDs (Fig. 1B) (8, 10). Furthermore, among SS patients, the increased 
Tfr/Tfh ratio is associated with patients with serum autoantibodies 
(Fig. 1C). On the contrary, we found no correlation between high Tfr/Tfh 
ratio with C-reactive protein and disease activity score [EULAR Sjögren’s 
syndrome disease activity index (ESSDAI)] (Fig. 1, D and E).
Blood and tissue Tfr cells present different follicular and 
regulatory markers
To test whether CXCR5+Foxp3+ Tfr cells in human peripheral blood 
are circulating counterparts of tissue Tfr cells, we studied peripheral 
blood from a cohort of 42 healthy volunteers between 22 and 92 years 
(mean age, 46.76 ± 18.14 years; 30 females and 12 males). We found 
that CXCR5 was expressed by 18.57 ± 6.55% of total Treg cells (de-
fined as CD4+CD25+Foxp3+ T cells) (Fig. 2A). The frequency and 
number of CXCR5+Foxp3+ T cells did not change with aging (Fig. 2B 
and fig. S2A).
Because CXCR5 is used to identify human circulating Tfh cells, we 
compared the phenotype of circulating CXCR5+Foxp3+ Tfr cells with that 
of circulating Tfh cells and CXCR5− conventional Treg cells. Peripheral 
blood CXCR5+Foxp3+ T cells share characteristics with both circulating 
Tfh cells and CXCR5− Treg cells (Fig. 2C). Taking advantage of routine 
tonsillectomies performed because of tonsil hyper trophy in otherwise 
healthy children, we compared the cell phenotype of paired blood and 
Fig. 1. Blood Tfr cells are indicators of ongoing humoral activity. (A) Frequency of total Treg cells, Tfr cells, and CXCR5− Treg 
cells in peripheral blood of SS patients and age-matched HDs (n = 25; unpaired Student’s t test with Welch’s correction for 
variance). Representative plots (left) and pooled data (right) are shown. (B) Blood Tfr/ Tfh ratio in SS patients and HDs (n = 25; 
unpaired Student’s t test with Welch’s correction for variance). (C) Blood Tfr/Tfh ratio in SS patients with and without serum auto-
antibodies (AAb) (anti-SSA/Ro52, anti-SSB/Ro60, and anti-SSB/La) (n = 25; unpaired Student’s t test). (D) Variation of blood 
Tfr/Tfh ratio according to C-reactive protein (CRP). Analysis by linear regression was used. (E) Variation of blood Tfr/ Tfh ratio 
according to disease severity score (ESSDAI). Analysis by linear regression was used. Bars represent SEM (A and C) or mini-
mum and maximum values (in box and whisker graphs) (C).
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tissue samples from the same 
child (Fig. 2C and fig. S2B). We 
found that circulating Tfh cells 
were phenotypically distinct 
from their tissue counterparts, 
in line with previous reports, 
especially regarding their PD-1, 
ICOS, and Bcl-6 expression 
(Fig. 2C) (14, 15). In a similar way, 
circulating CXCR5+Foxp3+ T 
cells were also ICOS−PD-1−Bcl- 
6−CD57− and consequently distinct from tonsil Tfr cells (Fig.  2C). In 
addition, we confirmed that these cell populations displayed a simi-
lar phenotype in adults (fig. S2, C and D). Our results are consistent 
with murine studies showing that blood and tissue Tfr cells are pheno-
typically distinct (9). ICOS was not differentially expressed by Treg 
and Tfr cells in tonsils (Fig. 2C). Bcl-6 expression was not detected 
in any population by real-time polymerase chain reaction (PCR) 
(fig. S1F), consistent with previous reports showing that blood Tfh 
cells do not express Bcl-6 (15–18, 34). We also confirmed that tis-
sue CXCR5+Foxp3+ T cells are localized within GCs, therefore corre-
sponding to Tfr cells (Fig. 2D and fig. S2G). Curiously, we observed 
different Tfr/Tfh ratios in the blood and tonsils (Fig. 2E).
CXCR5+Foxp3+ Tfr cells are a distinct subset of suppressive 
Foxp3+ T cells
It has been described that CXCR5 expression can transiently occur 
upon human T cell activation (30, 35, 36). Moreover, human T cells 
can also transiently express Foxp3 upon in vitro T cell receptor (TCR) 
stimulation in a transforming growth factor– (TGF-)–dependent 
manner (29, 37).
Fig. 2. Blood Tfr cells show expres-
sion of follicular and regulatory 
markers. (A) CXCR5+ Tfr cells con-
stitute 18.57 ± 6.55% of Treg cells 
(left) and 0.93 ± 0.56% of total CD4+ 
T cells (middle), representing 9985 ± 
9043 cells per milliliter of blood (right) 
(n = 42; adult HDs). (B) Variation of 
blood Tfr cell frequency (left) and ab-
solute number per milliliters of blood 
(right) according to age (age range, 
22 to 92 years) (n = 42; linear regres-
sion). (C) Expression of Foxp3, CD25, 
CD69, CTLA-4, CXCR5, ICOS, PD-1, Bcl-6, 
and CD57 by Tfh cells (blue), CXCR5− 
Treg cells (black), and Tfr cells (red) in 
children blood (top) and tonsils (bot-
tom). Naïve CD4+ T cells were used as 
control (gray). Representative plots 
from six healthy children are shown. 
CXCR5+ subsets in tonsils were de-
fined as CXCR5+ICOS+ cells (fig. S2B). 
Tconv, conventional T cells. (D) Immuno-
fluorescence microscopy of formalin- 
fixed, paraffin-embedded human 
tonsils stained for DAPI (blue), CXCR5 
(yellow), CD4 (red), and Foxp3 (green). 
Top, middle, and bottom outlined 
areas indicate top, middle, and bot-
tom enlarged areas on the right, re-
spectively. Data are representative of 
tonsil sections from five healthy chil-
dren. (E) Blood Tfr/ Tfh ratio in adult 
blood, children blood (tonsil donors), 
and tissues (tonsils). Black and red 
dots represent blood and tonsil re-
sults, respectively (n = 42 for adults 
and n = 6 for children; Student’s t test). 
Error bars represent SEM.
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To address whether ex vivo CXCR5+Foxp3+ Tfr cells were bona 
fide regulatory cells, we sorted that cell population, as well as CXCR5− 
conventional Treg cells (fig. S3, A and B), and cultured them with 
CellTrace Violet (CTV)–labeled conventional T cells. Proliferation 
of responder cells was analyzed after 5 days of soluble CD3 stimu-
lation (Fig. 3A). Blood CXCR5+Foxp3+ Tfr cells reduced conventional 
T cell proliferation (Fig. 3, B and C), definitely demonstrating their reg-
ulatory function.
Stability of Foxp3 expression is required for the suppressive func-
tion of Treg cells (38). To determine whether blood Tfr cells have stable 
Fig. 3. Blood Tfr cells are a distinct subset of suppressive Treg cells. (A) Schematic repre-
sentation of in vitro suppression assay. FACS-sorted 25 × 103 CXCR5−CD25−CD127+CD4+ 
Tconv cells were cocultured with 25 × 103 CXCR5−CD25+CD127−CD4+ Treg cells or 
CXCR5+CD25+CD127−CD4+ Tfr cells under stimulation by anti-CD3 (1 g/ml) in the 
presence of 105 irradiated (25 Gy) allo-PBMCs. After 5 days, responder cells were 
analyzed for CTV dilution by flow cytometry. Sorting strategy is described in fig. S2 
(A and B). (B) Proliferation of Tconv cells without Treg cells or in the presence of either 
CXCR5− Treg or Tfr cells. Representative plots (left) and pooled data (right) (n = 3, each 
with technical triplicates; one-way ANOVA with posttest Turkey’s multiple compar-
isons) are shown. ns, not significant. (C) Suppression curve of CXCR5− Treg and 
Tfr cells in different ratios using the same conditions described in (A) and (B) (n = 1, 
with technical triplicates; two-way ANOVA). (D) Stability of Foxp3 expression by 
sorted CXCR5− Treg cells and CXCR5+ Tfr cells after 5 days of in vitro culture under 
CD3/CD28 (1 l per well) stimulation. Percentage (left) and cell number (right) 
(n = 5, each with technical triplicates; Student’s t test) are shown. (E) Relative ex-
pression of Foxp3 and CXCR5 by sorted Tconv cells, Tfh cells, CXCR5− Treg cells, and 
Tfr cells from blood by real-time reverse transcription PCR. Gene expression was 
normalized to housekeeping genes (B2M, G6PD, and ACTB) (n = 2, each with tech-
nical duplicates; Student’s t test). (F) Expression of Foxp3, CD25, CTLA-4, and 
CXCR5 by sorted CXCR5− Treg and Tfr cells at baseline [day 0 (d0)] and after 5 days 
of in vitro culture under CD3/CD28 (1 l per well) stimulation. Data are represent-
ative histograms of three independent experiments, each one with technical tripli-
cates. Error bars indicate SEM.
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Foxp3 expression, we stimulated sorted Tfr cells and CXCR5− Treg cells 
with anti-CD3/CD28 microbeads for 5 days in the absence of exoge-
nous interleukin-2 (IL-2). In the absence of IL-2, Treg cells do not 
survive well in culture. Under these conditions, both CXCR5− Treg cells 
and Tfr cells retain a similar frequency of Foxp3+ cells, albeit lower 
than in the beginning of the culture (Fig. 3D). The frequency of recov-
ered live Foxp3-expressing cells was slightly higher for sorted Tfr cells as 
compared with CXCR5− conventional Treg cells. Next, we analyzed 
the relative expression of Foxp3 and CXCR5 in sorted conventional 
T cells, Tfh cells, Tfr cells, and CXCR5− Treg cells from human blood 
by real-time PCR. Although Foxp3 protein expression was lower in 
Tfr cells than in CXCR5− Treg cells (Fig. 2C and fig. S2D), Foxp3 gene 
expression was similar between the two subsets (Fig. 3E). In addition, 
circulating Tfh and Tfr cells also showed comparable CXCR5 gene 
expression (Fig. 3E).
To investigate whether activation of blood Tfr cells triggers up- 
regulation of Foxp3, CD25, and CTLA-4, a phenomenon known to 
be associated with increased Treg cell–suppressive function (38), we 
analyzed the phenotype of sorted CXCR5+ and CXCR5− Treg cells 
after 5 days of culture in the presence of CD3/CD28 microbeads. 
We found an up-regulation of Foxp3 and CD25 by Tfr cells, whereas 
CTLA-4 was increased in both populations (Fig. 3F and fig. S3C). The 
levels of expression of these markers by blood Tfr cells after activa-
tion resembled those from tissue Tfr cells (compare with Fig. 2C). 
CXCR5 up-regulation was not detected in sorted CXCR5− Treg cells, 
showing that CXCR5+ Tfr cells are a distinct subset of human blood 
Treg cells.
Blood Tfr cells do not preferentially suppress  
humoral responses
To address the function of blood Tfr cells, we first investigated whether 
this population could directly suppress Tfh cells. Using a similar in vitro 
assay used to prove the regulatory capacity of blood Tfr cells, but with 
sorted Tfh cells as responders, we found that blood Tfr cells strongly 
suppressed Tfh cell proliferation, but without a specific advantage when 
compared with CXCR5− Treg cells (Fig. 4A).
Next, to directly assess the impact of blood Tfr cells on B cell activa-
tion, we used in vitro T-B cocultures in the presence of staphylococcal 
enterotoxin B (SEB) superantigen (Fig. 4C). After 5 days of culture, 
B cells up-regulated CD38 and down-regulated immunoglobulin 
D (IgD) only in the presence of Tfh cells (Fig. 4C). Both CXCR5− and 
CXCR5+ Treg cells impaired the generation of CD38+IgD− GC-like 
B cells. Consistent with our results from suppression assays with Tfh cells 
(Fig. 4A), Tfh cell proliferation was similarly inhibited by CXCR5− and 
CXCR5+ Treg cells (Fig. 4, C and D, and fig. S4A). As expected, Tfh cells 
showed better proliferation responses in coculture with B cells.
To further address the function of blood Tfr cells on humoral re-
sponses, we analyzed class switch recombination by naïve B cells 
10 days after superantigen stimulation. We found that blood Tfr cells, 
although able to reduce activation of naïve B cells and proliferation of 
Tfh cells as shown before, did not limit class switch recombination by 
B cells because no impact on IgA or IgG production was observed 
(Fig. 4E). On the contrary, CXCR5− Treg cells efficiently suppressed 
humoral responses (Fig. 4E).
CXCR5/CXCL13-dependent migration to GC is critical for sup-
pression of humoral responses by Tfr cells (5, 7), and plasma CXCL13 
levels have been correlated to ongoing GC responses in humans (39). 
To prove that blood Tfr cells were capable of migrating toward a 
CXCL13 gradient, we conducted in vitro chemotaxis assays with sorted 
populations from human peripheral blood. We found that, although 
the CXCR5 mean fluorescence intensity (MFI) of peripheral Tfh and 
Tfr cells was slightly different (Fig. 2C and fig. S2D), both populations 
shared their ability to migrate toward a CXCL13 gradient, showing 
functional capacity of blood Tfr cells to enter CXCL13-enriched tis-
sues (Fig. 4F).
Blood Tfr cells have a distinctive naïve-like phenotype
To explain the unexpected observation that blood Tfr cells do not sup-
press antibody production, we hypothesized that this population could 
represent thymus-derived precursors of Tfr cells not yet fully com-
mitted to regulate humoral responses. We found that blood Tfr cells 
were predominantly CD45RO−Foxp3lo resting Treg cells (Fig. 5A), 
expressing high levels of CD45RA, CCR7, CD62L, and CD27 and low 
levels of human leukocyte antigen–DR (HLA-DR), reminiscent of a 
naïve phenotype (Fig. 5B). Virtually, all blood Tfr cells were quiescent 
Ki-67− nonproliferating cells when analyzed ex vivo (Fig. 5C). Moreover, 
circulating Tfr cells were virtually devoid of CD45RO+CCR7− effec-
tor memory cells, in notable contrast to CXCR5− Treg cells, a pheno-
type more similar to circulating Tfh cells (Fig. 5D). Although the vast 
majority of blood Tfh cells were CD45RO+CCR7+ central memory 
cells, consistent with previous reports (14–17), a substantial propor-
tion of Tfr cells were CD45RO−CCR7+ naïve cells (Fig. 5D). Further-
more, the few CD45RO− Tfh cells did not express high levels of CD45RA, 
indicating that those cells were not really naïve, in contrast to Tfr cells 
(fig. S5A). Therefore, blood Tfr cells constitute a pool of naïve resting 
cells.
To test whether blood Tfr cells were thymus-derived pre cursors of 
tissue Tfr cells, we analyzed the frequency of these cells according to age. 
Contrary to thymus-derived naïve Treg cells, CD45RO−CCR7+ naïve 
Tfr cells did not decrease with increasing age (Fig. 5E). In addition, 
the expression of CD31, a marker used to identify recent thymic em-
igrants in human blood (40–42), was not specifically enriched in the 
population (fig. S5, B and C). Although these observations suggest 
that blood Tfr cells are not a thymic population, this was not conclu-
sive. Therefore, we directly examined CXCR5-expressing T cells in 
the human thymus and neonatal cord blood. There was not a popu-
lation of CXCR5+ Treg cells detected in any of those tissues (Fig. 5, F 
and G, and fig. S5D). Although CXCR5-expressing Treg cells were not 
found in cord blood, some Foxp3+ cells expressed CD45RO, suggest-
ing that additional activation signals not present before birth are 
required to shape a CXCR5 phenotype in circulating Treg cells. Con-
sistent with our previous data, ICOS+ Treg cells were detected in 
cord blood, indicating that ICOS cannot be used as a specific follic-
ular marker in circulating human Treg cells (Fig. 5H).
Blood Tfr cells emerge from lymphoid organs before  
B cell interaction
Having demonstrated that circulating Tfr cells did not egress from 
the thymus, we investigated whether Tfr cells recirculate from sec-
ondary lymphoid tissues before being fully committed to tissue Tfr 
cells. We compared both CXCR5+ and CXCR5− Treg cell subsets 
from children paired blood and tissue (tonsils) concerning their ef-
fector memory, central memory, and naïve composition. We found 
that CD45RO+CCR7− effector Tfr cells were present in lymphoid 
tissues but not in the blood, suggesting that effector Tfr cells are se-
lectively retained in tissues, similarly to effector Tfh cells (Fig. 6A). 
Therefore, it is unlikely that blood CD45RO− Tfr cells derive from the 
fully mature tissue Tfr cells that express CD45RO, as the few CD45RA 
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Fig. 4. Blood Tfr cells do not show specialized humoral regulatory capacity. (A) Proliferation of CXCR5+CD25−CD127+CD4+ Tfh cells without Treg cells or in the presence of 
either CXCR5− Treg or Tfr cells after 5 days of in vitro culture as described in Fig. 3A. Representative plots (left) and pooled data (right) (n = 3, each with technical triplicates; one-way 
ANOVA with posttest Turkey’s multiple comparison) are shown. (B) Schematic representation of suppression coculture assay. FACS-sorted 25 × 103 CXCR5+CD25−CD127+CD4+ 
Tfh cells (or CXCR5−CD25−CD127+CD4+ Tconv cells) were cocultured for 5 days with 25 × 103 CXCR5+CD25+CD127−CD4+ Treg cells (or CXCR5−CD25+CD127−CD4+ Treg cells) under 
stimulation by SEB (1 g/ml) and in the presence of 30 × 103 CD27−IgD+CD19+ naïve B cells. (C) Up-regulation of CD38 and down-regulation of IgD by naïve B cells (top) and 
proliferation of Tfh cells by CTV dilution (bottom) without Treg cells or in the presence of either CXCR5− Treg or Tfr cells. Representative plots (left) and pooled data (right) (n = 5, 
each with technical triplicates; one-way ANOVA with posttest Turkey’s multiple comparisons) are shown. (D) Suppression curve of CXCR5− Treg and Tfr cells in different ratios 
using the same conditions described in (B) and (C) (n = 1, with technical triplicates; two-way ANOVA). (E) ELISA determination of IgA, IgM, and total IgG in supernatants after 10 days 
of in vitro coculture performed as described in (D) but using SEB (1 g/ml) + SEA (10 g/ml) + SEE (10 ng/ml) + TSST-1 (10 ng/ml) as superantigen stimulation (n = 3, each with 
technical triplicates; one-way ANOVA with posttest Turkey’s multiple comparisons). (F) In vitro migration of 75 × 103 sorted Tconv cells, Tfh cells, CXCR5− Treg cells, and Tfr cells 
toward a CXCL13 gradient (2 /ml) expressed by chemotaxis index (n = 3, each with technical triplicates; one-way ANOVA with posttest Turkey’s multiple comparisons). Error 
bars indicate SEM. SA, superantigens.
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re expressing end-stage mem-
ory CD4+ T cells do not be-
come CD45RO− (fig. S6A) 
(43, 44).
Our data suggest that 
blood Tfr cells are generated 
in secondary lymphoid tis-
sue before full differentiation 
toward mature Tfr cells. It has 
been known that full differ-
entiation of follicular T cells 
requires a two-step process, 
with an initial activation me-
diated by dendritic cells and a 
subsequent B cell interaction 
in the T-B border. We inves-
tigated whether blood Tfr cells, 
given their immature pheno-
type, could be generated be-
fore the B cell interactions 
required for acquisition of 
terminal differentiation. To 
investigate this issue, we analyzed peripheral blood from X-linked 
agammaglobulinemia [Bruton’s tyrosine kinase (BTK)–deficient] 
patients, with a complete absence of CD19+ cells. We observed a nota-
ble decrease in blood Tfh cells in those patients, in line with previous 
reports (Fig. 6B) (45). However, frequency of blood Tfr cells was not 
decreased in B cell–deficient patients (Fig. 6B). These observations 
are conclusive in establishing that blood Tfr cells enter the circu-
lation before B cell contact, whereas most of the blood Tfh cells 
require B cell interactions. To investigate whether CD45RO+ and 
CD45RO− blood Tfr cells could discriminate between Tfr cells re-
circulating before and after B cell interaction, we analyzed these 
two populations in peripheral blood of patients with B cell defi-
ciency, as well as in SS patients. We found no differences in CD45RO+ 
or CD45RO− Tfr cells in these two diseases (fig. S5E), although 
CD45RO up-regulation occurs irrespective of B cell interaction on 
Tfr cells.
Fig. 5. Blood Tfr cells are imma-
ture but are not committed in the 
thymus. (A) Backgate of CXCR5− 
and CXCR5+ Treg cells according to 
CD45RO and Foxp3 expression. 
(B) Expression of CD45RO, CD45RA, 
CCR7, CD62L, HLA-DR, and CD27 by 
Tfr cells (red) and CXCR5− Treg cells 
(black) in the blood. (C) Expression 
of Ki-67 by CXCR5+ Treg cells and 
CXCR5− Treg cells in the blood (n = 22; 
Student’s t test). (D) CD45RO+CCR7− 
effector memory, CD45RO+CCR7+ 
cen tral memory, and CD45RO−CCR7+ 
naïve subsets of Tfr cells and CXCR5− 
Treg cells in adult blood. Represen-
tative plots (left) and pooled data 
(right) (n = 22; Student’s t test). Tfh cells 
are represented in blue, CXCR5− 
Treg cells in black, and Tfr cells in red. 
(E) Variation of CD45RO−CCR7+ 
naïve Tfr cell and CXCR5− Treg cell 
frequency in blood according to 
age (n = 22; linear regression). (F) Ex-
pression of CXCR5 by Foxp3+CD4+ 
thymocytes (n = 4). (G) Expression 
of CXCR5 by cord blood Foxp3+CD4+ 
T cells (n = 3). (H) Expression of 
CD45RO, CCR7, and ICOS by cord 
blood Treg cells (n = 3). Bars repre-
sent SEM.
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Fig. 6. Blood Tfr cells are lymphoid tissue–derived Tfr precursors. (A) CD45RO+CCR7− effector memory, CD45RO+CCR7+ central memory, and CD45RO−CCR7+ naïve 
subsets of Tfr cells and CXCR5− Treg cells in children blood (top) and tissues (bottom). Representative plots (left) and pooled data (right) (n = 6; Student’s t test) are shown. 
Tfh cells are represented in blue, CXCR5− Treg cells in black, and Tfr cells in red. CXCR5+ subsets in tonsils were defined as CXCR5+ICOS+ cells (fig. S2B). (B) Blood Tfh and Tfr cells 
from X-linked agammaglobulinemia (BTK-deficient) patients compared with sex- and age-matched HDs. Representative plots (left) and pooled data (right) (n = 5; 
Student’s t test) are shown. (C) Model of CXCR5+ Tfh and Treg cell generation and recirculation in humans upon antigen stimulation. Tfh cells are shown in red, and Tfr cells 
in blue. DC, dendritic cell. (D) Frequency of peripheral blood Tfr cells on the day of influenza vaccination (d0) and 7 days later in healthy volunteers. Schematic representation 
and representative plots (left) and pooled data (right) (n = 32; Student’s t test) are shown. Bars represent SEM.
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We therefore hypothesized that blood Tfr cells are generated in 
secondary lymphoid tissue and enter the circulation before full dif-
ferentiation toward tissue Tfr cells (Fig. 6C). To test our model in 
vivo, we analyzed samples from healthy adults undergoing influen-
za vaccination. Previous studies have shown a positive correlation 
between circulating Tfh cell subsets and antibody responses after 
influenza vaccination in healthy adults (15, 18, 19). We therefore 
analyzed the impact of vaccination in circulating Tfr cells. Consis-
tent with our hypothesis, we found that circulating Tfr cells increased 
on day 7 after influenza vaccination (Fig. 6D). This observation is 
in line with our prediction that, during ongoing GC responses, Tfr 
cells are generated and some exit from the tissue to the peripheral 
blood.
DISCUSSION
Our comprehensive evaluation of human Tfr supports a model in 
which blood Tfr cells are generated following the initial steps that 
lead to GC responses in secondary lymphoid tissues, exiting the tis-
sue before interactions with B cells that are required for complete 
differentiation toward tissue-resident Tfr cells. Although some studies 
have quantified blood CXCR5+ Treg cells as circulating Tfr cells in dif-
ferent diseases, the human biology of CXCR5+ Treg cells remains elusive 
(24, 25, 27, 46, 47). Moreover, most of the literature studies define 
blood Tfh cells as cells that contain both Tfh and CXCR5+ Tfr cells, 
whereas many other studies identify Treg cells as a mixture of bona 
fide conventional Treg cells and CXCR5+ Tfr cells. Hence, results may 
be confounded by combining effector and regulatory cell popula-
tions. As an example, our cohort of SS patients shows an increase in 
the frequency of Foxp3+ Treg cells compared with the control popu-
lation. However, only CXCR5+ Tfr cells, and not conventional CXCR5− 
Treg cells, are increased in those patients. As a consequence, the ap-
parent increase of Treg cells in the blood of SS patients is an increase 
of CXCR5+ Tfr cells that reflect the ongoing humoral activity. It was 
the search for an explanation for this apparent counterintuitive ob-
servation that led us to establish the ontogeny and function of hu-
man circulating Tfr cells.
We found that Tfr cells in tonsils have follicular and regulatory 
markers and were found within GCs, whereas blood Tfr cells do not 
express ICOS, PD-1, or Bcl-6, apparently diverging these cells from 
follicular imprinting. Previous studies have described low ICOS and 
PD-1 expression and no Bcl-6 expression in human blood Tfh cells 
(14). In mice, blood Tfr cells have also lower expression of ICOS (9). 
It was also reported that murine circulating Tfr cells can bypass the 
B cell zone and do not gain full activation as part of a memory pro-
grammed state (9). In line with these studies, the absence of ICOS, 
PD-1, and Bcl-6 from human blood CXCR5+ Tfr cells does not ex-
clude their follicular ontogeny.
Our results show key differences between mice and humans regard-
ing the function of blood CXCR5+ Tfr cells: Although murine blood 
Tfr cells appear to be specialized in suppressing antibody production 
(despite their lower suppressive capacity when compared with tis-
sue Tfr cells) (9, 10, 12, 13), human blood Tfr cells do not have the 
ability to fully suppress humoral responses.
Nevertheless, we found that blood Tfr cells specifically migrated 
toward CXCL13 gradient, suggesting that these cells have the capacity 
to reach the follicles. CXCR5− conventional Treg cells did not up-regulate 
CXCR5 upon in vitro activation, further confirming CXCR5-expressing 
Tfr cells as a distinctive subset.
We also found that blood Tfr cells have a prominent naïve pheno-
type. However, they are absent from the thymus and cord blood (where 
activated Treg cells can already be found). These observations provide 
compelling evidence that activation signals generated in peripheral 
lymphoid organs are required to shape a CXCR5+ phenotype on hu-
man Foxp3+ T cells. Conversely, tissue Tfr cells are almost all CD45RO+ 
antigen-experienced effector cells. Together, these observations led us 
to hypothesize that blood Tfr cells leave lymphoid tissues as immature 
cells before B cell interaction in T-B border and full differentiation into 
Tfr cells. This view was supported by the presence of blood Tfr cells in 
peripheral blood of patients lacking B cells due to genetic defects. This 
finding provides an explanation for the incomplete suppressive func-
tion of blood Tfr cells.
An important limitation of our study is the difficulty to isolate 
tissue Tfr cells for functional assays because CD25 and CD127 are 
not reliable to identify tonsil Foxp3-expressing cells. However, the 
phenotype between blood and tissue Tfr cells is remarkably differ-
ent, in particular, with respect to maturation markers.
Our results from vaccination and SS patient cohorts show that 
blood Tfr cells are indicative of ongoing humoral activity. In SS pa-
tients, where ongoing GC reactions promote the production of auto-
antibodies (31, 32), blood Tfr cells were substantially increased (directly 
contributing to an increased Tfr/Tfh ratio). Although we expected to 
find a decrease in this putative humoral suppressive cell population 
in autoimmune conditions, our results suggest that blood Tfr cells 
indicate ongoing humoral activity and are not a measurement of 
suppressive potential. This is in line with recently published reports 
showing an increase in blood CXCR5+ Treg cells in other autoimmune 
conditions and infectious diseases (27, 28, 47). Therefore, studies re-
garding blood CXCR5+ Treg cells in different human settings should 
be carefully interpreted.
Given that circulating Tfr cells have an immature phenotype, it is 
not unexpected that blood Tfr cells are not fully endowed with sup-
pressive function, because the suppressive capacity of conventional 
Treg cells has been ascribed predominantly to those cells with a more 
mature phenotype. Although the TCR repertoire of Tfr cells is dif-
ferent from Tfh and probably skewed toward autoantigens (48), it is 
possible that circulating Tfr cells represent a pool of cells ready to be 
recruited into subsequent GC responses as they retain the ability to 
migrate toward CXCL13.
In conclusion, our data support a model in which CXCR5+Bcl-6− 
T cells egress from secondary lymphoid tissues during antigen-driven 
immune responses. Whereas the frequency of blood Tfh cells is re-
duced in the absence of B cells, Tfr cells do not require interactions 
with B cells. Thus, the acquisition of a CXCR5+Foxp3+ phenotype in 
the tissues precedes access to the follicle, where the cells acquire a 
fully mature phenotype. As a consequence, circulating Tfr cells rep-
resent lymphoid tissue–derived Tfr precursors not yet endowed with 
full B cell and humoral regulatory function.
MATERIALS AND METHODS
Study design
Sample sizes were estimated on the basis of previous studies and accord-
ing to each cohort (see the next section). No outliers were excluded. 
The number of biological and technical replicates is stated in the figure 
legends. Human samples from different conditions were used (see 
the next section) with appropriate age-matched controls. This experi-
mental study was performed unblinded.
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Human samples
Fresh peripheral blood samples were collected from patients referred 
to the Rheumatology Department of Hospital de Santa Maria, Centro 
Hospitalar Lisboa Norte, for salivary gland biopsy due to clinical sus-
picion of SS. Blood samples were collected on the day of salivary gland 
biopsy. All patients with exclusion criteria for SS (33) or treated with 
biologic drugs, disease-modifying antirheumatic drugs, or prednisolone 
(more than 7.5 mg/day) were excluded. Patients diagnosed with an 
infectious disease in the previous month were also excluded, as well as 
those who received any vaccine in the same period of time. Patients 
were diagnosed as having SS if they met the AECG diagnosis criteria 
(n = 25) (33). Routine C-reactive protein plasma levels (mg/dl) closest 
to blood collection were used. Age-matched healthy volunteers (from 
the cohort described below) were used for statistical comparison. Fresh 
peripheral blood samples were collected from healthy adult volunteers 
(n = 42). Fresh buffy coats (blood collection in less than 24 hours) 
were used for in vitro suppression and coculture assays. Tonsils and 
peripheral blood samples were collected from healthy children sub-
mitted to tonsillectomy due to tonsil hypertrophy (n = 6). Children 
with any clinical condition, under any drug treatment, or submitted 
to tonsillectomy due to chronic tonsillitis were excluded. Umbilical 
cord blood samples were collected from healthy pregnant women 
during delivery (n = 3). Thymus tissue was collected from children 
submitted to cardiac surgery due to congenital heart disease who 
were otherwise healthy (n = 4). Blood samples were also collected 
from X-linked agammaglobulinemia (BTK-deficient) patients during 
routine blood tests (n = 5). All blood samples were collected in EDTA- 
coated tubes. These studies were approved by the Lisbon Academic 
Medical Center Ethics Committee (reference no. 505/14). Informed 
consent was obtained from all adult volunteers, parents, or legal 
guardians.
For vaccination studies, we used healthy adult volunteers (n = 32) 
recruited from the Cambridge BioResource as part of the vaccination 
study during the 2014–2015 winter season. Participants were excluded 
if they have had a previous adverse reaction to any vaccination, have 
a known allergy to any components of the vaccine, were taking im-
munomodulating medication, and are pregnant or breastfeeding. Partic-
ipants were administered the inactivated influenza vaccine (split virion) 
BP vaccine (Sanofi Pasteur) by intramuscular injection in the right 
deltoid. Blood samples were collected in EDTA-coated tubes on the 
day of vaccination (before administration of the vaccine) and 7 days 
after vaccination. The influenza vaccination study protocol was ap-
proved by the Health Research Authority, National Research Ethics 
Service Committee South Central, Hampshire A, UK (REC reference: 
14/SC/1077).
Cell isolation and flow cytometry
Peripheral blood mononuclear cells (PBMCs) were isolated from blood 
samples by Ficoll gradient medium (Histopaque-1077, Sigma-Aldrich) 
using SepMate tubes (STEMCELL Technologies). Lymphocytes from 
tonsils and thymocytes were also isolated by Ficoll gradient medium 
after mechanical disruption. Before cell sorting, PBMCs from buffy 
coats were enriched for CD4+ T cells using MojoSort Human CD4 
T Cell Isolation Kit (BioLegend). The CD4+ fraction was used for cell 
sorting of CD4+ T cell subsets. The CD4− fraction was used for cell 
sorting of naïve B cells (see fig. S1A for sorting strategy). For flow 
cytometry, cells were stained with anti–Bcl-6 (K112-91, BD Biosciences), 
anti-CCR7 (#150503, R&D Systems), anti-CD127 (eBioRDR5, eBioscience), 
anti-CD19 (HIB19, BioLegend), anti-CD25 (BC96, eBioscience), anti- 
CD27 (LG.7F9, eBioscience), anti-CD3 (OKT3, eBioscience), anti-CD31 
(WM-59, eBioscience), anti-CD38 (HB-7, BioLegend), anti-CD4 (OKT4, 
BioLegend), anti-CD45RA (HI100, eBioscience), anti-CD45RO (UCHL1, 
BioLegend), anti-CD57 (HNK-1, BioLegend), anti-CD62L (DREG-56, 
BioLegend), anti-CD69 (FN30, BioLegend), anti-CD8 (RPA-T8, 
eBioscience), anti–CTLA-A (L3D10, BioLegend), anti-CXCR5 (J252D4, 
BioLegend), anti-Foxp3 (PCH101, eBioscience), anti–HLA-DR (G46-6, 
BD Biosciences), anti-ICOS (C398.4A, BioLegend), anti-IgD (IA6-2, 
BioLegend), anti–Ki-67 (Ki-67, BioLegend), and anti–PD-1 (EH12.2H7, 
BioLegend). For Bcl-6, CTLA-4, Foxp3, and Ki-67 intracellular staining, 
Foxp3 Fix/Perm Kit (eBioscience) was used according to the manufac-
turer’s instructions. For cell viability staining, Live/Dead Fixable Aqua 
Dead Cell Stain Kit (Life Technologies) was used. CellTrace Violet Cell 
Proliferation Kit (Life Technologies) was used for cell proliferation 
assessment. Cell sorting was performed in Aria IIu and Aria III instru-
ments (BD Biosciences). Flow cytometry analysis was performed in an 
LSRFortessa instrument (BD Biosciences) and further analyzed with 
FlowJo v10 software (Tree Star).
Cell culture and functional assays
For in vitro suppression assays, 25 × 103 CXCR5−CD25−CD127+CD4+ 
conventional T cells or 25 × 103 CXCR5+CD25−CD127+CD4+ Tfh 
cells were plated with CXCR5−CD25+CD127−CD4+ Treg cells or 
CXCR5+CD25+CD127−CD4+ Treg cells in a 1:1 ratio. Cells were cultured 
with anti-CD3 (1 g/ml) (OKT3, eBioscience) in the presence of 105 
irradiated (25 Gy) allo-PBMCs. After 5 days, cells were harvested and 
responder cells were analyzed for CTV dilution by flow cytometry. 
For TCR stimulation assays, 25 × 103 CXCR5−CD25+CD127−CD4+ 
Treg cells and CXCR5+CD25+CD127−CD4+ Treg cells were plated with 
anti-CD3/anti-CD28 MACSiBead particles (1 l per well) (T Cell Ac-
tivation Kit, Miltenyi Biotec). For coculture in vitro suppression as-
says, 25 × 103 CXCR5+CD25−CD127+CD4+ Tfh cells were plated with 
CXCR5−CD25+CD127−CD4+ Treg cells or CXCR5+CD25+CD127−CD4+ 
Treg cells in a 1:1 ratio in the presence of 30 × 103 CD27−IgD+CD19+ naïve B 
cells. Cells were cultured with SEB (1 g/ml) (Sigma-Aldrich). After 5 days, 
responder Tfh cells were analyzed for CTV dilution, B cells for CD38 
up-regulation, and Treg cells for follicular and activation markers. For 
immunoglobulin measurement, 25 × 103 CXCR5+CD25−CD127+CD4+ 
Tfh cells were plated with CXCR5−CD25+CD127−CD4+ Treg cells or 
CXCR5+CD25+CD127−CD4+ Treg cells in a 1:1 ratio in the presence of 
30 × 103 CD27−IgD+CD19+ naïve B cells. Cells were cultured with SEB 
(1 g/ml) (Sigma-Aldrich) + staphylococcal enterotoxin A (SEA) 
(10 ng/ml) (Toxin Technology) + staphylococcal enterotoxin E (SEE) 
(10 ng/ml) (Toxin Technology) + toxic shock syndrome toxin–1 (TSST-1) 
(10 ng/ml) (Toxin Technology). After 10 days, supernatants were col-
lected and immunoglobulin concentration was determined by enzyme- 
linked immunosorbent assay (ELISA). Cultures were performed in 
U-shaped 96-well plates in RPMI 1640 (Life Technologies) sup-
plemented with 10% heat-inactivated fetal bovine serum (Life Tech-
nologies), 1% Hepes (Sigma-Aldrich), 1% sodium pyruvate (Life 
Technologies), 1% penicillin-streptomycin (Life Technologies), and 
0.05% gentamicin (Life Technologies) in 37°C, 5% CO2 incubator 
conditions.
Enzyme-linked immunosorbent assay
IgA, IgM, and total IgG concentrations were determined in super-
natants from T-B coculture (as described above) by ELISA using Human 
ELISA Ready Set Go Kit according to the manufacturer’s instructions 
(eBioscience).
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Migration assays
For in vitro chemotaxis assays, 75 × 103 CXCR5−CD25−CD127+CD4+ 
conventional T cells, CXCR5+CD25−CD127+CD4+ Tfh cells, 
CXCR5−CD25+CD127−CD4+ Treg cells, and CXCR5+CD25+CD127−CD4+ 
Treg cells were loaded on top wells of HTS Transwell 96-well perme-
able supports (5-m pore size) (Corning). Plain RPMI 1640 (Life 
Technologies) or medium supplemented with CXCL13 (0.2 g/ml) 
(PeproTech) was added to the bottom wells of the plate. After 4 hours 
of incubation (37°C, 5% CO2), filters were removed and cells that 
migrated to the lower chamber were counted in an LSRFortessa in-
strument (BD Biosciences) and further analyzed with FlowJo v10 soft-
ware (Tree Star). Chemotaxis index was calculated as the ratio of cells 
migrating toward CXCL13 and cells randomly migrating.
Real-time reverse transcription PCR
Total RNA was extracted and reverse-transcribed from FACS (fluorescence- 
activated cell sorting)–sorted CXCR5−CD25−CD127+CD4+ conventional T 
cells, CXCR5+CD25−CD127+CD4+ Tfh cells, CXCR5−CD25+CD127−CD4+ 
Treg cells, and CXCR5+CD25+CD127−CD4+ Treg cells using RNeasy Micro 
Kit (Qiagen) according to the manufacturer’s instructions. Complemen-
tary DNA was generated using SuperScript III reverse transcriptase (Life 
Technologies) according to the manufacturer’s instructions. Real-time 
PCR was set up with Power SYBR Green PCR Master Mix (Applied 
Biosystems) and performed on ViiA 7 Real-Time PCR System (Ap-
plied Biosystems) according to the manufacturer’s instructions. The 
expression of each gene was normalized to housekeeping genes 
(B2M, ACTB, or G6PD) and calculated by change-in-threshold meth-
od (CT) using QuantStudio Real-Time PCR software v1.1 (Applied 
Biosystems). The following primers (Invitrogen) were used: Foxp3, 
5′-GCAAATGGTGTCTGCAAGTG-3′ (forward) and 5′-GCCCTTCT-
CATCCAGAAGAT-3′ (reverse); CXCR5, 5′-CTGGAAATGGACCTC-
GAGAA-3′ (forward) and 5′-GCAGGGCAGAGATGATT TTC-3′ (reverse); 
Bcl-6, 5′-TTCCGCTACAAGGGCAAC-3′ (forward) and 5′-CGAGT-
GTGGGTTTTCAGGTT-3′ (reverse); B2M, 5′-TATGCCTGCCGTGT-
GAACCAT-3′ (forward) and 5′-CGGCATCTT CAAACCTCCATG-3′ 
(reverse); ACTB, 5′-CTCTTCCAGCC T TCCTTCCT-3′ (forward) 
and 5′-AGCACTGTGTTGGCGTACAG-3′ (reverse); G6PD, 5′-CCAAG-
CCCATCCCCTATATT-3′ (forward) and 5′-CCACTTGTAGGTGC-
CCTCAT-3′ (reverse).
Immunofluorescence microscopy
After paraffin removal and antigen retrieval by heat (HIER pH 9, 
Leica Biosystems), 3-m sections of formalin-fixed, paraffin-embedded 
human tonsil were stained with anti-human CXCR5–Alexa Fluor 
488 (J252D4, BioLegend), anti-human CD4 (SP35, Cell Marque), and 
anti-human Foxp3 (PCH101, eBioscience) primary antibodies. Alexa 
Fluor 488 (anti-mouse), Alexa Fluor 546 (anti-rabbit), and Alexa 
Fluor 488 (anti-rat) were used as secondary antibodies. 4′,6-Diamidino- 2-
phenylindole (DAPI) was used as nuclei counterstaining. Images 
were acquired with ZEN 2012 software on a Zeiss LSM 710 confocal 
point-scanning microscope (Carl Zeiss) using a dry Plan-Apochromat 
20× objective (×200 magnification) and with a numerical aperture 
of 0.80. Images were further analyzed using ImageJ Fiji software.
Statistical analysis
Unpaired, paired Student’s t test, one-way analysis of variance (ANOVA) 
with posttest Turkey’s multiple comparisons, and two-way ANOVA 
with posttest Bonferroni’s multiple comparison were used as described. 
Linear regression analysis was also conducted for some data. Results 
are presented as means ± SD. P values of less than 0.05 were considered 
statistically significant. GraphPad Prism v5 software was used for statis-
tical analysis.
SUPPLEMENTARY MATERIALS
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Table S1. Clinical characteristics of 25 patients with primary (pSS) and secondary (sSS) Sjögren 
syndrome.
Fig. S1. Gating strategy for Tfh cells, CXCR5− Treg cells, and Tfr cells in human blood.
Fig. S2. Variation of blood Tfh cells and total Treg cells according to age.
Fig. S3. Sorting strategy for human blood naïve B cells, Tfh cells, CXCR5− Treg cells, and Tfr cells.
Fig. S4. Representative plots of CXCR5− Treg and Tfr cell suppression curves for coculture assay.
Fig. S5. Expression of CD45RO, CD45RA, and CD31 by human blood Tfh and Tfr cells.
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Figure S1: 
(A) Gating  strategy  for  identification  and  analysis  of  conventional T cells 
 
(Tconv), Tfh cells, CXCR5- Tregs and CXCR5+ Tfr in human peiprheral blood. (B) 
 
Absolute numbers of Tfh cells, total Tregs and Tfr cells (cells/mL of blood) in 
 
peripheral blood of Sjögren’s syndrome (SS) patients and healthy donors (HD) (n = 25, 
 
Student t-test). (C) Frequency and absolute numbers (cells/mL of blood) of CD4+ T 
 
cells in peripheral blood of SS patients and HD (n = 25, Student t-test).  (D) Blood 
 
Tfr/Tfh ratio in SS patients accordingly with treatment regimen (HCQ, 
 
hydroxychloroquine; PDN, prednisolone) (n = 25, Student t-test). (E) CXCR5 MFI in 
 
Tfh (left) and Tfr cells (right) in SS patients accordingly with treatment (n = 25, Student 
 
t-test). Error bars represent SEM.
 
 
Gating strategy for Tfh cells, CXCR5  Treg cells, and Tfr cells in human
 blood. 
 
 
  
Figure S2: 
(A) Variation of blood Tfh cells (left) and total Tregs (right) frequency 
 
 
Variation of blood Tfh cells and total Treg cells according to age. 
 strategy for identification and analysis of Tconv, Tfh cells, CXCR5- Tregs and CXCR5+ 
Tregs in human tonsils. (C) Expression of Foxp3, CD25, CD69, CTLA-4, CXCR5, 
ICOS, PD-1 Bcl-6, and CD57 by Tfh cells (blue), CXCR5- Tregs (black) and CXCR5+ 
Tfr cells (red) in adult blood. Naïve CD4+ T cells were used as control 
(gray).Representative plots from 42 healthy volunteers. (D) MFI of Foxp3, CD25, 
CD69, CTLA-4, CXCR5, ICOS, PD-1 Bcl-6, and CD57 by Tfh cells (blue), CXCR5- 
Tregs (black) and Tfr cells (red) in adult blood (**p<0.01, ***p<0.001, n = 6, one-way 
ANOVA with post-test Turkey’s multiple comparison) (E) Isotype controls for 
intracellular Bcl-6 and Foxp3 staining by flow cytometry. (F) Relative expression of 
Bcl-6 by sorted Tconv, Tfh cells, CXCR5- Tregs and Tfr cells from blood, by real-time 
RT-PCR. Gene expression normalized to housekeeping genes (B2M, G6PD and ACTB) 
(n = 2, each with technical duplicates, Student t-test). CD38hiIgD- germinal center B 
cells sorted from human tonsils were used as positive control. (G) Negative control for 
immunofluorescence microscopy, merge (left) and composite of the four 
immunofluorescence channels (right). After paraffin removal and antigen retrieval by 
heat sections of formalin-fixed paraffin-embedded human tonsil were stained with 
Alexa-Fluor 488 (anti-mouse), Alexa-Fluor 546 (anti-rabbit) and Alexa-Fluor (anti-Rat) 
secondary antibodies, without primary antibodies. DAPI was used as nuclei 
counterstaining. Unspecific binding of secondary antibodies and cross-reactivity 
between secondary antibodies were excluded. Error bars represent SEM. (ns = not 
significant). 
 
 
 
 
accordingly to age (age range: 22 – 92 years old) (n = 42, linear regression). (B) Gating 
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 (A)  Sorting strategy for FACS-sort of CXCR5+CD25- CD127+CD4+ 
Tfh cell, 
 
CXCR5-CD25-CD127+CD4+ Tconv cell, CXCR5+CD25+CD127-CD4+ Tfr cells, 
 
CXCR5-CD25+CD127-CD4+ Tregs, and CD27-IgD+CD19+ naïve B cell populations 
 
from peripheral blood (buffy-coats). (B) Purity of FACS-sorted CXCR5+CD25+CD127-
 
CD4+ Tfr cells, CXCR5-CD25+CD127-CD4+ Tregs. (C) MFI of Foxp3, CD25, CD69, 
 
CTLA-4, CXCR5, ICOS, PD-1 Bcl-6, and CD57 by CXCR5- Tregs (black) and Tfr 
 
cells (red) by sorted CXCR5- Tregs and Tfr cells at baseline (d0) and after 5 days of in 
  
 
Sorting strategy for human blood naïve B cells, Tfh cells, CXCR5− Treg 
cells, and Tfr cells. 
 **p<0.01, ***p<0.001, n = 3, one-way ANOVA with post-test Turkey’s multiple 
comparison). Error bars represent SEM. (ns = not significant). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vitro culture under αCD3/αCD28 (1 μL/well) stimulation in adult blood (*p<0.05, 
  
Figure S4: 
Proliferation of Tfh cells by CTV dilution without Tregs or in the 
 
presence of either CXCR5- Tregs or Tfr cells (n = 1, each with technical triplicates), at 
 
1:1, 1:2, 1:4 and 1:8 suppressor cell to responder cell ratios.  
 
 
 
 
 
 
 
  
  
  
  
  
  
  
  
Representative plots of CXCR5− Treg and Tfr cell suppression curves 
for coculture assay. 
   
Figure S5: 
(A)  Expression of CD45RO and CD45RA in adult blood by total Tfh cells 
 
and Tfr cells (left) and by CCR7+CD45RO- naïve Tfh cells (nTfh cells) and by 
 
CCR7+CD45RO- naïve Tfr cells (nTfr cells) (right). Representative plots from 22 
 
healthy donors. (B) Variation of CD45RO-CD31+ naïve Tfr cells and CXCR5- Tregs 
 
frequency in blood accordingly to age (n = 22, linear regression). (C) Expression of 
 
CD31 by Tfh and Tfr cells in adult blood of healthy donors. Representative plots (left) 
 
and pooled data (right) (n = 22, Student t-test). (D) Expression of CXCR5, ICOS and 
 
PD-1 by cord blood Foxp3+CD25+ Tregs. Representative plots from 3 healthy 
 
newborns. (E) CD45RO+CCR7- effector-memory (EM), CD45RO+CCR7+ central-
 
 
Expression of CD45RO, CD45RA, and CD31 by human blood Tfh and
 Tfr  cells. 
 
 peripheral blood of SS and BTK patients. Representative plots of 25 SS patients and 5 
BTK patients. Error bars represent SEM. 
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ABSTRACT 
Objectives: To investigate whether the balance of blood T follicular helper (Tfh) and 
Foxp3+ T follicular regulatory (Tfr) cells can inform on ectopic lymphoid neogenesis 
and disease activity in primary Sjögren’s syndrome (SS). 
Methods: We prospectively recruited 56 patients with clinical suspicion of SS, 16 of 
which subsequently fulfilled American European Consensus Group primary SS 
classification criteria and were compared with 16 patients with non-Sjögren sicca 
syndrome. Paired blood and minor salivary gland (MSG) biopsies were analysed to 
study Tfh subsets and Tfr cells in both compartments. 
Results: Primary SS patients had normal Tfh cell counts in peripheral blood, however, 
blood activated PD-1+ICOS+ Tfh cells were strongly associated with disease activity 
assessed by EULAR SS Disease Activity Index (r=0.85, p=0.0008). Conversely, blood 
Tfr/Tfh ratio indicated ectopic lymphoid structure formation in MSG, being strongly 
associated with B, CD4+ T and PD-1+ICOS+ T cell infiltration in MSG, and especially 
increased in patients with focal sialadenitis (FSA). Further analysis showed that blood 
Tfr/Tfh ratio allowed discrimination between SS patients and healthy donors with 
excellent accuracy and was a strong predictor of SS diagnosis (OR=12.96, p=0.028) and 
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FSA presence (OR=10.0, p=0.022) in patients investigated for sicca symptoms, thus 
highlighting the potential clinical value of this marker. 
Conclusions: Blood Tfr/Tfh ratio and PD-1+ICOS+ Tfh cells constitute potential novel 
biomarkers for different features of primary SS. While blood Tfr/Tfh ratio is associated 
with ectopic lymphoid neogenesis, activated Tfh cells indicate disease activity.  
 
Keywords 
Sjögren’s syndrome; Ectopic lymphoid structures; T follicular helper cells; T follicular 
regulatory cells. 
 
INTRODUCTION 
Sjögren’s syndrome (SS) is characterized by lymphocytic infiltration of salivary and 
lachrymal glands, leading to xerostomia and keratoconjunctivitis sicca (1–3).  However, 
like in other autoimmune diseases, disease heterogeneity remains a hurdle challenge to 
the development of better therapeutic approaches. Disease manifestations are mediated 
by complex mechanisms involving innate type I IFN signature and autoantibodies 
produced during dysregulated adaptive immune responses (2). Ectopic lymphoid 
structures (ELS)  (4–6) found in salivary and lachrymal glands are a major site of 
autoantibody production (2,7,8). These B-T lymphocyte aggregates define the so-called 
focal sialadenitis (FSA), the histological hallmark of SS, and have prognostic 
significance (9,10). Nevertheless, many patients fulfil classification criteria for SS with 
almost normal salivary gland histology, consistently with a highly heterogeneous 
disease. Whether clinical heterogeneity could be explained by different 
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immunopathogenic mechanisms is unknown. However, it is reasonable to hypothesize 
that patients with FSA, especially those with ectopic germinal centre (GC) formation, 
constitute a subgroup of patients more suitable for therapies targeting B-T interactions.   
Dysregulated GC reactions in secondary and tertiary lymphoid organs underlie the 
generation of self-reactive autoantibodies and many aspects of autoimmune diseases 
(4,5). GC reactions are orchestrated mainly by T follicular helper (Tfh) and T follicular 
regulatory (Tfr) cells. Tfh cells provide cognate help to B cells, thus promoting their 
clonal selection and affinity maturation (11). Conversely, Tfr cells regulate and limit the 
GC reaction assuring antigen-specific antibodies are produced (12–16). While the 
precise mechanisms of Tfr cell functions are not fully understood, unbalanced Tfh and 
Tfr cell responses may prompt antibody-mediated autoimmune diseases.   
We have previously described an increased Tfr/Tfh ratio in peripheral blood of SS 
patients (17). Furthermore, we demonstrated that blood Tfr cells are immature and not 
yet fully specialized in suppressing humoral responses. However, the relationship 
between blood and tissue Tfr cells remains elusive in patients with immune-mediated 
diseases. Herein we investigated the potential role of blood Tfr and Tfh cells as 
biomarkers of ectopic lymphoid activity in the target organ of SS.  
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METHODS 
Human samples  
We recruited patients referred to the Rheumatology and Metabolic Bone Diseases 
Department of Hospital de Santa Maria, for minor salivary gland (MSG) biopsy due to 
clinical suspicion of SS. Fresh blood samples were collected on the day of MSG biopsy. 
MSG tissue was divided for routine diagnostic purposes and for flow cytometry and 
microscopy. We excluded patients treated with biologic drugs, disease modifying anti-
rheumatic drugs (DMARDs) other than hydroxychloroquine or more that 7.5 mg per 
day of prednisolone equivalent, diagnosed with an infectious disease or who had 
received any vaccine in the previous month, and those with exclusion criteria for SS 
(Fig. S1) (18). Patients were classified as having primary SS if they fulfilled American 
European Consensus Group (AECG) 2002 classification criteria (n=16) (18), whereas 
those with sicca symptoms and no evidence of an inflammatory rheumatic disease were 
classified as non-Sjögren sicca syndrome and used as appropriate controls (n=16) (Fig. 
S1, Table 1, S1). Patients with secondary SS (n=6) or with clinical diagnosis of primary 
SS but not fulfilling AECG criteria (n=5) were excluded from analysis to standardize 
populations. Disease activity was evaluated by the European League Rheumatism SS 
disease activity score (ESSDAI) (19). Routine serum autoantibodies, c-reactive protein 
(mg/dL), erythrocyte sedimentation rate (mm) and serum electrophoresis gamma-
fraction (g/dL) levels closest to blood collection were used. Fresh blood was collected 
from age and gender-matched healthy controls. Tonsils were obtained from children 
submitted to tonsillectomy due to tonsil hypertrophy (n=6). Children with any clinical 
condition, under any drug treatment, or with chronic tonsillitis were excluded. Blood 
samples were collected in EDTA coated tubes.  
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This study was approved by the Lisbon Academic Medical Center Ethics Committee 
(reference number 505/14). Informed consent was obtained from all study participants. 
Cell isolation and flow cytometry 
Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-gradient medium 
(Histopaque-1077, Sigma-Aldrich) using SepMate tubes (StemCell Technologies). 
Lymphocytes from tonsils were also isolated by Ficoll-gradient medium after 
mechanical disruption. To study human MSG biopsies, we first optimized the 
experimental protocol to ensure that enzymatic digestion of tissue had negligible impact 
on cellular markers (Fig. S3A). Then, we used the optimized protocol to obtain a cell 
suspension from MSG. Briefly, MSG fragments were incubated at 37ºC with Liberase 
TM 0.1 mg/mL and DNAse I 0.1 mg/mL in RPMI medium followed by mechanical 
digestion to obtain a cell suspension. To normalize cell counts, MSG were weighed 
before digestion (Fig. S3B). Antibodies used for flow cytometry are described in Table 
S2. For Bcl-6, and Foxp3 intracellular staining, Foxp3 Fix/Perm Kit (eBioscience) was 
used accordingly to manufacturer instructions. For cell viability staining, Live/Dead 
Fixable Aqua Dead Cell Stain Kit (Life Technologies) was used. Flow cytometry 
analysis was performed in a LSR Fortessa (BD Biosciences) and further analyzed with 
FlowJo v10 software (TreeStar). 
 
Immunohistochemistry microscopy 
MSG were fixed in 10% buffered formaldehyde, embedded in paraffin wax and 
sectioned into 3µm sequential sections. Sections were stained after deparaffinisation, 
pretreatement with Ultra CC1 (Ventana Medical Systems, USA), antigen retrieval and 
endogenous peroxidase blocking using Benchmark machine. Sections were 
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immunohistochemically stained with anti-human CD20 (L26, DAKO), anti-human 
CD21 (EP3093, Roche), anti-human Bcl-6 (LN22, Leica), anti-human CXCR5-Alexa-
Fluor 488 (J252D4, BioLegend), and anti-human Foxp3 (236A/E7, eBiosciences). The 
sections were then treated with peroxidase-labelled secondary antibody and visualized 
with the chromogen DAB solution and/or universal AP Red. Hematoxylin was used as 
counterstaining. Images were acquired with NanoZoomer-SQ (Hamamatsu, Japan) 
using a 20x objective with a numerical aperture of 0.75. Images were further analyzed 
using NDP.view software. Number of CXCR5 and Foxp3 double positive cells were 
counted manually. Routine hematoxylin and eosin staining was used to define 
histological diagnosis in MSG: Normal, section with no pathological findings; LI, 
sections with unspecific lymphocytic infiltration; and FSA, sections with ≥1 dense 
aggregate of ≥50 lymphocytes per 4mm2 of tissue located in perivascular or periductal 
locations (Fig. S3G) (20). 
 
Statistical analysis 
Unpaired Student T-test, one-way ANOVA with post-test Turkey’s multiple 
comparison, and two-way ANOVA with post-test Bonferroni’s multiple comparison 
were used as described. Normality of data was assessed by Shapiro-Wilk test. Variance 
across groups was assessed with Levene’s and Brown–Forsythe’s tests and, where 
different, Welch correction of T-test or Mann Whitney U test were preferred. Pearson 
correlation and linear regression were also conducted for some data. For categorical 
variables Fisher’s exact test was used. Logistic regression and receiver operating 
characteristic (ROC) analysis were conducted to study the association of Tfr/Tfh ratio 
with SS and FSA and the cut-off with the best discriminative value was determined. 
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Results are presented as mean ± SD. P values of less than 0.05 were considered 
statistically significant. GraphPad Prism v5 and Stata v.12.1 were used for statistical 
and graphical analysis. Correlation heatmaps were computed in R studio v3.1.2. 
 
RESULTS 
Blood activated PD-1+ICOS+ Tfh cells correlate with SS disease activity 
We previously reported that SS patients had normal CXCR5+CD45RO+ Tfh cells, 
increased CXCR5+Foxp3+ Tfr cells and increased Tfr/Tfh ratio in peripheral blood (17). 
To refine our analysis, we now studied only patients with primary SS, and we further 
characterized blood Tfh cell subsets in those patients. Consistently, primary SS patients 
showed an increased frequency of blood Tfr cells and an increased blood Tfr/Tfh ratio 
compared to healthy donors (Fig. 1A, B). Interestingly, while primary SS patients had 
decreased absolute number of all CD4+ T cell subsets, in line with their CD4+ T cell 
lymphopenic state, the absolute number of Tfr cells were not different when compared 
to healthy donors (Fig. S2A-D), suggesting that the Tfr cell subset is indeed over-
represented in these patients. We did not find a significant increase of activated PD-
1+ICOS+ Tfh cells or PD-1+CXCR3- GC-like Tfh cells in SS patients (Fig. 1C, D) (21–
25). Contrary to previous reports (26), SS patients had a normal distribution of Tfh1, 
Tfh2 and Tfh17-like cells (Fig. 1E, S2E). To investigate whether follicular T cell 
subsets correlated with autoantibodies, inflammatory markers and disease activity we 
conducted correlation heatmaps. We found that blood Tfr/Tfh ratio and PD-1+ICOS+ 
Tfh cells significantly correlated with the presence of anti-SSA/Ro60 (r=0.580, 
p=0.0298) and anti-SSA/Ro52 (r=0.558, p=0.047), respectively (Fig. 1F, G). While 
most correlations were barely significant, we found a very strong association between 
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frequency of activated PD-1+ICOS+ Tfh cells and disease activity (ESSDAI, r=0.855, 
p=0.0008) (Fig. 1F, G). Interestingly, blood Tfr/Tfh ratio and PD-1+ICOS+ Tfh cells 
consistently correlated in opposite directions with the variables analysed, albeit not 
always reaching statistical significance (Fig. 1F). 
 
Blood Tfr/Tfh ratio identifies pathological lymphocytic infiltration in SS target 
organ 
As the Tfr/Tfh ratio may predict the outcome of GC reactions (12,27), we hypothesized 
that in patients with autoimmune diseases with abnormal GC reactions leading to 
autoantibody production may have an altered Tfr/Tfh ratio. As GC reactions take place 
in lymphoid tissues and ectopic (or tertiary) lymphoid structures, we studied MSG 
tissue biopsies from patients with primary SS and controls with non-Sjögren sicca 
syndrome (Fig. S1 and Table S1).  
Sjögren’s syndrome patients had an increased frequency and absolute number (per mg 
of tissue) of non-epithelial CD45+ cells (Fig. 2A) and CD19+ B cells (Fig. 2B). Loss of 
CXCR5 receptor following enzymatic digestion due to a tissue-intrinsic factor excluded 
direct analysis of tissue Tfh and Tfr cells (Fig. S3A, C, D). Nevertheless, as around 
90% of PD-1+ICOS+ T cells in lymphoid tissues were CXCR5+ Tfh cells, we assessed 
salivary gland infiltration by PD-1+ICOS+ T cells (Fig. 2C, S3E). We found a striking 
increased frequency and absolute number of infiltrating PD-1+ICOS+ T cells in SS 
patients (Fig. 2C). Although, it is likely that this cell population comprise tissue Tfh 
cells, we cannot exclude the existence of CXCR5-PD-1+ICOS+ T cells, described as a 
specific type of helper T cells within ELS of rheumatoid arthritis patients (28). In both 
cases, our findings suggest that MSG tissue from primary SS patients host active T-
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dependent humoral immune responses. To validate our results, we compared MSG 
analysis by flow cytometry with routine histological diagnosis of the same biopsies 
(Fig. S3F). Infiltration by CD19+ B cells was found in all SS patients irrespectively of 
salivary gland morphology. Yet, only patients with ELS/FSA had a significantly higher 
infiltration by B cells as compared to MSG of patients with non-Sjögren sicca syndrome 
(Fig. S3G).  
When we compared blood Tfh and Tfr populations with lymphocytic MSG infiltration 
of patients with SS, we found a strong correlation between blood Tfr/Tfh ratio and the 
presence of ELS in exocrine glands. Indeed blood Tfr/Tfh ratio was positively 
correlated with tissue infiltration by CD4+ T cells (r=0.8475, p=0.0039), PD-1+ICOS+ T 
cells (r=0.8400, p=0.0180), and CD19+ B cells (r=0.6748, p=0.0462) (Fig. 2D, E). 
Moreover, blood Tfr cells were also positively correlated with tissue CD19+ B cells 
(r=0.6690, p=0.0488) and a positive trend was seen with other local populations (Fig 
2D). Interestingly, despite not significantly, blood Tfh cells and Tfh cell subsets tended 
to negatively correlate with tissue infiltration by all inflammatory cells analysed, 
showing an opposite trend to blood Tfr cells and Tfr/Tfh ratio (Fig 2D). Taken together, 
these data suggest that blood Tfr cells and Tfr/Tfh ratio indicate pathological 
lymphocytic infiltration in the target organ of SS. On the other hand, blood activated 
PD-1+ICOS+ Tfh cells correlated with disease severity assessed by ESSDAI (Fig. 1F), 
but nor with the presence of FSA (Fig.2D). Indeed, the presence of FSA did not 
correlate with ESSDAI (Fig. S4A), as previously shown (29,30).  
To test whether increased blood Tfr cells and Tfr/Tfh ratio observed in patients is due to 
selective exclusion of Tfr cells from ELS we directly access CXCR5+Foxp3+ Tfr cells 
infiltration in MSG biopsies by microscopy. MSG biopsies from patients with FSA 
were further studied to identify ELS based on the presence of organized CD20+ B cell 
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aggregates and infiltration by CD21+ follicular dendritic cells (Fig. S4B, C) (31). As, 
only one patient had FSA without infiltration by CD21+ follicular dendritic cells we 
assumed that FSA was a good indicator for ELS in our cohort (Fig. S4B). Additionally, 
two patients with FSA were also found to have Bcl-6+ ectopic GC formation (Fig. S4B, 
C).  We found a substantial number of CXCR5+Foxp3+ Tfr cells within ELS in MSG of 
SS patients following a bimodal distribution, with a group of patients having a tissue Tfr 
density 10-fold greater that the other group (Fig. 2F). We therefore assessed whether 
the tissue density of Tfr cells correlated with disease-related parameters (Table S3). We 
found a strong correlation of tissue Tfr cells with ICOS+PD-1+ T cell infiltration (Fig. 
2G). Overall our data show Tfr cells are not excluded from ELS in inflamed SS 
exocrine glands.  
 
Blood Tfr/Tfh ratio as a marker of SS and focal sialadenitis  
The presence of focal sialadenitis (FSA) on MSG biopsy is a major diagnostic and 
prognostic marker of primary SS (9,20,32), and one of the diagnostic criteria established 
by American European Consensus Group in 2002 (Vitali C, et al. Ann Rheum Dis 
2002). As blood Tfr/Tfh ratio was increased in SS patients compared to healthy donors 
and associated with MSG lymphocytic infiltration we wondered whether this ratio could 
aid in the identification of patients with SS and ectopic lymphoid activity (typical FSA).  
The blood Tfr/Tfh ratio was significantly higher in SS patients compared to healthy 
donors and patients with non-Sjögren sicca syndrome (Fig. 3A). This ratio was a 
significant predictor of SS when compared to healthy donors, with an increase of 4.97 
in the odds of having SS for every decimal increase in the Tfr/Tfh ratio (AUC=0.82, 
p=0.008) (Fig. 3B, C). Through ROC analysis, we found that a cut-off of ≥0.278 
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correctly classified 87.1% of patients with 100% specificity and 73.3% sensitivity. 
Compared to non-Sjögren sicca syndrome, Tfr/Tfh ratio tended to associate with SS 
diagnosis (OR=1.93, p=0.099, AUC=0.716), with the best cut-off to diagnose SS being 
a blood Tfr/Tfh ratio ≥0.3009 (Fig. 3B, C). Thus, patients with sicca symptoms and a 
Tfr/Tfh ratio ≥0.3009 had 13 times the odds of having SS, with very high specificity 
(90.9%) but moderate sensitivity (56.3%) (Fig. 3C). 
Importantly, blood Tfr/Tfh ratio was significantly increased in patients with FSA, 
compared to those with normal histology or mild unspecific inflammation, irrespective 
of diagnosis (Fig. 3D). Moreover, it significantly predicted the result of MSG biopsy 
(FSA vs. no-FSA), with an increase in the odds of having FSA of 2.03 per each decimal 
increase (AUC 0.793, p=0.047),(Fig. 3C, E). Values of blood Tfr/Tfh ratio ≥0.302 were 
significantly associated with FSA (OR=10, p=0.022, AUC=0.757), with good 
sensitivity (71.4%) and very good specificity (80%) (Fig. 3C). 
 
DISCUSSION 
Our results show that blood activated Tfh cells and Tfr/Tfh ratio are associated, 
respectively, with disease activity and ectopic lymphoid structures in MSG, 
respectively, in primary SS. Indeed, there is a striking association between high Tfr/Tfh 
ratio and ectopic lymphoid activity in salivary glands, the target organ of this disease. In 
addition, circulating PD-1+ICOS+ Tfh cells seem to provide a different information, 
indicating disease activity and not ELS formation. 
The relationship between circulating PD-1+ICOS+ Tfh cells with ESSDAI was an 
exciting finding. While, many studies have established that circulating activated Tfh 
cells are correlated with disease severity in autoimmunity (33–35), so far circulating Tfh 
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cells were not correlated with ESSDAI. Notably, other Tfh subsets, namely Tfh17-like 
cells identified in other immune-mediated diseases (35), were not altered in our cohort 
of primary SS patients., These results suggest that PD1+ICOS+ Tfh cells may be directly 
involved in the pathogenesis of SS, particularly in those patients with greater 
inflammatory activity and high ESSDAI scores. A recent study showed that ESSDAI is 
an independent predictor of lymphoma development in primary SS (36) thus raising the 
possibility that increased circulating PD1+ICOS+ Tfh cells are somehow related to the 
same mechanism that will culminate in hematologic malignancy. 
The predictive value of Tfr cells, and especially the Tfr/Tfh ratio, regarding the 
diagnosis of primary SS and pathological lymphocytic infiltration in salivary glands 
may appear counterintuitive, given the regulatory role attributed to Tfr cells (12,13). 
However, we have recently shown that human blood Tfr cells remain immature and are 
generated prior to T-B interactions required for acquisition of follicle access and full 
regulatory function (17). The increased proportion of Tfr cells in peripheral blood of SS 
patients did not seem to be due to anatomic exclusion of Tfr cells from inflamed 
exocrine glands, as substantial numbers of Tfr cells were found within ELS containing 
B cells in the majority of patients. It is generally assumed that ELS are populated by 
lymphocytes formed outside these structures, in secondary lymphoid organs (4,6). 
Thereby, it is likely that Tfr cells result from enhanced differentiation in secondary 
lymphoid organs due to ongoing humoral responses. Our data suggest that accumulation 
of Tfr cells are not sufficient to restore tolerance in exocrine glands (where the first step 
of SS pathogenesis occur), although we did not directly address the presence of Tfr cells 
in ELS with and without GCs (3). A recent report claimed salivary gland epithelial cells 
induce Tfh cell differentiation from naïve CD4+ T cells (37). While, it is not known 
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whether Tfr cell differentiation can also occur in situ, this could possibility provide an 
alternative explanation for the increased proportion of blood Tfr cells in SS. 
The blood Tfr/Tfh ratio does seem to be a specific marker of SS and of ELS formation 
within salivary glands. Indeed we found that Tfr/Tfh ratio could discriminate between 
SS patients and healthy donors with excellent accuracy, with a specific cut-off above 
which the diagnosis of SS was almost certain. Even more importantly, this ratio was 
also helpful in predicting a diagnosis of primary SS and the presence of FSA in MSG 
biopsy in a group of patients investigated for sicca symptoms, thus highlighting the 
potential clinical value of this marker. The proposed cut-offs of blood Tfr/Tfh ratio 
above/equal 0.3009 and 0.302 were strong predictors of SS and FSA, respectively, and 
constitute promising tools for SS clinical evaluation. It should be noted that the 
specificity and sensitivity of Tfr/Tfh ratio to predict FSA and SS was remarkably high, 
in particular given the small number of patients studied. We anticipate that greater 
patient numbers may reinforce the significance of our findings, potentially establishing 
the usefulness of Tfr and Tfh quantification for primary SS patient stratification. This is 
particularly important both for diagnostic and therapeutic purposes as there are major 
unmet needs in these fields in primary SS (38). The potential to confirm diagnosis in 
patients who do not fulfil classification criteria, or to identify clusters of patients more 
prone to respond to targeted therapies are some of the applications that such a biomarker 
could have.  
In this report, we decided to study fresh blood of patients at the time of diagnosis who 
were not under immunosuppressant drugs, in order to overcome potential drug effects 
on Tfh and Tfr cell subsets. Consequently, the studied cohort of patients was small, but 
uniform and consistent. Other limitations of our study included the fact that paired 
samples for every parameter were in some cases not available and the technical issue of 
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CXCR5 staining in salivary gland cell suspension, which precluded a direct assessment 
of tissue Tfr cells at a phenotypical and functional level. It also remains to be shown 
whether alterations of Tfr and Tfh subsets that we describe here are specific for SS or 
can be generalized to other immune-mediated inflammatory diseases, in particular the 
ones with ELS and autoantibody-mediated pathology. 
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Figure Legends 
Figure 1: Blood activated PD-1+ICOS+ Tfh cells indicate disease activity in 
primary Sjögren’s syndrome. (A) Frequency of CXCR5+CD45RO+CD25-Foxp3-CD4+ 
Tfh, CD25+Foxp3+CD4+ Treg, and CXCR5+CD25+Foxp3+CD4+ Tfr cells in peripheral 
blood of primary Sjögren’s syndrome (SS, n=16) and healthy donors (HD, n=16). 
Unpaired Student T-test with Welch’s correction for variance. Representative plots 
(left) and pooled data (right). (B) Blood Tfr/Tfh ratio in SS (n=16) and HD (n =16). 
Unpaired Student T-test with Welch’s correction for variance. (C) Frequency of PD-
1+ICOS+ Tfh cells in peripheral blood of SS (n=14) and HD (n=13). Unpaired Student 
T-test with Welch’s correction for variance. Representative plots (left) and pooled data 
(right). (D) Frequency of PD-1+CXCR3- Tfh cells in peripheral blood of SS (n=14?) and 
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HD (n=13). Unpaired Student T-test. Representative plots (left) and pooled data (right). 
(E) Distribution of CCR6+CXCR3- Tfh17-like cells, CCR6-CXCR3+ Tfh1-like cells, 
and CCR6-CXCR3- Tfh2-like cells in peripheral blood of SS (n=16) and HD (n=16). 
Unpaired Student T-test . (F) Heatmap representation of correlation between peripheral 
blood Tfh cells, PD-1+ICOS+ Tfh cells, PD-1+CXCR3- Tfh cells, Tfr cells, CXCR5- 
Treg/Tfh ratio, and Tfr/Tfh ratio and serum autoantibodies titers (antinuclear antibodies 
(ANA), anti-SSA/Ro52, anti-SSA/Ro60, anti-SSB), rheumatoid factor (RF, IU/mL), 
serum electrophoresis gamma-fraction (γ-fraction, g/dL), C-reactive protein (CRP, 
mg/dL), erythrocyte sedimentation rate (ESR, mm/1st hour) and disease activity 
measured by European League Against Rheumatism Sjögren’s Syndrome Disease 
Activity Index (ESSDAI), in SS patients (n = 16, Pearson coefficient, r). (G) 
Correlation between peripheral blood Tfr/Tfh ratio and serum anti-SSA/Ro60 titers 
(left); correlation between blood PD-1+ICOS+ Tfh cells and serum anti-SSA/Ro52 
(centre) and ESSDAI (right) (n = 16, linear regression with interpolated 95% confidence 
interval curves). Bars on scatterplots represent SEM. On linear regression plots, dashed 
line represent interpolated 95% confidence interval. 
 
Figure 2: Blood Tfr/Tfh ratio identifies pathological lymphocytic infiltration in 
Sjögren’s syndrome target organ. (A) Frequency and absolute numbers of CD45+ 
hematopoietic cells in minor salivary gland biopsies (MSG) of primary Sjögren’s 
syndrome patients (SS, n=14) and non-Sjögren sicca syndrome (non-SSS) patients 
(n=6). Representative plots (left) and pooled data (right). Unpaired Student T-test. (B) 
Frequency and absolute numbers of CD4+ T cells and CD19+ B cells in MSG biopsies 
of SS (n=14) and non-SSS (n=6). Representative plots (left) and pooled data (right). 
Unpaired Student T-test with Welch’s correction for variance. (C) Frequency and 
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absolute numbers of PD-1+ICOS+ T cells in MSG biopsies of SS (n=10) and non-SSS 
(n=6). Representative plots (left) and pooled data (right). Unpaired Student T-test with 
Welch’s correction for variance. (D) Heatmap representation of correlation between 
peripheral blood Tfh cells, PD-1+ICOS+ Tfh cells, PD-1+CXCR3- Tfh cells, Tfr cells, 
CXCR5- Treg/Tfh ratio, and Tfr/Tfh ratio (rows) and salivary gland infiltration by 
CD45+ hematopoietic cells, CD4+ T cells, ICOS+PD-1+CD4+ T cells and CD19+ B cells 
(columns), in primary SS patients (n=14, Pearson coefficient, r). (E) Correlation 
between peripheral blood Tfr/Tfh ratio with salivary gland infiltration by CD45+ 
hematopoietic cells, CD4+ T cells, ICOS+PD-1+CD4+ T cells and CD19+ B cells (n=14, 
linear regression). (F) Identification of CXCR5+Foxp3+ Tfr cells (arrows on extreme 
right image) within FSA containing CD20+ B cells in MSG biopsies of primary SS 
patients by immunohistochemistry. Extreme left image shows FSA containing B cells 
(CD20 in brown) (x100, digital zoom). The three images on right show double 
immunohistochemistry for CXCR5 (purple/red) and Foxp3 (brown). The squares in 
each image are amplified successively on the right (x100, x200, x400, digital zoom). 
Representative sections (left) and pooled data (right) (n=16). Bars on scatterplots 
represent SEM. On linear regression plots, dashed line represent interpolated 95% 
confidence interval. 
 
Figure 3: Blood Tfr/Tfh ratio as a marker of primary Sjögren’s syndrome and 
focal sialadenitis. (A) Blood Tfr/Tfh ratio in Sjögren’s syndrome (SS, n=16) and non-
Sjögren sicca syndrome (non-SSS, n=11) patients and healthy donors (HD, n =16). 
Unpaired Student T-test with Welch’s correction for variance was used except when 
variance was not significantly different between groups (non-SSS vs. HD comparison). 
One-way ANOVA comparison across groups represented on top. (B) Receiver 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
operating characteristic (ROC) curve for prediction of SS diagnosis (vs. HD and vs. 
non-SSS) based on Tfr/Tfh ratio. AUC, area under the curve. (C) Odds-ratio (OR), p-
value and AUC of logistic regression models predicting SS diagnosis (vs. HD and vs. 
non-SSS) and focal sialadenitis (FSA, vs. normal histology or unspecific lymphocytic 
infiltration, LI) based on Tfr/Tfh ratio as a continuous variable or as specific cut-offs. 
Tfr/Tfh ratio transformed by 1 decimal place (*101) for better interpretation of the OR. 
Percentages of sensitivity, specificity and correct classification of patients based on 
given cut-offs. (D) Blood Tfr/Tfh ratio of patients with sicca symptoms undergoing 
minor salivary gland biopsy, with focal sialadenitis (FSA, n=7) and normal histology or 
unspecific lymphocytic infiltration (LI, n=20). Mann-Whitney U test used due to 
skewed distribution of values and non-different variance according to Brown–
Forsythe’s test. (E) Receiver operating characteristic (ROC) curve for prediction of 
FSA diagnosis (vs. normal/LI) based on Tfr/Tfh ratio. AUC, area under the curve. 
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Tables 
 
Table 1: Summary of demographic characteristics of Sjögren’s syndrome patients, non-
Sjögren sicca syndrome patients, and healthy donors. 
 
 
Primary SS 
n = 16 
Non-SSS 
n = 16 
Healthy donors 
n = 16 p-value 
     
Age, y 52.3 ± 17.7 47.3 ± 14.9 48.3 ± 19.7 ns 
Gender (f / m), n 15 / 1 15 / 1 11 / 5 ns
Disease duration, y 4.8 ± 6.5 - - N/A 
ESSDAI 3.8 ± 5.0 - - N/A 
Extraglandular involvement, n (%) 12 (75) - - N/A 
Prednisolone (≤5mg/d), n (%) 5 (31) 0 - 0.0434 
Hydroxychloroquine, % 3 (19) 0 - ns 
ANA positive, n (%) 15 (94) 2 (13) - <0.0001 
Anti-SSA positive, n (%) 15 (94) 0  <0.0001
Anti-SSA/Ro52 titer, UQ 7824 ± 15430 - - N/A 
Anti-SSA/Ro60 titer, UQ 8728 ± 6079 - - N/A 
Anti-SSB positive, n (%) 10 (63) 0  <0.0001 
Anti-SSB titer, UQ 1206 ± 4236 - - N/A
RF positive, n (%) 8 (50) 1 (6)  0.0024 
RF titer, UI/mL 45.7 ± 26.1 18.7 ± 0.0 - N/A
CRP, mg/dL 0.53 ± 0.58 0.52 ± 0.78 - ns
ESR, mm 43.7 ± 25.6 22.1 ± 16.3 - 0.010
γ-fraction, g/dL 1.76 ± 0.58 1.07 ± 0.31 - 0.002 
MSG histology, n (%) 
Focal sialadenitis 
Non-specific lymphocytic infiltrate 
Normal 
 
7 (44) 
6 (38) 
3 (19) 
 
0 
5 (31) 
11 (69) 
 
- 
- 
- 
 
0.0068 
ns 
0.0113 
 
Supplementary Information 
Table S1: Demographic and clinical characteristics of primary Sjögren’s syndrome 
(SS) and non-Sjögren sicca syndrome (non-SSS) patients. 
Table S2: Antibodies used for flow cytometry. 
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Table S3: Correlation between absolute number of Tfr cells per mm2 of minor salivary 
gland tissue section (Fig. 2F) wit clinical and laboratory parameters, and minor salivary 
gland infiltration by CD45+, CD4+, CD19+ and PD-1+ICOS+ lymphocytes. (n=16, 
Pearson coefficient, r). 
 
Figure S1: Flowchart of patient recruitment and selection. DMARDs, disease 
modifying anti-rheumatic drugs; TNF, tumor necrosis factor; AECG, American-
European Consensus Group criteria for Sjögren’s syndrome.  
 
Figure S2: Blood T cell subsets in primary Sjögren’s syndrome. (A) Frequency and 
absolute number (per mL of blood) of CD4+ T cells in primary Sjögren’s syndrome (SS) 
patients (n=16) and healthy donors (HD) (n=16). Unpaired Student T-test. (B) Absolute 
numbers (per mL of blood) of Tfh, Treg, CXCR5+ Treg (Tfr cells) and CXCR5- Treg 
cells in SS (n=16) and HD (n=16). Unpaired Student T-test with Welch’s correction for 
variance. (C) Mean fluorescence intensity of CXCR5 and Foxp3 in peripheral blood Tfh 
and Tfr cells in SS (n=16) and HD (n=16). Unpaired Student T-test. (E) Blood CXCR5- 
Treg/Tfh ratio in SS (n=16) and HD (n =16). Unpaired Student T-test. (F). Distribution 
of CCR6+CXCR3- Th17 cells, CCR6-CXCR3+ Th1 cells, and CCR6-CXCR3- Th2 cells 
in peripheral blood of SS (n=16) and HD (n=16). Unpaired Student T-test. Bars in 
scatterplots represent SEM. 
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Figure S3: Characteristics of minor salivary gland biopsies of primary Sjögren’s 
syndrome patients. (A) Impact of different enzymes in membrane markers used for 
identification of cellular components of minor salivary gland tissue infiltrates, including 
CXCR5-expressing T cells. Human tonsil fragments from healthy children were used 
for optimization. Liberase TM (0.1 mg/mL), DNAse I (0.1 mg/mL), Collagenase P (0.1 
mg/mL). All enzymes led to significant duction of CXCR5 on PD-1+CD4+ T cells. 
Representative plots of 2 independent experiments. (B) Weight of salivary gland tissue 
removed during minor salivary gland (MSG) biopsy in primary Sjögren’s syndrome 
(SS) patients (n=14) and non-Sjögren sicca syndrome (non-SSS) patients (n=6). (C) 
CXCR5 and ICOS expression by salivary gland CD4+ B cells and CD19+ T cells after 
enzymatic digestion by Liberase TM (0.1 mg/mL) plus DNAse I (0.1 mg/mL), 
confirming the loss of CXCR5 staining. Representative plots of 14 MSG biopsies. (D) 
Microscopy of formalin-fixed paraffin-embedded MSG stained for CXCR5 (brown, 
right), with correspondent negative control (left) by immunohistochemistry. Data are 
representative of MSG sections from 4 SS patients. (E) CXCR5 and Bcl-6 expression 
by ICOS+PD-1+CD4+ T cells from human tonsils. Representative plots (left) and pooled 
data (right) (n=6). (F) Microscopy of formalin-fixed paraffin-embedded MSG stained 
for CD20 (brown) in a SS patient with FSA (top) and a SS patient with no pathologic 
findings (normal, bottom). (G) Frequency of CD4+ T cells, CD19+ B cells, and PD-
1+ICOS+ T cells in MSG biopsies of SS (n=14) and non-SSS (n=6), according to 
histological diagnosis (normal, no infiltration by lymphocytes; LI, unspecific 
lymphocytic infiltration; FSA, focal sialadenitis). Two-way ANOVA with post-test 
Bonferroni’s Multiple Comparison. Bars on scatterplots represent SEM. 
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Figure S4: Identification of ectopic lymphoid structures in minor salivary glands of 
Sjögren’s syndrome patients. (A) Correlation between SS disease activity as measured 
by ESSDAI and histological diagnosis (normal, no infiltration by lymphocytes; LI, 
unspecific lymphocytic infiltration; FSA, focal sialadenitis). (B) Microscopy of 
formalin-fixed paraffin-embedded MSG stained for CD20, CD21 and Bcl-6 in a SS 
patient with FSA harboring features of ectopic lymphoid structures (ELS) with ectopic 
germinal centre formation (top) and without ELS (bottom). (C) Number of primary SS 
patients with normal, LI and FSA patients further characterized for the presence of ELS 
and ectopic germinal centre accordingly to CD21 and Bcl-6 immunohistochemistry. 
Bars on scatterplots represent SEM. 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
Supplementary Figure 1: Flowchart of patient recruitment and selection. DMARDs,
disease modifying anti-rheumatic drugs; TNF, tumor necrosis factor; AECG, American-
European Consensus Group criteria for Sjögren’s syndrome.
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Supplementary Figure 2: Characteristics of minor salivary gland biopsies of primary
Sjögren’s syndrome patients (legend on the next page).
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Supplementary Figure 2: Characteristics of minor salivary gland biopsies of primary
Sjögren’s syndrome patients. (A) Impact of different enzymes in membrane markers
used for identification of cellular components of minor salivary gland tissue infiltrates,
including CXCR5-expressing T cells. Human tonsil fragments from healthy children were
used for optimization. Liberase TM (0.1 mg/mL), DNAse I (0.1 mg/mL), Collagenase P
(0.1 mg/mL). All enzymes led to significant duction of CXCR5 on PD-1+CD4+ T cells.
Representative plots of 2 independent experiments. (B) Weight of salivary gland tissue
removed during minor salivary gland (MSG) biopsy in primary Sjögren’s syndrome (SS)
patients (n=14) and non-Sjögren sicca syndrome (non-SSS) patients (n=6). (C) CXCR5
and ICOS expression by salivary gland CD4+ B cells and CD19+ T cells after enzymatic
digestion by Liberase TM (0.1 mg/mL) plus DNAse I (0.1 mg/mL), confirming the loss of
CXCR5 staining. Representative plots of 14 MSG biopsies. (D) Microscopy of formalin-
fixed paraffin-embedded MSG stained for CXCR5 (brown, right), with correspondent
negative control (left) by immunohistochemistry. Data are representative of MSG sections
from 4 SS patients. (E) CXCR5 and Bcl-6 expression by ICOS+PD-1+CD4+ T cells from
human tonsils. Representative plots (left) and pooled data (right) (n=6). (F) Microscopy of
formalin-fixed paraffin-embedded MSG stained for CD20 (brown) in a SS patient with
FSA (top) and a SS patient with no pathologic findings (normal, bottom). (G) Frequency
of CD4+ T cells, CD19+ B cells, and PD-1+ICOS+ T cells in MSG biopsies of SS (n=14)
and non-SSS (n=6), according to histological diagnosis (normal, no infiltration by
lymphocytes; LI, unspecific lymphocytic infiltration; FSA, focal sialadenitis). Two-way
ANOVA with post-test Bonferroni’s Multiple Comparison. Bars on scatterplots represent
SEM.
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Supplementary Figure 3: Blood T cell subsets in primary Sjögren’s syndrome. (A)
Frequency and absolute number (per mL of blood) of CD4+ T cells in primary Sjögren’s
syndrome (SS) patients (n=16) and healthy donors (HD) (n=16). Unpaired Student T-test.
(B) Absolute numbers (per mL of blood) of Tfh, Treg, CXCR5+ Treg (Tfr cells) and
CXCR5- Treg cells in SS (n=16) and HD (n=16). Unpaired Student T-test with Welch’s
correction for variance. (C) Mean fluorescence intensity of CXCR5 and Foxp3 in
peripheral blood Tfh and Tfr cells in SS (n=16) and HD (n=16). Unpaired Student T-test.
(E) Blood CXCR5- Treg/Tfh ratio in SS (n=16) and HD (n =16). Unpaired Student T-test.
(F). Distribution of CCR6+CXCR3- Th17 cells, CCR6-CXCR3+ Th1 cells, and CCR6-
CXCR3- Th2 cells in peripheral blood of SS (n=16) and HD (n=16). Unpaired Student T-
test. Bars in scatterplots represent SEM.
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Supplementary Figure 4: Identification of ectopic lymphoid structures in minor
salivary glands of Sjögren’s syndrome patients. (A) Correlation between SS disease
activity as measured by ESSDAI and histological diagnosis (normal, no infiltration by
lymphocytes; LI, unspecific lymphocytic infiltration; FSA, focal sialadenitis). (B)
Microscopy of formalin-fixed paraffin-embedded MSG stained for CD20, CD21 and Bcl-6
in a SS patient with FSA harboring features of ectopic lymphoid structures (ELS) with
ectopic germinal centre formation (top) and without ELS (bottom). (C) Number of primary
SS patients with normal, LI and FSA patients further characterized for the presence of ELS
and ectopic germinal centre accordingly to CD21 and Bcl-6 immunohistochemistry. Bars
on scatterplots represent SEM.
Supplementary Table 1: Demographic and clinical characteristics of primary Sjögren’s
syndrome (SS) and non-Sjögren sicca syndrome (non-SSS) patients.
Supplementary Table 2: Antibodies used for flow cytometry.
Supplementary Table 3: Correlation between absolute number of Tfr cells per mm2 of
minor salivary gland tissue section (Fig. 2F) wit clinical and laboratory parameters, and
minor salivary gland infiltration by CD45+, CD4+, CD19+ and PD-1+ICOS+ lymphocytes.
(n=16, Pearson coefficient, r).
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Summary
It has long been known that CD4 T cells are necessary to provide help to
B cells, triggering a germinal centre (GC) reaction where affinity matura-
tion and isotype switching occur. However, the nature of the dedicated
CD4 helper T cells, known as T follicular helper (Tfh), was only recently
described. Here, we review the biology and function of the recently
described T follicular regulatory (Tfr) cells, another CD4 T-cell popula-
tion also found within GCs but with regulatory function and characteris-
tics. Tfr cells have been identified in mice and humans as simultaneously
presenting characteristics of T follicular cells (namely CXCR5 expression)
and regulatory T cells (including Foxp3 expression). These Tfr cells have
been implicated in the regulation of the magnitude of the GC reaction, as
well as in protection from immune-mediated pathology.
Keywords: autoimmunity; germinal centres; regulation; T follicular helper
cells; T follicular regulatory cells.
Introduction
Germinal centres (GCs) are secondary lymphoid struc-
tures within B-cell follicles where B cells go through affin-
ity maturation (somatic hypermutation and positive
selection) and class-switch recombination to generate
high-affinity antibodies.1 For B cells to undergo these
processes, they require the help of T follicular helper
(Tfh) cells, a specialized CD4+ T-cell subset that provides
survival, proliferation and selection signals by engaging in
cognate interactions with B cells.2 Moreover, Tfh cells
also produce important cytokines for the GC reaction,
namely interleukin-21 (IL-21) and IL-4.2 Another CD4+
T-cell population has been recently described as present
in GCs, the T follicular regulatory (Tfr) cell population.
The Tfr cells are a subset of forkhead box P3 positive
(Foxp3+) regulatory T (Treg) cells that acquire a follicular
phenotype and migrate into GCs, where they act as regu-
lators of the GC reaction on multiple levels.3–5
The importance of Treg cells for the control of anti-
body responses has been long known. Indeed, one of the
consequences of the absence of Treg cells is the increased
level of circulating antibodies, namely IgG and IgE, which
originate in GCs.6,7 Further studies showed that Treg cells
are capable of controlling antibody responses by inhibit-
ing activation-induced cytidine deaminase expression and
class-switch recombination, and by directly killing B
cells.8–10 Also, CXC chemokine receptor type 5 positive
(CXCR5+) Treg cells could be found within GCs of
immunized mice.11 However, the confirmation of the
existence of a specialized subset of Treg cells, which
migrates into GCs and controls antibody responses, came
with the identification of the Tfr cell population by three
independent groups.3–5 These studies, performed in
mouse models, described a population with mixed char-
acteristics of Treg and Tfh cells.3–5 Tfr cells express not
only the Treg master regulator Foxp3 but also other
Treg-related molecules such as CD25, cytotoxic T-lym-
phocyte-associated protein 4 (CTLA-4), glucocorticoid-
induced tumour necrosis factor receptor-related protein,
and granzyme B. In addition, Tfr cells express Tfh cell-
associated molecules including CXCR5, inducible T-cell
Abbreviations: Bcl-6, B-cell lymphoma 6; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; CXCR5, CXC chemokine recep-
tor type 5; DC, dendritic cell; Foxp3, forkhead box P3; GC, germinal centre; ICOS, inducible T-cell co-stimulator; IL, interleukin;
NFAT2, nuclear factor of activated T cells 2; NP, 4-hydroxy-3-nitrophenyl; PD-1, programmed cell death 1; PD-L1, PD-1 ligand
1; Tconv, conventional CD4+ T; TCR, T-cell receptor; Tfh, T follicular helper; Tfr, T follicular regulatory; TGF-b, transforming
growth factor b; TRAF3, tumour necrosis factor receptor-associated factor 3; Treg, regulatory T
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co-stimulator (ICOS), programmed cell death 1 (PD-1),
signalling lymphocytic activation molecule-associated pro-
tein, and, importantly, the master transcription factor of
both Tfh and Tfr cells B-cell lymphoma 6 (Bcl-6). Hence,
Tfr cells present, simultaneously, the characteristics of
both Treg and Tfh cells by maintaining a suppressive
function and gaining ability to access B-cell follicles and
GCs.
Tfr cells have been described in mice and humans: one
of the first reports describing Tfr cells demonstrated the
presence of these cells within GCs of human tonsils.3
However, as for Tfh cells, the difficulty in obtaining
human samples of secondary lymphoid tissues has led to
most of the work being performed in mice. Nevertheless,
several recent studies have investigated a population of
CXCR5+ Foxp3+ CD4+ T cells from human blood, con-
sidered to be circulating Tfr cells, in samples from
patients with autoimmunity or infectious diseases.
The initial studies describing Tfr cells described several
key characteristics of this population, namely Tfr ability
to regulate GC reactions. Further studies, in mice and
human samples, have complemented our knowledge
regarding Tfr function, origin, repertoire and specificity,
as well as the regulatory mechanisms employed. Never-
theless, as most of the studies have been performed in
mouse models, whether human Tfr cells have the same
characteristics awaits confirmation. A brief summary of
the known characteristics and markers used to identify
Tfr cells in mice and humans can be found in Table 1.
The biology of Tfr cells
The differentiation of Tfr cells is still not as characterized
as the differentiation of Tfh cells. Nevertheless, Tfr cells
seem to undergo a multi-step differentiation process simi-
lar to Tfh cells (Fig 1). For Tfh cells, such multistep
priming is initiated, as for other CD4+ T-cell subsets, fol-
lowing antigen recognition on dendritic cells. For the
subsequent step, cognate interactions with B cells are
required for full Tfh differentiation and expansion.2,12,13
The same priming requirements were demonstrated for
Tfr cells, which were substantially reduced in immunized
mice where dendritic cells had been ablated.14 The full
differentiation of Tfr cells is also dependent on interac-
tions with B cells. Indeed, Tfr cells are almost absent in
draining lymph nodes of immunized mice that lack B
cells.14 However, these mice still contain a population of
circulating Tfr cells upon immunization.14 Hence, this
population of blood Tfr cells originates upon the initial
interaction with dendritic cells and before full commit-
ment to the GC fate. The same study also showed that
circulating Tfr cells can persist for long periods of time,
representing a pool of cells that can later be recruited into
the GC to suppress subsequent responses.14
Another similarity between the differentiation processes
of Tfr and Tfh cells is the requirement of cognate sig-
nalling through the T-cell receptor (TCR) and co-stimu-
latory signals through CD28 and ICOS.4,15–17 The CD28
requirement for Tfr cell commitment was first shown
with bone marrow chimeras, containing a mixture of
CD28-deficient and CD28-sufficient cells, where Tfr and
Tfh cells originated exclusively from CD28-sufficient pre-
cursors.4 These results were later corroborated by a study
showing the absence of Tfr and Tfh cells in CD28-defi-
cient and in ICOS-deficient mice.17
There are, however, some differences between the dif-
ferentiation processes of Tfr and Tfh cells. A striking dif-
ference is that only the differentiation of Tfr cells seems
to be affected by co-inhibitory signals. Although PD-1 is
equally expressed by Tfr and Tfh cells, PD-1-deficient
mice display an increased number of Tfr cells whereas the
Tfh population remains unaffected.17 The authors further
established that the negative effect of PD-1 in Tfr cells is
dependent on binding of PD-1 ligand 1 (PD-L1), but not
PD-L2, since only PD-L1-deficient mice could replicate
the Tfr phenotype observed in PD-1-deficient mice.
Another inhibitory molecule that has a negative impact
on Tfr cell differentiation and function is CTLA-4. Using
mouse strains where CTLA-4 was conditionally deleted
on Foxp3+ Treg cells, two groups simultaneously demon-
strated that, under those conditions, the suppressive
capacity Tfr cells and their ability to control B-cell
responses were diminished even though there was an
increase of total Tfr cell numbers.18,19 Similar results were
reported following CTLA-4 targeting with a blocking anti-
body.18 The cytokine IL-21 also has a negative impact on
Tfr cell numbers even though it supports Tfh differentia-
tion.20,21 Interleukin-21 induces Bcl-6 expression, which,
in turn, limits CD25. The reduction of CD25 expression
then leads to lower responsiveness to IL-2 that, conse-
quently, has a negative impact on the proliferation of Tfr
cells.20
Figure 1. Dynamics of germinal centre (GC) development and T follicular regulatory (Tfr) cell recruitment. GC responses are initiated by antigen
recognition by B cells within the follicle and CD4+ T-cell priming by dendritic cells (DCs) in the T-cell zone. Within 1–2 days after activation,
both activated B and pre-T follicular helper (Tfh) cells migrate into the T–B border where they engage in cognate interactions. Upon commit-
ment to the GC programme, GC B and Tfh cells migrate into the centre of the follicle where an early GC is established between a network of fol-
licular dendritic cells (FDCs). At day 7, the now mature GC has increased in size due to fast cell proliferation and it can be divided into two
zones: the dark and light zones. The dark zone is mainly composed of rapidly dividing B cells, whereas in the light zone other cell types like Tfh
and FDCs can be found. Tfr cells start to accumulate in the GC at this point, however, besides also requiring priming by DCs, the differentiation
mechanism and required signals are still not well understood.
ª 2017 John Wiley & Sons Ltd, Immunology2
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There are also similarities and differences in the tran-
scription factors involved in Tfr and Tfh cell differentia-
tion. As referred above, Bcl-6 is the master regulator for
both subsets.3,4,22 Signal transducer and activator 3 is also
required by both Tfr and Tfh populations but, although
Tfh numbers are reduced in mice where signal transducer
and activator 3 was conditionally deleted on CD4+ T
cells, Tfr differentiation is almost abrogated in those
mice.23,24 A key difference on the transcription factors
present in Tfr and Tfh cells is the balance between Bcl-6
and Blimp-1.4 Whereas Tfh cells only express Bcl-6, Tfr
cells express, simultaneously, both mutual antagonists and
repressors Bcl-6 and Blimp-1.4 It has been suggested that,
while Bcl-6 is important to acquire a Tfh-like phenotype
by Tfr cells, Blimp-1 may be necessary for the Treg-like
suppressive function of Tfr cells.4 Another difference is
that CXCR5 expression in both subsets seems to have a
distinct regulation. Tfh cells require achaete-scute homo-
logue-2 for initial CXCR5 expression.25 Tfr cells, however,
do not express achaete-scute homologue-2 and appear to
rely on nuclear factor of activated T cells 2 (NFAT2) to
express CXCR5.25,26 Indeed, NFAT2 was shown to bind
to the CXCR5 promoter and induce its transcription, and
Tfr cell numbers are reduced in NFAT2-deficient mice. In
addition, the tumour necrosis factor receptor-associated
factor 3 is only important for Tfr differentiation and
function, and is involved in the regulation of ICOS in
Treg cells.27 Therefore, Treg-conditional tumour necrosis
factor receptor-associated factor 3-deficient mice have
impaired Tfr cell differentiation.27
The temporal accumulation of Tfr and Tfh cells in the
GC is also different. Although the same type of cellular
interactions seems to trigger both Tfr and Tfh cell differ-
entiation, kinetic studies of the accumulation of both
populations after immunization revealed that Tfr cells
appear in the GC at later time-points, reaching their
maximum frequency around 5 days later than Tfh cells
do (Fig 1).5,28 This unsynchronized accumulation of Tfr
and Tfh cells may be required for the initial establishment
of the GC, where few Tfh and GC B cells need to rapidly
expand without the suppressive action of Tfr cells. On
the contrary, once the GC has reached a significant size,
Tfr cells would be important for the control of the GC
reaction and its outcome.
The origin and specificity of Tfr cells are two other fea-
tures that have been addressed in several studies. The first
three studies describing Tfr cells reported that these cells
derived from thymic Treg cells.3–5 Linterman et al.
observed that antigen-specific TCR-transgenic CD4+ cells,
which do not contain thymic Treg cells, did not differen-
tiate into Tfr cells (even though they readily gave rise to
Tfh cells).4 Our group used T-cell-deficient mice as recip-
ients of antigen-specific TCR-transgenic CD4+ cells and
thymic Treg cells to demonstrate that only the thymic
Tconv
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THYMUS
THYMUS
Thymic
Treg
Thymic
Treg
Thymic
Treg Tfr
Tfr
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Tfr
Tfh
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GERMINAL
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B cell
GC
B cell
FDC
FDC
Tfr
Tfh
Tfh cells: oligoclonal and specific to
the immunizing antigen
Tfr cells: oligoclonal but not specific 
to the immunizing antigen:
repertoire similar to Treg cells
Figure 2. T follicular helper (Tfh) and T follic-
ular regulatory (Tfr) cell ontogeny. While Tfh
cells originate from conventional CD4+ T
(Tconv) cells, Tfr cells originate mainly from
thymic regulatory T (Treg) cells. Moreover,
although Tfr cells undergo some clonal expan-
sion, their T-cell receptors (TCRs) are not
specific for the non-self antigen driving the GC
response. In fact, Tfr cells keep a TCR reper-
toire similar to that of Treg cells.
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Treg cells could differentiate into Tfr cells.5 Finally,
Chung et al. also used T-cell-deficient mice as recipient,
but co-transferred wild-type naive CD4+ T cells and Fox-
p3+ Treg cells with different congenic markers, and
showed that Tfr cells originated from the Treg cell popu-
lation.3
A recent report showed that, under specific conditions,
Tfr cells can originate from naive conventional CD4+ T
cells and be specific for the immunizing antigen.29
Indeed, in bone marrow chimeras, where only CD4+ T
cells devoid of thymic Treg cells can express CXCR5 and,
consequently, in the absence of physiological competition
with thymic Treg cells, some Tfr cells originated from
those naive conventional T cells. However, we have
recently reported that under physiological competition
with thymic Treg cells, virtually all Tfr cells derived from
the thymic Treg cell population (Fig 2).30 Moreover, we
found that GCs from immunized mice contained Tfh
cells stained with an appropriate MHC class II tetramer,
whereas Tfr cells from the same GCs did not bind the tet-
ramer.30 Indeed, we could not detect antigen-specific tet-
ramer-positive Tfr cells in any of the conditions tested.
Furthermore, sorted Tfr cells did not preferentially prolif-
erate or survive in vitro with immunizing antigen signals
when compared with a control antigen. Finally, we
sequenced the TCR-a-chain (TRA gene) of Tfr, Tfh and
Treg cell populations from immunized TCR-b-restricted
mice. The repertoire analysis showed that, although Tfr
cells are an oligoclonal population, they have a repertoire
that resembles the repertoire of Treg cells, but that is
different from that of Tfh cells.30 Hence, our work
showed that the TCR repertoire of Tfh and Tfr cells from
the same GCs are considerably different:30 Tfh cells bear
TCRs specific for the immunizing antigen, but the TCR
repertoire of Tfr cells lacks those antigen-specific clones
while being similar to the predominantly self-reactive
repertoire of thymic Treg cells (Fig 2).
Tfr cell regulatory mechanisms
Tfr cells constitute a regulatory T-cell subset specialized
in the control of the GC response. The initial studies that
described Tfr cells already showed that this population
controls the GC size and the amount of antibodies pro-
duced.3–5 Indeed, in the absence of Tfr cells, the size of
the GC detected by immunofluorescence was increased,5
as well as the total numbers of Tfh and GC B cells.3–5 In
the same line, the amount of antigen-specific IgM and
IgG antibodies was higher in the serum of immunized
mice lacking Tfr cells.3,5
Another feature that has been studied is the impact of
Tfr cells in the affinity of the antibodies produced. Chung
et al. reported that Tfr cells led to reduced antibody affin-
ity.3 This conclusion was obtained by observing lower levels
of high affinity 4-hydroxy-3-nitrophenyl (NP)-specific
antibodies in T-cell-deficient mice, immunized with NP
conjugated to a protein, that had received wild-type CD4+
naive T and Bcl-6-deficient Foxp3+ Treg cells when com-
pared with mice that had received wild-type Foxp3+ Treg
and naive CD4+ T cells. Two other studies, however,
Table 1. Biology of T follicular regulatory (Tfr) cells in mice and humans
Mice Humans
Membrane markers CD25, CXCR5, PD-1, ICOS CD25, CXCR5, PD-1, ICOS1
Transcription factors Foxp3, Bcl-6, Blimp-1 Foxp3, Bcl-6
Cell of origin Thymic Treg cells Not directly studied
Function Control Tfh and GC B-cell numbers by inducing a suppressive
state and inhibiting their proliferation;
Impair IL-4 and IL-21 production by Tfh cells; Reduce the
amount of antibodies produced (namely IgM and IgG) and
the occurrence of class switch recombination;
Control antibodies’ quality by inducing production
of high-affinity antibodies.
Impair Tfh cell proliferation;
Impair IL-4 and IL-21 production by Tfh cells.
Impair immunoglobulin (namely IgA)
production by B cells.
TCR repertoire Tfr cell repertoire is different from that of Tfh cells but
similar to the repertoire of Treg cells.
Not studied
Immune compartments Lymph node, spleen, blood2 Tonsil, lymph node, spleen, blood2, ectopic
lymphoid structures
Identification by
flow cytometry
CD4+ Foxp3+
plus at least two of the following: CXCR5+, PD-1+, ICOS+,
Bcl-6+
CXCR5+ Foxp3+ CD25+ CD4+
(for tissue Tfr cells use at least one of the
following: PD-1, ICOS)
Identification by
microscopy
Foxp3+ cells within GC Foxp3+ cells within GC
1ICOS expression in humans does not discriminate Tfr cells from other effector Treg cells.
2The function and biological role of Tfr cells in peripheral blood is still elusive, especially in humans.
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associated impaired Tfr function with the production of
antibodies with lower affinity.19,31 Kawamoto et al. demon-
strated that Tfr cells are required in GCs of Peyer’s patches
for the generation of high-affinity IgA antibodies, which in
turn are essential for maintenance of normal and diverse
microbiota.31 The authors co-transferred naive CD4+ T
cells with Bcl-6-deficient or Bcl-6-sufficient CD25+ Treg
cells into T-cell-deficient mice, and verified that IgA
Table 2. Human studies that include analysis of Foxp3+ T follicular regulatory (Tfr) cells
Ref. Condition Tissue Tfr cells Major findings
Faghih Z et al.67 Breast cancer Lymph nodes CXCR5+
Foxp3+
Bcl-6+
CD4+
No impact on Tfr cell frequency.
Wallin et al.40 Kidney transplant recipients
undergoing therapy with
rituximab
Lymph nodes CD57+
CXCR5+
Foxp3+
CD127
CD4+
Rituximab had no impact on Tfr cells.
Tfr cells reduce IgA production by B cells
(in vitro).
Wang et al.48 Chronic hepatitis B
(HBV) and C (HCV)
Blood CXCR5+
Foxp3+
CD4+
Tfr cells increased during HBV and HCV
infection. Tfr cells positively correlate with
HBsAg titres and viral load.
Chen et al.49 Schistosoma japonica infection Blood CXCR5+
Foxp3+
CD4+
Tfr cell frequency increased during S. japonica
infection.
Colineau et al.63 HIV Spleen Foxp3+
CXCR5+
CD45RA
CCR7
CD4+
Tfr cell frequency increased during HIV infection.
De Bruyne et al.53 Food allergy Blood CXCR5+
CD45RO+
Foxp3+
CD25+
CD4+
No impact on Tfr cell frequency.
Dhaeze et al.50 Multiple sclerosis (MS) Blood CXCR5+
PD-1+
CD25+
CD127
CD4+
Tfr cell frequency increased upon influenza
vaccination, positively correlating with specific
antibody titres.
Tfr cell frequency was decreased in MS patients,
showing less suppressive capacity.
Miles et al.62 HIV infection
In vitro
Lymph nodes CD25+
CD127
CXCR5+
CD3+
CD8
Tfr cell expanded upon HIV infection (TGF-b
dependent). Tfr cells reduced ICOS+ IL-21+ IL-
4+ Tfh cells.
Shan et al.61 Ankylosing spondylitis (AS) Blood CXCR5+
Foxp3+
CD4+
Tfr cells were increased in AS, increasing further
upon therapy. Tfr cells negatively correlated with
serum IgA titres.
Di Fonte et al.41 PI3KR1 gain-of-function
(c.1425 + 1G>T)
Tonsil CXCR5+
Foxp3+
CD4+
No impact on Tfr cell frequency.
Xu X et al.69 Kidney allograft rejection Kidney CXCR5+
Foxp3+
Tfr cells were rarely present in kidney tertiary
lymphoid structures.
Wen et al.52 Myasthenia gravis (MG) Blood CXCR5+
Foxp3+
CD4+
Tfr cells were decreased in MG, inversely
correlating with disease severity. Treatment with
steroids re-established the frequency of Tfr cells.
Vaeth et al.26 ORAI1 p.R91W Blood CD45RO+
Helios+
Foxp3+
CD4+
SOCE signalling defects impaired Tfr cell
frequency.
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produced in Peyer’s patches from mice lacking Tfr cells had
lower affinity and diversity. In the other study, Sage et al.
showed that, when the action of Tfr cells is compromised
by Treg-conditional deletion of CTLA-4, the amount of
antibodies produced was higher, but the affinity generated
(measured as the ratio between high- and low-affinity NP-
specific antibodies on mice immunized with NP-ovalbu-
min) was lower.19 This possible effect on antibody affinity
could be explained by the facilitated help from Tfh cells to
B cells in the absence of Tfr cells, and consequent genera-
tion of low-affinity plasma cells.32
The impact of Tfr cells on the GC reaction seems to be
due to its direct action on Tfh and GC B cells. Tfh cells
cultured in the presence of Tfr cells express lower levels of
Ki-67 and produce less IL-4 and IL-21, indicating a sup-
pressive impact of Tfr cells on Tfh proliferation and
cytokine production.14 In addition, in the absence of Tfr
and Treg cells (by transiently depleting Foxp3+ cells 6 days
after immunization), there is a reduction of GC B cells
specific for the dominant epitope of the immunizing anti-
gen, so implicating Tfr cells in the regulation of non-anti-
gen-specific B-cell clones in the GC.4 Whether this impact
was due to a direct effect of Tfr cells on GC B cells or a con-
sequence of less regulation of Tfh clones by Tfr cells leading
to greater ‘uncontrolled’ help to B cells was not addressed.
CTLA-4 is the only molecule expressed by Tfr cells so far
described as a direct mediator of Tfr cell suppressive func-
tion.18,19 As referred previously, in the absence of CTLA-4
on Treg cells, there is an increase in the Tfr cell numbers, but
those Tfr cells lose most of their suppressive capacity.18,19
At least part of the suppressive mechanism of Tfr cells
seems to involve the modulation of Tfh and GC B cells
metabolism.33 Indeed, in in vitro co-cultures, Tfr cells
induce a suppressive state on Tfh and GC B cells, especially
at metabolic level (i.e. glucose uptake, glycolysis and one-
carbon metabolism), that persists in the absence of Tfr cells
and is associated with epigenetic changes.33 This suppres-
sive effect translates in the inhibition of class-switch recom-
bination and antibody production by B cells, and IL-21 and
IL-4 production by Tfh cells. The suppressive state is rever-
sible, as it can be abrogated in the presence of high levels of
IL-21, which acts directly on both B cells (restoration of
B-cell activation) and Tfr cells (inhibition of prolifera-
tion).33 In fact, this observation is in line with IL-21 specifi-
cally rendering Tfr cells less responsive to IL-2, in both
mice and humans, and, consequently, having a negative
impact on the proliferation of Tfr cells.20
Despite the fact that most of the suppressive capacity of
Tfr cells is lost in the absence of CTLA-4, it is expected
that these cells employ multiple and complementary regu-
latory mechanisms, as has been described for Treg cells.34–
36 Several mechanisms have been proposed that involve:
(i) the secretion of the regulatory cytokines IL-10 and
transforming growth factor b (TGF-b); (ii) the induction
of cell death by secretion of granzyme B; (iii) displacement
of Tfh cells from GC B-cell surface; and (iv) interaction
with Tfh and/or GC B cells through a still unknown
receptor.37
Although IL-10 is regarded as a suppressive cytokine,
evidence seems to exclude the production of IL-10 by Tfr
cells as a regulatory mechanism of the GC reaction. Tfr
cells produce IL-10, but high amounts of this cytokine
were detected in the supernatants of Tfh and GC B-cell
cultures when Tfr cells were not present.14 Indeed, and
contrary to what would be expected, Tfr cells seem to
inhibit IL-10 production; however, IL-10 inhibition may
still be in agreement with Tfr cell suppressive functions,
as IL-10 is important for GC B-cell survival and prolifera-
tion.14,38 The production of TGF-b may be an additional
mechanism of Tfr suppression, as Tfh cells are suppressed
by this cytokine.39 Tfr cells also express granzyme B,
Box 1 CXCR5+Foxp3+ Tfr cells may affect the evaluation of
other cell subsets
Many studies on T cell subsets in human blood have been per-
formed without addressing Tfr cells as a separate population.
This can influence the outcome of those studies.
1 Tfr cells are about 1857  655% of CD25+ Foxp3+ T cells
(generally assumed to be Treg cells) in peripheral blood of
healthy adults.
CD
25
Foxp3
CD
4
CXCR5
Gated on
CD4+T cells
5.6 21.9
2 Tfr cells represent 401  228% of CD45RO+ CXCR5+ T
cells (generally assumed to be Tfh cells) in peripheral blood of
healthy adults.
CD4+ T cells
CD
45
RO
CXCR5
17.9
CD
25
Foxp3
3.9
Gated on
As a consequence, for adequate quantification of Tfh and Treg
subsets, CXCR5+ Foxp3+ Tfr cells should be considered as a dis-
tinct cell population and studied separately.
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though in lower levels than Treg cells, and granzyme
B-mediated cytolysis can be another regulatory mecha-
nism employed by Tfr cells.4
Tfr cells in humans
Pioneering work from Lim et al. have established the
existence of a CD69 human tonsil Treg cell subset with
B-cell suppressive function.8,9 Upon activation, this subset
up-regulated CXCR5, acquiring the capacity to migrate
towards CXCL13-enriched GC. In their in vitro assays,
Lim et al. demonstrated that these cells suppressed class-
switch recombination by B cells, as they inhibited
immunoglobulin production and activation-induced cyti-
dine deaminase expression. Those earlier observations
gained a new importance following the identification of
Tfr cells as a specialized cell subset.3–5
Since their discovery, Tfr cells have been regarded as puta-
tive important players in the pathogenesis of human diseases
characterized by disrupted GC responses, like autoimmune
and chronic infectious diseases (Table 2). The first evidence
of Bcl-6+ Tfr cells in humans was afforded by Chung et al.
through the identification of tonsil CD4+ T cells bearing the
Foxp3+ CXCR5+ Bcl-6+ phenotype.3 As in mice, Tfr cells in
human lymph nodes do not require B cells for their mainte-
nance, as depletion of CD20+ B cells by rituximab did not
decrease the number of CD57+ CXCR5+ Foxp3+ CD127
Tfr cells.40 Similar to findings in mice, there is evidence sug-
gesting some divergence in differentiation of human Tfr and
Tfh cells: a primary immunodeficiency defined by PI3KR1
gain-of-function mutation did not affect the frequency of
tonsil Tfr cells, but it significantly reduced the frequency of
Tfh cells.41
Tfr cells, as well as Tfh cells, play their functional role
in B-cell follicles and GC in secondary lymphoid tissues.
The restricted access to human tissues forced the search
for these cells in human blood. Several studies confirmed
circulating CXCR5+ T cells as the counterparts of tissue
Tfh cells, arising from lymphoid tissue cells before reach-
ing the GC, in spite of low Bcl-6 expression.42–46 It is well
known that some human blood Treg cells express CXCR5
among other CXC chemokine receptors.47 Hence, many
studies have been using circulating CXCR5+ Foxp3+ T
cells to define Tfr cells in humans (Box 1).48–53 Surpris-
ingly, no study specifically addressed whether blood
CXCR5+ Foxp3+ T cells are truly circulating Tfr cell
counterparts. Although circulating memory Tfr cells were
observed after immunization protocols in mice,14,17
CXCR5 and Foxp3 transient up-regulation upon human
T-cell activation challenged the assumption that human
blood CXCR5+ Foxp3+ T cells are Tfr cells.54–58 Dhaeze
et al. found that blood CXCR5+ PD-1+ CD25+ CD127+ T
cells increased on day 7 following influenza vaccination
(showing a positive correlation with plasma antibody
titres for influenza), and suppressed T cells in vitro upon
aCD3/CD28 stimulation.50 Although this report has cor-
related blood CXCR5+ PD-1+ CD25+ CD127+ T cells
with influenza vaccination responses, it did not provide
any evidence of an intrinsic humoral regulatory capacity.
Our group has found that human circulating CXCR5+
Treg cells are Tfr cell precursors that emerge after birth
from lymphoid tissues as immature cells not yet endowed
with full humoral regulatory function.59 Our observation
is in line with murine studies showing that circulating Tfr
cells have less suppressive capacity than their tissue coun-
terparts.14,33
Tfr cells in different human diseases
Autoimmune diseases
A disturbed B–T-cell interaction can be responsible for
the generation of self-reactive antibodies in autoimmune
diseases.60 Although Tfh cells are indispensable for GC
formation and generation of high-affinity antibodies, Tfh
and Tfr cells are still poorly understood in human
autoimmunity, mostly because of difficult access to the
lymphoid tissues where those populations operate. Tfr
cells are particularly attractive to study in the setting of
autoimmunity as their modulation may have therapeutic
potential.
Few studies have addressed Tfr cells in human autoim-
munity (Table 2). Blood CXCR5+ PD-1+ CD25+ CD127
Tfr cells were reduced in patients with multiple sclero-
sis.50 In addition, blood Tfr cells from patients with mul-
tiple sclerosis were less suppressive than equivalent cells
sorted from healthy controls, using CD25 CD127+ T
cells as responders in vitro.50 This work suggests that
blood Tfr cells might be functionally defective in autoim-
munity. However, the functional assays performed in this
study did not evaluate the putative specialization of Tfr
cells in the suppression of humoral responses. An addi-
tional study also found a decreased frequency of blood
CXCR5+ Foxp3+ Tfr cells in untreated patients with
myasthenia gravis, recovering to normal levels after corti-
costeroid-based treatment.52 However, not all studies of
CXCR5+ Foxp3+ T cells in autoimmunity are concordant.
A higher frequency of blood CXCR5+ Foxp3+ Tfr cells
was found in patients with ankylosing spondylitis,
increasing even further after treatment with Etanercept.61
The blood frequency of Tfr cells did not correlate with
disease severity of multiple sclerosis or ankylosing
spondylitis, questioning the direct role of blood
CXCR5+ Foxp3+ T cells in autoimmune pathogenesis.
Besides organ-specific autoimmune diseases, it would be
important to assess Tfr cells in systemic autoimmune dis-
eases, where potentially more severe tolerance disruption
mechanisms are operating. We found that blood Tfr cell
frequency is increased in patients with Sj€ogren syn-
drome.59 Therefore, our data suggest that blood Tfr cells,
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as well as the Tfr : Tfh cell ratio, may constitute markers
of disturbed GC responses in human autoimmunity.
HIV and other infectious diseases
During acute infection, a vigorous immune response leads
to high-affinity antibody production within GCs.
Although Tfr cell biology in humans remains largely
uncharacterized, it is tempting to target Tfh and Tfr cells
in conditions where antibody production is not sufficient
to contain microorganism replication, like HIV infection.
HIV-1-infected individuals (not receiving highly active
antiretroviral therapy) have an increased frequency of GC
Foxp3+ CD4+ T cells,62 spleen Foxp3+ CXCR5+ CD45RA
CCR7 CD4+ Tfr cells,63 and blood CXCR5+ CD25+ Fox-
p3+ CD4+ Tfr cells.64 Tfh cells (defined as CXCR5+
CD45RA CCR7 CD4+ T cells for spleen and as
PD-1+ CXCR3 CXCR5+ CD4+ T cells for peripheral
blood) were also increased, suggesting that Tfr and Tfh cell
expansion could occur simultaneously in cases of antigen
persistence. Consistently, in vitro studies using tonsil cells
spinoculated with X4 and R5 HIV have shown Tfr cell
expansion (with increased CTLA-4, lymphocyte-activation
gene 3 (LAG-3) and IL-10 expression) upon HIV infection
in a TGF-dependent manner.62
In blood, the presence of broad neutralizing antibodies
did not impact the frequency of Tfr cells, although
patients with high titres of neutralizing antibodies dis-
played a higher expression of PD-1 in Tfr cells.64
Although increased PD-1 signalling has been shown to
inhibit Tfr cell function in mice,17 it is still speculative to
correlate the presence of broad neutralizing antibodies
with putative Tfr cell exhaustion.
Blood CXCR5+ Foxp3+ Tfr cells were also found
increased in hepatitis B virus and hepatitis C virus chroni-
cally infected patients, showing a significant correlation with
blood viral load in both infections. An increased frequency
of blood CXCR5+ Foxp3+ CD45RA Tfr cells was also
found in helminthic infection by Schistosoma japonica.49
Primary immunodeficiencies
Many human monogenic primary immunodeficiencies are
associated with defective B-cell responses. In STAT3, IL-
10R, CD40L, NEMO, BTK and ICOS mutations there is a
decreased frequency of Tfh cells.65 Although frequency of
blood CXCR5+ Foxp3+ Tfr cells have not been studied in
these pathological conditions, patients with < 2% of
IgD CD27+ B cells in the setting of common variable
immunodeficiency have a reduction of blood
CXCR5+ CD25hi CD127low Tfr cell frequency, in line with
a reduction of total Treg cell frequency in peripheral
blood.66 This study suggests a relationship between this B-
cell subset and blood Tfr cells, but the clinical heterogene-
ity and largely unknown molecular mechanisms driving
common variable immunodeficiency preclude a definite
conclusion about blood Tfr cell ontogeny. Recently, the
SOCE (store-operated calcium entry) pathway in T cells
has been implicated in Tfr cell differentiation in humans,
as patients with severe combined immunodeficiency-like
disease due to inherited loss-of-function mutations in
ORAI1 and STIM1 genes that abolish SOCE have a signifi-
cant reduction in blood CD45RO+ Helios+ Foxp3+ Tfr-
like cells.67 In another recent study, IL-21R-deficienct
patients have been shown to have a significant increase in
frequency of blood Foxp3+ CXCR5+ PD-1+ Tfr cells. In
contrast, a marked decrease in circulating CXCR5+ PD-1+
Tfh cells was observed in IL-21R-deficiency patients.20
Taken together, these recent studies suggest that human
Tfh and Tfr cells have different, sometimes reciprocal,
requirements for their differentiation. Therefore, the
impact of the IL-21–IL-2 axis in Tfh and Tfr balance
deserves further investigation, as its modulation may
influence the outcome of GC responses.
Conclusions
The GC reaction is a key event in humoral responses.
The B-cell–Tfh cell interactions are important for the
production of high-affinity protective antibodies,
following B-cell receptor hypermutation and selection.
However, immune dysregulation may lead to autoanti-
body production and autoimmunity. The understanding
of the interplay of Tfr, Tfh and GC B cells may lead to
more effective vaccines and to novel therapeutic strategies
for immune-mediated diseases.
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